

## BC Cancer Benefit Drug List May 2025

| DEFINITIONS                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                               |                 |                                                                                                                                                                                                                       |                |       |                                                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|----------------------------------------------------------------------------------------------------------------|
| Class I                                                                                                                                                                                                                                                                                                                   | Reimbursed for active cancer or approved treatment or approved indication only.                                                                                                               |                 |                                                                                                                                                                                                                       |                |       |                                                                                                                |
| Restricted Funding (R)                                                                                                                                                                                                                                                                                                    | Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application is necessary to provide the appropriate clinical information for each patient. |                 |                                                                                                                                                                                                                       |                |       |                                                                                                                |
| NOTES                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                               |                 |                                                                                                                                                                                                                       |                |       |                                                                                                                |
| 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. |                                                                                                                                                                                               |                 |                                                                                                                                                                                                                       |                |       |                                                                                                                |
| 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated.                                                                                                                                                                                                                                   |                                                                                                                                                                                               |                 |                                                                                                                                                                                                                       |                |       |                                                                                                                |
| 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified.                                                                                                                                                                                                                                           |                                                                                                                                                                                               |                 |                                                                                                                                                                                                                       |                |       |                                                                                                                |
| 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or cap_bcca@bccancer.bc.ca                                                                                                                                              |                                                                                                                                                                                               |                 |                                                                                                                                                                                                                       |                |       |                                                                                                                |
| DRUG                                                                                                                                                                                                                                                                                                                      | DOSAGE FORM                                                                                                                                                                                   | TUMOUR SITE     | APPROVED INDICATIONS                                                                                                                                                                                                  | PROTOCOL CODES | CLASS | NOTES                                                                                                          |
| abemaciclib                                                                                                                                                                                                                                                                                                               | tablet                                                                                                                                                                                        | Breast          | Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist                                                                                                            | UBRAJABEI      | R     |                                                                                                                |
|                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                               |                 | Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist                                                                                                                      | UBRAJABET      | R     |                                                                                                                |
| abiraterone                                                                                                                                                                                                                                                                                                               | tablet                                                                                                                                                                                        | Genitourinary   | Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone                                                                                                                          | GUMCSPABI      | I     |                                                                                                                |
|                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                               |                 | Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and prednisone                                                                                                               | UGUPABI        | R     |                                                                                                                |
|                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                               |                 | Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer using Abiraterone and predniSONE                                                                                                       | UGUPAJABI      | R     |                                                                                                                |
|                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                               |                 | Treatment for Metastatic Castration-Resistant Prostate Cancer using Olaparib with Abiraterone and predniSONE                                                                                                          | UGUPAVOABI     | R     |                                                                                                                |
| acalabrutinib                                                                                                                                                                                                                                                                                                             | capsule/tablet                                                                                                                                                                                | Lymphoma        | Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib                                                                                                       | LYACAL         | I     |                                                                                                                |
|                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                               |                 | Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Acalabrutinib                                                                                                      | LYFACAL        | I     |                                                                                                                |
| acitretin                                                                                                                                                                                                                                                                                                                 | capsule                                                                                                                                                                                       | Lymphoma        | reversal of early dysplastic and neoplastic stem changes                                                                                                                                                              | LYNOS          | I     |                                                                                                                |
| afatinib                                                                                                                                                                                                                                                                                                                  | tablet                                                                                                                                                                                        | Lung            | first-line treatment of epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer with afatinib                                                                                          | LUAVAFAT       | I     |                                                                                                                |
| aldesleukin                                                                                                                                                                                                                                                                                                               | injectable                                                                                                                                                                                    | Skin & Melanoma | Treatment of In-Transit Melanoma with Intralesional Aldesleukin IL-2                                                                                                                                                  | SMILALD        | I     |                                                                                                                |
|                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                               | Pediatric       | pediatric patients with high risk neuroblastoma treated on the ANBL0032 study                                                                                                                                         |                | I     |                                                                                                                |
|                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                               |                 | treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in combination with sargramostim, aldesleukin and tretinoin |                | I     |                                                                                                                |
| alectinib                                                                                                                                                                                                                                                                                                                 | capsule                                                                                                                                                                                       | Lung            | treatment of ALK-positive advanced non-small cell lung cancer with alectinib                                                                                                                                          | LUVALE         | I     |                                                                                                                |
| alemtuzumab                                                                                                                                                                                                                                                                                                               | injectable                                                                                                                                                                                    | Lymphoma        | treatment of fludarabine-refractory B-chronic lymphocytic leukemia and T-prolymphocytic leukemia                                                                                                                      | LYALEM         | I     |                                                                                                                |
| alitretinoin                                                                                                                                                                                                                                                                                                              | tablet                                                                                                                                                                                        | Lymphoma        | Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides/ Sézary Syndrome)                                                                                                                                           | LYALIT         | I     |                                                                                                                |
| aminolevulinic acid (LEVULAN® KERASTICK®)                                                                                                                                                                                                                                                                                 | topical solution                                                                                                                                                                              | Skin & Melanoma | topical therapy for skin cancer with PDT (Photodynamic Therapy)                                                                                                                                                       | SMPDT          | I     | Only reimbursable when prescribed by physicians in the Skin Tumour Group within the BC Cancer Skin PDT Program |
| amsacrine                                                                                                                                                                                                                                                                                                                 | injectable                                                                                                                                                                                    | Leukemia & BMT  |                                                                                                                                                                                                                       | LKNOS          | I     |                                                                                                                |
| anagrelide                                                                                                                                                                                                                                                                                                                | capsule                                                                                                                                                                                       | Leukemia & BMT  | patients with thrombocytosis related to a myeloproliferative disorder who have had an inadequate response to or are intolerant of hydroxyurea and/or interferon                                                       | LKANAG         | I     |                                                                                                                |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                               | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                                      | PROTOCOL CODES | CLASS | NOTES |
|------------------------------------|-------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| anastrozole                        | tablet      | Breast           | Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist                                                                                                | UBRAJABEI      | R     |       |
|                                    |             |                  | neoadjuvant or adjuvant therapy for breast cancer using anastrozole in postmenopausal women                                                                                                               | BRAJANAS       | I     |       |
|                                    |             |                  | Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer                                                             | BRAJLHRHAI     | I     |       |
|                                    |             |                  | first or second line hormonal treatment for advanced breast cancer in postmenopausal women                                                                                                                | BRAVANAS       | I     |       |
|                                    |             |                  | therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor                                                                                                                        | BRAVLHRHAI     | I     |       |
|                                    |             |                  | therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist                                                                                                  | BRAVPALAI      | I     |       |
|                                    |             |                  | therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist                                                                                                   | BRAVRIBAI      | I     |       |
|                                    |             | Gynecology       | hormonal treatment for advanced endometrial cancer in postmenopausal women with contraindications to tamoxifen or intolerant of tamoxifen                                                                 | GOENDAI        | I     |       |
|                                    |             |                  | therapy for advanced ovarian cancer using an aromatase inhibitor                                                                                                                                          | GOOVAI         | I     |       |
| apalutamide                        | tablet      | Genitourinary    | Treatment of Metastatic Castration Sensitive Prostate Cancer using Apalutamide                                                                                                                            | GUMCSPAPA      | I     |       |
|                                    |             |                  | Treatment of Non- Metastatic Castration Resistant Prostate Cancer Using Apalutamide                                                                                                                       | UGUPAPA        | R     |       |
| arsenic trioxide                   | injectable  | Leukemia & BMT   | first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide and tretinoin                                                                                       | LKATOATRA      | I     |       |
|                                    |             |                  | first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin                                                                         | LKATOP         | I     |       |
|                                    |             |                  | induction and consolidation therapy of relapsed acute promyelocytic leukemia using arsenic trioxide and tretinoin (All-Trans Retinoic Acid)                                                               | LKATOR         | I     |       |
|                                    |             |                  | Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and Dexamethasone on the COG AAML1331 Study |                | I     |       |
|                                    |             | Pediatric        |                                                                                                                                                                                                           |                |       |       |
| asciminib                          | tablet      | Leukemia & BMT   | Treatment of Chronic Myeloid Leukemia using Asciminib                                                                                                                                                     | LKCLA          | I     |       |
| asparaginase (KIDROLASE®)          | injectable  | Leukemia & BMT   |                                                                                                                                                                                                           | LKNOS, LYNOS   | I     |       |
| asparaginase-erwinia (ERWINASE®)   | injectable  | Leukemia & BMT   | treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma using asparaginase-Erwinia (Erwinase®) in patients allergic to asparaginase (Kidrolase®) or pegaspargase (Oncaspar®)                 | LKNOS, LYNOS   | I     |       |
| atezolizumab                       | injectable  | Gastrointestinal | First-Line Treatment of Advanced Hepatocellular Carcinoma using Atezolizumab and Bevacizumab                                                                                                              | GIATZB         | I     |       |
|                                    |             | Lung             | Treatment of Resected Non-Small Cell Lung Cancer using Atezolizumab                                                                                                                                       | ULUAJATZ       | R     |       |
|                                    |             |                  | Treatment of Advanced Non-Small Cell Lung Cancer Using Atezolizumab                                                                                                                                       | LUAVATZ        | I     |       |
|                                    |             |                  | Treatment of Advanced Non-Small Cell Lung Cancer Using 4-Weekly Atezolizumab                                                                                                                              | LUAVATZ4       | I     |       |
|                                    |             |                  | Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide                                                                                                      | LUSCATPE       | I     |       |
| avelumab                           | injectable  | Genitourinary    | Maintenance Therapy of Locally Advanced or Metastatic Urothelial Carcinoma using Avelumab                                                                                                                 | GUBAVE         | I     |       |
|                                    |             | Skin & Melanoma  | second-line treatment of recurrent or metastatic merkel cell carcinoma using avelumab                                                                                                                     | SMMCCAVE       | I     |       |
| axicabtagene ciloleucel (YESCARTA) | CAR T-cell  | Lymphoma         | Second line treatment of adults with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)                                                                                          | LYCARTDL2      | R     |       |
|                                    |             |                  | Third line treatment of adults with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)                                                                                           | LYCARTDL3      | R     |       |
|                                    |             |                  | Third line treatment of adults with follicular lymphoma (Grade 1, 2 or 3a) and marginal zone lymphoma                                                                                                     | LYCARTFL3      | R     |       |
| axitinib                           | tablet      | Genitourinary    | therapy for metastatic renal cell carcinoma using axitinib                                                                                                                                                | GUAXIT         | I     |       |
|                                    |             |                  | Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Axitinib                                                                                                                             | GUAVPEMAX      | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                           | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                | PROTOCOL CODES | CLASS | NOTES |
|--------------------------------|-------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| azacitidine                    | injectable  | Leukemia & BMT   | Therapy of Acute Myeloid Leukemia using azacitidine and sorafenib                                                                                                   | LKAMLAS        | I     |       |
|                                |             |                  | Therapy of Acute Myeloid Leukemia using Azacitidine and Venetoclax                                                                                                  | ULKAMLAVEN     | R     |       |
|                                |             |                  | Therapy of Myelodysplastic Syndrome                                                                                                                                 | LKMSDA         | I     |       |
|                                |             | Pediatric        | Treatment of pediatric myelodysplastic syndrome (MDS) prior to hematopoietic stem cell transplant (HSCT)                                                            |                | I     |       |
|                                | tablet      | Leukemia & BMT   | Maintenance Oral Azacitidine for Acute Myeloid Leukemia                                                                                                             | ULKAMLAMTN     | R     |       |
| bacillus calmette guerin (BCG) | injectable  | Genitourinary    | Therapy for High- or Intermediate-Risk Non-Muscle Invasive Bladder Cancer using BCG                                                                                 | GUBCG          | I     |       |
| belzutifan                     | tablet      | Genitourinary    | Belzutifan Therapy for von Hippel-Lindau Disease-Associated Renal Cell Carcinoma, Hemangioblastomas and Pancreatic Neuroendocrine Tumours                           | UGUVHBLBEL     | R     |       |
| bendamustine                   | injectable  | Lymphoma         | treatment of Non-Hodgkin Lymphoma with bendamustine                                                                                                                 | LYBEND         | I     |       |
|                                |             |                  | Treatment of Rituximab-refractory Follicular Lymphoma with Bendamustine in Combination with Obinutuzumab                                                            | LYBENDO        | I     |       |
|                                |             |                  | treatment of Non-Hodgkin Lymphoma with bendamustine and rituximab                                                                                                   | LYBENDR        | I     |       |
|                                |             |                  | treatment of relapsed chronic lymphocytic leukemia with bendamustine                                                                                                | LYCLLBEND      | I     |       |
|                                |             |                  | treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with bendamustine and rituximab                                         | LYCLLBENDR     | I     |       |
|                                |             |                  | treatment of previously untreated chronic lymphocytic leukemia (CLL) with bendamustine and rituximab                                                                | LYCLLFBR       | I     |       |
|                                |             |                  | Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab             | LYPOLABR       | I     |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |
| bevacizumab                    | injectable  | Gastrointestinal | First-Line Treatment of Advanced Hepatocellular Carcinoma using Atezolizumab and Bevacizumab                                                                        | GIATZB         | I     |       |
|                                |             |                  | palliative therapy of metastatic colorectal cancer using capecitabine and bevacizumab                                                                               | GIAVCAPB       | I     |       |
|                                |             |                  | Therapy of Advanced Colorectal Cancer using Trifluridine-Tipiracil and Bevacizumab                                                                                  | GIAVTTB        | I     |       |
|                                |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine                                                 | GICIRB         | I     |       |
|                                |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine                                                | GICOXB         | I     |       |
|                                |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab                      | GIFFIRB        | I     |       |
|                                |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab                                   | GIFFOXB        | I     |       |
|                                |             | Neuro-Oncology   | patients with relapsed malignant gliomas                                                                                                                            | CNBEV          | I     |       |
|                                |             | Gynecology       | alternative treatment of gynecological malignancies using bevacizumab, carboplatin and paclitaxel NAB (ABRAXANE)                                                    | GOCABRBEV      | I     |       |
|                                |             |                  | Alternative Treatment of Gynecological Malignancies using Bevacizumab, Cisplatin and Paclitaxel                                                                     | GOCISPBEV      | I     |       |
|                                |             |                  | Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Pembrolizumab with or without Bevacizumab                               | GOCXBP         | I     |       |
|                                |             |                  | Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with 6-Weekly Pembrolizumab with or without Bevacizumab                      | GOCXBP6        | I     |       |
|                                |             |                  | primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab, carboplatin and paclitaxel                                                         | GOCXCATB       | I     |       |
|                                |             |                  | Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab                    | UGOCXCATBP     | R     |       |
|                                |             |                  | Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and Pembrolizumab | GOCXCPNBP      | I     |       |
|                                |             |                  | Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine                                                            | GOOVBEVG       | I     |       |
|                                |             |                  | Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and DOXOrubicin Pegylated Liposomal                                                              | GOOVBEVLD      | I     |       |
|                                |             |                  | Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel                                                                          | GOOVBEVP       | I     |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |
|                                |             |                  |                                                                                                                                                                     |                |       |       |

Note: Biosimilar bevacizumab (ZIRABEV®, AYBINTIO®) is funded for treatment started on or after November 1st, 2019. AVASTIN® is funded for treatment started prior to November 1st, 2019.

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                 | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                               | PROTOCOL CODES                                       | CLASS | NOTES                                                                                                                                                                                    |
|----------------------|-------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| bevacizumab (cont'd) | injectable  | Gynecology              | Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine                                                                                                           | GOOVBEVV                                             | I     | Note: Biosimilar bevacizumab (ZIRABEV®, AYBINTIO®) is funded for treatment started on or after November 1st, 2019. AVASTIN® is funded for treatment started prior to November 1st, 2019. |
|                      |             |                         | primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel                                             | GOOVCATB                                             | I     |                                                                                                                                                                                          |
|                      |             | Pediatric               | treatment with bevacizumab as a single agent or in combination with chemotherapy for pediatric patients with low-grade glioma progressing after first-line chemotherapy                                            |                                                      | I     |                                                                                                                                                                                          |
|                      |             | Sarcoma                 | therapy for advanced solitary fibrous tumours and hemangiopericytoma using temozolomide and bevacizumab                                                                                                            | SATEMBEV                                             | I     |                                                                                                                                                                                          |
| bexarotene (SAP)     | capsule     | Lymphoma                | patients with refractory cutaneous T-cell lymphoma                                                                                                                                                                 | LYMFBEX                                              | I     | Approval from Health Canada Special Access Programme is required for each patient.                                                                                                       |
| bicalutamide         | tablet      | Genitourinary           | Androgen Deprivation Therapy for Prostate Cancer                                                                                                                                                                   | GUPADT                                               | I     | Not reimbursed for vasomotor symptoms (hot flashes)                                                                                                                                      |
|                      |             |                         | Treatment of Prostate Cancer with High-Dose Bicalutamide                                                                                                                                                           | GUPHDBIC                                             | I     |                                                                                                                                                                                          |
| binimetinib          | tablet      | Skin & Melanoma         | Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Encorafenib and Binimetinib                                                                                                     | SMAVEB                                               | I     |                                                                                                                                                                                          |
| bleomycin            | injectable  | Gynecology              | therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide, and cisplatin                                                                                                                 | GOBEP                                                | I     | Not reimbursed for pleurodesis                                                                                                                                                           |
|                      |             | Genitourinary           | curative therapy for germ cell cancer using with bleomycin, etoposide, cisplatin for germ cell cancers                                                                                                             | GUBEP                                                | I     |                                                                                                                                                                                          |
|                      |             | Kaposi's Sarcoma        | palliative therapy for kaposi's sarcoma using vinblastine alternating with vincristine                                                                                                                             | KSVB                                                 | I     |                                                                                                                                                                                          |
|                      |             | Lymphoma                | treatment of Hodgkin lymphoma with doxorubicin, bleomycin, vinblastine, and dacarbazine                                                                                                                            | LYABVD                                               | I     |                                                                                                                                                                                          |
|                      |             |                         | treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone                                                                                                                     | LYCVPPABO                                            | I     |                                                                                                                                                                                          |
|                      |             | Not Otherwise Specified |                                                                                                                                                                                                                    | Other tumour site code followed by 'NOS' (e.g. LYNS) | I     |                                                                                                                                                                                          |
| blinatumomab         | injectable  | Leukemia & BMT          | Treatment of Philadelphia chromosome (Ph)-positive or Ph-negative refractory or relapsed pre-B-cell acute lymphoblastic leukemia with blinatumomab                                                                 | ULKBLIN                                              | R     |                                                                                                                                                                                          |
|                      |             |                         | Treatment of Pre-B-Cell Acute Lymphoblastic Leukemia with Minimal Residual Disease using Blinatumomab                                                                                                              | ULKMRDBLIN                                           | R     |                                                                                                                                                                                          |
|                      |             | Pediatric               | Treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory pre-B-cell acute lymphoblastic leukemia using blinatumomab                                                      |                                                      | R     |                                                                                                                                                                                          |
|                      |             |                         | Pediatric patients with Philadelphia chromosome-negative and CD19-positive pre-B-cell acute lymphoblastic leukemia (ALL) in complete hematologic remission (CR) and with minimal residual disease (MRD) positivity |                                                      | R     |                                                                                                                                                                                          |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                                 | DOSAGE FORM     | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                                                                                                                      | PROTOCOL CODES                            | CLASS | NOTES |
|--------------------------------------|-----------------|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-------|-------|
| bortezomib                           | injectable      | Lymphoma                | Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone                                                                                                                                                     | LYDARCBD                                  | I     |       |
|                                      |                 | Myeloma                 | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone                                                                                                                                                                             | MYBLDF                                    | I     |       |
|                                      |                 |                         | Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant                                                                                                                                                                                                      | MYBLDPRE                                  | I     |       |
|                                      |                 |                         | Maintenance Therapy of Multiple Myeloma using Bortezomib for Patients with the High-Risk Chromosome Abnormality                                                                                                                                                                                                           | MYBORMTN                                  | I     |       |
|                                      |                 |                         | Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant                                                                                                                                                                                      | MYBOPPRE                                  | I     |       |
|                                      |                 |                         | Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide                                                                                                                                                                                                                   | MYBORREL                                  | I     |       |
|                                      |                 |                         | Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide                                                                                                                                                                                                             | MYBSD                                     | I     |       |
|                                      |                 |                         | treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide                                                                                                                                                                  | MYDARBD                                   | I     |       |
|                                      |                 |                         | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone                                                                                                                                                            | MYDARCBD                                  | I     |       |
|                                      |                 |                         | treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan                                                                                                                                                                            | MYMPBOR                                   | I     |       |
|                                      |                 | Pediatric               | Treatment of Children with T-cell Lymphoblastic Lymphoma with Bortezomib                                                                                                                                                                                                                                                  |                                           | I     |       |
|                                      |                 |                         | Bortezomib with chemotherapy for pediatric patients with T-cell lymphoblastic lymphoma treated with on the AALL1231 study                                                                                                                                                                                                 |                                           | I     |       |
| bosutinib                            | tablet          | Leukemia & BMT          | treatment of chronic myeloid leukemia using bosutinib                                                                                                                                                                                                                                                                     | LKCLMB                                    | I     |       |
| brentuximab vedotin                  | injectable      | Lymphoma                | Treatment of Previously Untreated, Stage III or IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin                                                                                                                                                                                    | LYAVDBV                                   | I     |       |
|                                      |                 |                         | treatment of Hodgkin lymphoma and anaplastic large cell lymphoma with brentuximab vedotin                                                                                                                                                                                                                                 | LYBRENTUX                                 | I     |       |
|                                      |                 |                         | treatment for consolidation therapy post-autologous stem cell transplant (ASCT) for Hodgkin lymphoma using brentuximab vedotin                                                                                                                                                                                            | LYBV                                      | I     |       |
|                                      |                 |                         | Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients 60 Years or Older                                                                                                                                               | LYBVAVDBV                                 | I     |       |
|                                      |                 |                         | treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin                                                                                                                                                                                 | LYCHPBV                                   | I     |       |
|                                      |                 | Pediatric               | Brentuximab Vedotin in Combination with Doxorubicin, Vincristine, Etoposide and Cyclophosphamide for First Line High Risk Pediatric Hodgkin's Lymphoma                                                                                                                                                                    |                                           | I     |       |
|                                      |                 |                         | pediatric patients following autologous hematopoietic stem cell transplant (HSCT) for relapsed or refractory Hodgkin lymphoma                                                                                                                                                                                             |                                           | I     |       |
| brexucabtagene autoleucel (TECARTUS) | CAR T-cell      | Leukemia & BMT          | Treatment of relapsed B-cell acute lymphocytic leukemia (ALL) within 12-months of first remission, refractory/relapsed after two or more treatments, or after an allogeneic stem cell transplantation, OR Ph+ disease with intolerance to tyrosine kinase inhibitors (TKIs) or refractory/relapsed after two or more TKIs | LKCARTALL3                                | R     |       |
|                                      |                 | Lymphoma                | Treatment of adults with relapsed or refractory mantle cell lymphoma after 2 or more lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor                                                                                                                                                               | LYCARTMC3                                 | R     |       |
| brigatinib                           | tablet          | Lung                    | First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Brigatinib                                                                                                                                                                                                                          | LUAVBRI                                   | I     |       |
| bromocriptine                        | tablet, capsule | Neuro-Oncology          | therapy for pituitary adenomas using bromocriptine                                                                                                                                                                                                                                                                        | CNB                                       | I     |       |
| busulfan                             | tablet          | Not Otherwise Specified |                                                                                                                                                                                                                                                                                                                           | Tumour site code followed by 'NOS' (e.g., | I     |       |
|                                      | injectable      | Leukemia & BMT          | myeloablative conditioning therapy prior to hematopoietic stem cell transplantation for myeloid malignancies                                                                                                                                                                                                              | BMTIVBUCY                                 | I     |       |
|                                      |                 | Pediatric               | pediatric patients who cannot swallow oral busulfan                                                                                                                                                                                                                                                                       |                                           | I     |       |
| cabazitaxel                          | injectable      | Genitourinary           | palliative therapy for metastatic castration resistant prostate cancer using cabazitaxel and prednisone                                                                                                                                                                                                                   | GUPCABA                                   | I     |       |
| cabergoline                          | tablet          | Neuro-Oncology          | therapy for pituitary adenomas using cabergoline                                                                                                                                                                                                                                                                          | CNCAB                                     | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG               | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                                                                                                                                                   | PROTOCOL CODES | CLASS | NOTES |
|--------------------|-------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| cabozantinib       | tablet      | Gastrointestinal | Treatment of Advanced Hepatocellular Carcinoma using Cabozantinib                                                                                                                                                                                                                                                      | UGICABO        | R     |       |
|                    |             | Genitourinary    | Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab and Cabozantinib                                                                                                                                                                                                                              | GUAVNIVC       | I     |       |
|                    |             |                  | Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-weekly Nivolumab and Cabozantinib                                                                                                                                                                                                                     | GUAVNIVC4      | I     |       |
|                    |             |                  | Therapy for Metastatic Renal Cell Carcinoma using Cabozantinib                                                                                                                                                                                                                                                         | GUCABO         | I     |       |
|                    |             | Head and Neck    | Therapy of Advanced Differentiated Thyroid Cancer using Cabozantinib                                                                                                                                                                                                                                                   | HNOTDCABO      | I     |       |
| calaspargase pegol | injectable  | Pediatric        | As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric patients and young adults aged 1- 21 years                                                                                                                                                     |                | I     |       |
| capecitabine       | tablet      | Breast           | therapy of adjuvant breast cancer using capecitabine                                                                                                                                                                                                                                                                   | BRAJCAP        | I     |       |
|                    |             |                  | metastatic breast cancer as first line treatment if anthracyclines and taxanes contraindicated, or where side effect profile and/or treatment delivery concerns favour initial use of BRAVCAP; second or third line treatment of metastatic breast cancer that has previously responded to an anthracycline and taxane | BRAVCAP        | I     |       |
|                    |             |                  | therapy for metastatic breast cancer using capecitabine and lapatinib                                                                                                                                                                                                                                                  | BRAVLCAP       | I     |       |
|                    |             |                  | palliative therapy for metastatic breast cancer using trastuzumab and capecitabine                                                                                                                                                                                                                                     | BRAVTCAP       | I     |       |
|                    |             |                  | Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and Capecitabine                                                                                                                                                                                                                          | UBRAVTTCAP     | R     |       |
|                    |             | Gastrointestinal | adjuvant therapy of colon cancer using capecitabine                                                                                                                                                                                                                                                                    | GIAJCAP        | I     |       |
|                    |             |                  | adjuvant combination chemotherapy for stage III and IIB colon cancer with oxaliplatin                                                                                                                                                                                                                                  | GIAJCAPOX      | I     |       |
|                    |             |                  | Palliative Therapy of Advanced Gastrointestinal Cancer using Capecitabine                                                                                                                                                                                                                                              | GIAVCAP        | I     |       |
|                    |             |                  | palliative therapy of metastatic colorectal cancer using capecitabine and bevacizumab                                                                                                                                                                                                                                  | GIAVCAPB       | I     |       |
|                    |             |                  | combined modality therapy for metastatic rectal carcinoma using capecitabine and radiation therapy                                                                                                                                                                                                                     | GIAVCRT        | I     |       |
|                    |             |                  | palliative therapy of metastatic neuroendocrine cancer using temozolomide and capecitabine                                                                                                                                                                                                                             | GIAVTZCAP      | I     |       |
|                    |             |                  | Adjuvant Therapy of Biliary Cancer using Capecitabine                                                                                                                                                                                                                                                                  | GIBAJCAP       | I     |       |
|                    |             |                  | Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Irinotecan and Capecitabine in Patients Unsuitable for GIFOIFIRI                                                                                                                                                           | GICAPIRI       | I     |       |
|                    |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin and capecitabine                                                                                                                                                                                                                | GICAPOX        | I     |       |
|                    |             |                  | combination with mitomycin and radiation therapy as curative combined modality therapy for carcinoma of the anal canal                                                                                                                                                                                                 | GICART         | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                  | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                               | PROTOCOL CODES | CLASS | NOTES |
|-----------------------|-------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| capecitabine (cont'd) | tablet      | Gastrointestinal | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine                                                                | GICIRB         | I     |       |
|                       |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine                                                               | GICOXB         | I     |       |
|                       |             |                  | curative-intent combined modality therapy for cancer of the anal canal, using cisplatin, capecitabine and radiation therapy                                                        | GICPART        | I     |       |
|                       |             |                  | adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin and capecitabine                    | GIGAJCOX       | I     |       |
|                       |             |                  | adjuvant chemotherapy in gastric cancer patients with completely resected gastric cancer using cisplatin and capecitabine and radiation therapy                                    | GIGAJCPRT      | I     |       |
|                       |             |                  | palliative therapy of metastatic or locally advanced anal squamous cell carcinoma using cisplatin and capecitabine                                                                 | GIGAVCC        | I     |       |
|                       |             |                  | Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab               | GIGAVCCT       | I     |       |
|                       |             |                  | Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin                               | GIGAVCOX       | I     |       |
|                       |             |                  | First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab                               | GIGAVCOXN      | I     |       |
|                       |             |                  | First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab                                                   | GIGAVCOXP      | I     |       |
|                       |             |                  | palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab            | GIGAVCOXT      | I     |       |
|                       |             |                  | Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab                               | GIGAVPCOXT     | I     |       |
|                       |             |                  | treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine       | GIGECC         | I     |       |
|                       |             |                  | adjuvant chemotherapy for resected pancreatic adenocarcinoma using capecitabine and gemcitabine                                                                                    | GIPAJGCAP      | I     |       |
|                       |             |                  | Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin and Capecitabine                                                                    | GIRAJCOX       | I     |       |
|                       |             |                  | Adjuvant Therapy for Stage II and III Rectal Cancer using Capecitabine in Patients Previously Treated with Preoperative Radiation Therapy Alone                                    | GIRCAP         | I     |       |
|                       |             |                  | combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine and radiation therapy                                                                         | GIRCRT         | I     |       |
|                       |             |                  | combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine, infusional fluorouracil and radiation therapy                                                | GIRINFRT       | I     |       |
|                       |             | Head and Neck    | treatment of recurrent or metastatic squamous cell cancer of the head and neck with capecitabine                                                                                   | HNAVCAP        | I     |       |
|                       |             |                  | treatment of recurrent or metastatic nasopharyngeal cancer with capecitabine                                                                                                       | HNNVCAP        | I     |       |
| capivasertib          | tablet      | Breast           | Therapy of Advanced Breast Cancer using Capivasertib and Fulvestrant With or Without LHRH Agonist                                                                                  | UBRAVCAFLV     | R     |       |
| carboplatin           | injectable  | Breast           | neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and trastuzumab                                                                                     | BRAJDCARBT     | I     |       |
|                       |             |                  | Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab                                                         | BRAJPNCT       | I     |       |
|                       |             |                  | palliative therapy for metastatic breast cancer using cisplatin and gemcitabine                                                                                                    | BRAVGEMP       | I     |       |
|                       |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin                                                                                  | BRAVPGC        | I     |       |
|                       |             |                  | Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide                     | BRLACPNAC      | I     |       |
|                       |             |                  | Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide | BRLACPNACG     | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                 | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                                                                  | PROTOCOL CODES | CLASS | NOTES |
|----------------------|-------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| carboplatin (cont'd) | injectable  | Breast           | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide                                                                                            | BRLACTWAC      | I     |       |
|                      |             |                  | Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide                                                                        | BRLACTWACG     | I     |       |
|                      |             |                  | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide                                                                        | BRPCTAC        | I     |       |
|                      |             |                  | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide                                                                     | BRPCWTAC       | I     |       |
|                      |             | Neuro-Oncology   | carboplatin and etoposide in the treatment of recurrent ependymoma                                                                                                                                                                    | CNCARV         | I     |       |
|                      |             | Gastrointestinal | First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using Carboplatin and Weekly Paclitaxel                                                                                                                    | GIAAVCT        | I     |       |
|                      |             |                  | First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum                                                                                                                           | GIAVDURPG      | I     |       |
|                      |             |                  | First-line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum                                                                                                                        | GIAVPEMPG      | I     |       |
|                      |             |                  | First-Line Palliative Chemotherapy for Advanced Gallbladder or Pancreatic Carcinoma and Cholangiocarcinoma using Gemcitabine and Cisplatin                                                                                            | GIAVPG         | I     |       |
|                      |             |                  | neoadjuvant treatment of esophageal and gastroesophageal carcinomas using carboplatin, paclitaxel and radiation therapy                                                                                                               | GIENACTRT      | I     |       |
|                      |             |                  | alternative treatment of gynecological malignancies using carboplatin and paclitaxel                                                                                                                                                  | GOCABR         | I     |       |
|                      |             | Gynecology       | NAB (ABRAXANE)                                                                                                                                                                                                                        |                |       |       |
|                      |             |                  | alternative treatment of gynecological malignancies using bevacizumab, carboplatin and paclitaxel NAB (ABRAXANE)                                                                                                                      | GOCABRBEV      | I     |       |
|                      |             |                  | treatment of advanced/recurrent non-small cell cancer of the cervix with carboplatin and docetaxel                                                                                                                                    | GOCXCAD        | I     |       |
|                      |             |                  | primary treatment of advanced/recurrent non-small cell cancer of the cervix with carboplatin and paclitaxel                                                                                                                           | GOCXCAT        | I     |       |
|                      |             |                  | primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab, carboplatin and paclitaxel                                                                                                                           | GOCXCATB       | I     |       |
|                      |             |                  | Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab                                                                                      | UGOCXCATBP     | R     |       |
|                      |             |                  | Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel, and Pembrolizumab                                                                                                  | UGOCXCATP      | R     |       |
|                      |             |                  | Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and Pembrolizumab                                                                   | GOCXCPNBP      | I     |       |
|                      |             |                  | Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel NAB (ABRAXANE), and Pembrolizumab                                                                               | GOCXCPNP       | I     |       |
|                      |             |                  | Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel                                                                                        | UGOEAVDCAT     | R     |       |
|                      |             |                  | Alternative Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin                                                                        | UGOEAVDPNC     | R     |       |
|                      |             |                  | Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using CARBOplatin and PACLitaxel                                                                                                                                              | GOENDAJCAT     | I     |       |
|                      |             |                  | Treatment of Advanced or Recurrent Endometrial Cancer using CARBOplatin and PACLitaxel                                                                                                                                                | GOENDAVCAT     | I     |       |
|                      |             |                  | treatment of primarily advanced or recurrent endometrial cancer using carboplatin and docetaxel                                                                                                                                       | GOENDCAD       | I     |       |
|                      |             |                  | primary treatment with visible or no visible residual tumour (moderate, high, or extreme risk) or treatment at relapse of invasive epithelial ovarian, fallopian tube, and primary peritoneal cancer, using carboplatin and docetaxel | GOOVCAD        | I     |       |
|                      |             |                  | carboplatin and gemcitabine for the treatment of recurrent platinum-sensitive ovarian cancer                                                                                                                                          | GOOVCAG        | I     |       |
|                      |             |                  | first or second line therapy for invasive epithelial ovarian cancer using single-agent carboplatin                                                                                                                                    | GOOVCARB       | I     |       |
|                      |             |                  | primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel                                                                | GOOVCATB       | I     |       |



**BC Cancer Benefit Drug List  
May 2025**

| DRUG                 | DOSAGE FORM | TUMOUR SITE   | APPROVED INDICATIONS                                                                                                                                                                                                                                                  | PROTOCOL CODES | CLASS | NOTES |
|----------------------|-------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| carboplatin (cont'd) | injectable  | Gynecology    | primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer, with no visible residual tumour (moderate-high risk) using carboplatin and paclitaxel                                                                                 | GOOVCATM       | I     |       |
|                      |             |               | second line treatment using paclitaxel and carboplatin for epithelial ovarian cancer relapsing after primary treatment                                                                                                                                                | GOOVCATR       | I     |       |
|                      |             |               | primary treatment of visible residual (extreme risk) invasive epithelial ovarian cancer in ambulatory care settings using paclitaxel and carboplatin                                                                                                                  | GOOVCATX       | I     |       |
|                      |             |               | primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using carboplatin and weekly paclitaxel                                                                                                                             | GOOVDDCAT      | I     |       |
|                      |             |               | first line treatment of epithelial ovarian cancer using doxorubicin pegylated liposomal and carboplatin                                                                                                                                                               | GOOVFPLDC      | I     |       |
|                      |             |               | primary treatment of stage III less than or equal to 1 cm visible residual invasive epithelial ovarian cancer or stage 1 grade 3 or stage II grade 3 papillary serous ovarian cancer using intravenous and intraperitoneal paclitaxel and intraperitoneal carboplatin | GOOVIPP        | I     |       |
|                      |             |               | second line treatment for epithelial ovarian cancer relapsing after primary treatment using pegylated liposomal doxorubicin (PLD) and carboplatin                                                                                                                     | GOOVPLDC       | I     |       |
|                      |             |               | treatment of small-cell gynecologic cancer with cisplatin and etoposide                                                                                                                                                                                               | GOSCP          | I     |       |
|                      |             |               | treatment of small-cell gynecologic cancer with cisplatin and etoposide with radiation therapy                                                                                                                                                                        | GOSCPERT       | I     |       |
|                      |             | Genitourinary | palliative therapy for urothelial carcinoma using cisplatin and gemcitabine                                                                                                                                                                                           | GUAVPG         | I     |       |
|                      |             |               | adjuvant therapy for stage I high risk seminoma using carboplatin                                                                                                                                                                                                     | GUSCARB        | I     |       |
|                      |             |               | therapy of genitourinary small cell tumors with a platin and etoposide                                                                                                                                                                                                | GUSCP          | I     |       |
|                      |             |               | Therapy of Genitourinary Small Cell Tumors with a Platinum and Etoposide with Radiation                                                                                                                                                                               | GUSCPERT       | I     |       |
|                      |             | Head and Neck | treatment of advanced squamous cell carcinoma of the head and neck cancer using fluorouracil and platinum                                                                                                                                                             | HNAVFUP        | I     |       |
|                      |             |               | treatment for unresectable, locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin                                                                                                         | HNAVPC         | I     |       |
|                      |             |               | First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Paclitaxel, Carboplatin and Pembrolizumab                                                                                                                                          | HNAVPCPMB      | I     |       |
|                      |             |               | treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with platinum and docetaxel                                                                                                                                                         | HNAVPD         | I     |       |
|                      |             |               | treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide                                                                                                                                                                                | HNAVPE         | I     |       |
|                      |             |               | First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab                                                                                                                                          | HNAVFPMB       | I     |       |
|                      |             |               | combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck                                                                                                                        | HNLACAFRT      | I     |       |
|                      |             |               | Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent Weekly CARBOplatin and Radiation                                                                                                                                           | HNLACARTW      | I     |       |
|                      |             |               | Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent 3-Weekly Carboplatin and Radiation                                                                                                                                         | HNLACART3      | I     |       |
|                      |             |               | treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil                                                                                                                                                                     | HNAVVFUP       | I     |       |
|                      |             |               | treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide                                                                                                                                                                            | HNAVPE         | I     |       |
|                      |             |               | treatment of locoregionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine                                                                                                                                                           | HNAVPG         | I     |       |
|                      |             |               | treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin and paclitaxel                                                                                                                                                                         | HNAVPC         | I     |       |
| carboplatin          | injectable  | Head and Neck | combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck                                                                                                                        | HNLACAFRT      | I     |       |
|                      |             |               | Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent Weekly CARBOplatin and Radiation                                                                                                                                           | HNLACARTW      | I     |       |
|                      |             |               | Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent 3-Weekly Carboplatin and Radiation                                                                                                                                         | HNLACART3      | I     |       |
|                      |             |               | treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil                                                                                                                                                                     | HNAVVFUP       | I     |       |
|                      |             |               | treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide                                                                                                                                                                            | HNAVPE         | I     |       |
|                      |             |               | treatment of locoregionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine                                                                                                                                                           | HNAVPG         | I     |       |
|                      |             |               | treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin and paclitaxel                                                                                                                                                                         | HNAVPC         | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                 | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                              | PROTOCOL CODES                                        | CLASS | NOTES |
|----------------------|-------------|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-------|
| carboplatin (cont'd) | injectable  | Lung                    | Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PAClitaxel                                                    | LUAJNIVPC                                             | I     |       |
|                      |             |                         | Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum                                          | LUAJNIVPP                                             | I     |       |
|                      |             |                         | adjuvant carboplatin and paclitaxel following resection of stage I, II and IIIA non-small cell lung cancer                                        | LUAJPC                                                | I     |       |
|                      |             |                         | first-line treatment of advanced non-small cell lung cancer with carboplatin and paclitaxel                                                       | LUAVPC                                                | I     |       |
|                      |             |                         | First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab                       | LUAVPCIPNI                                            | I     |       |
|                      |             |                         | first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel, carboplatin and pembrolizumab                               | LUAVPCPMB                                             | I     |       |
|                      |             |                         | treatment of advanced non-small cell lung cancer with platinum and gemcitabine                                                                    | LUAVPG                                                | I     |       |
|                      |             |                         | first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab                                 | LUAVPGPMB                                             | I     |       |
|                      |             |                         | first-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed                                                          | LUAVPP                                                | I     |       |
|                      |             |                         | First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab                      | LUAVPPIPNI                                            | I     |       |
|                      |             |                         | first-line treatment of advanced non-squamous non-small cell lung cancer with platinum, pemetrexed and pembrolizumab                              | LUAVPPPMB                                             | I     |       |
|                      |             |                         | treatment of locally advanced non-small cell lung cancer using carboplatin and paclitaxel with radiation therapy                                  | LULACATRT                                             | I     |       |
|                      |             |                         | treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation therapy                                     | LULAPERT                                              | I     |       |
|                      |             |                         | treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy               | LULAPE2RT                                             | I     |       |
|                      |             |                         | treatment of thymoma with cisplatin and etoposide                                                                                                 | LUOTPE                                                | I     |       |
|                      |             |                         | treatment of thymoma using cisplatin and etoposide with radiation therapy                                                                         | LUOTPERT                                              | I     |       |
|                      |             |                         | treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide                                                          | LUPUPE                                                | I     |       |
|                      |             |                         | Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide                                              | LUSCATPE                                              | I     |       |
|                      |             |                         | Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide                                                | LUSCDURPE                                             | I     |       |
|                      |             |                         | Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide                                                            | LUSCPE                                                | I     |       |
|                      |             |                         | Treatment of Extensive Stage Small Cell Lung Cancer with Platinum and Oral Etoposide                                                              | LUSCPEPO                                              | I     |       |
|                      |             |                         | Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy                                        | LUSCPEPORT                                            | I     |       |
|                      |             |                         | Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide with Radiation Therapy                                             | LUSCPERT                                              | I     |       |
|                      |             |                         | second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum                                   | LUSCPI                                                | I     |       |
|                      |             | Lymphoma                | Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXimab                                                                      | LYDHAPR                                               | I     |       |
|                      |             |                         | treatment of lymphoma with gemcitabine, dexamethasone and platinum                                                                                | LYGDP                                                 | I     |       |
|                      |             |                         | Treatment of ritUXimab-refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and oBINutuzumab                                  | LYGDPO                                                | I     |       |
|                      |             | Primary Unknown         | treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab | LYRICE                                                | I     |       |
|                      |             |                         | primary treatment of cancer of unknown primary origin using carboplatin and paclitaxel                                                            | PUCAT                                                 | I     |       |
|                      |             | Skin & Melanoma         | treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide                                                           | SMMCCE                                                | I     |       |
|                      |             | Not Otherwise Specified |                                                                                                                                                   | Other tumour site code followed by 'NOS' (e.g. HNNOS) | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG         | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                        | PROTOCOL CODES                                               | CLASS | NOTES                                                                                              |
|--------------|-------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------|
| carfilzomib  | injectable  | Myeloma                 | Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide                                                                                                            | MYCARDEX                                                     | I     |                                                                                                    |
|              |             |                         | Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone                                                                                                                              | MYCARLD                                                      | I     |                                                                                                    |
|              |             |                         | Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide                                                                                                | UMYISACARD                                                   | R     |                                                                                                    |
| carmustine   | injectable  | Not Otherwise Specified |                                                                                                                                                                                                             | Other tumour site code followed by 'NOS' (e.g. LKNOS)        | I     |                                                                                                    |
| cemiplimab   | injectable  | Skin & Melanoma         | Cemiplimab for Treatment of Cutaneous Squamous Cell Carcinoma                                                                                                                                               | SMAVCEM                                                      | I     |                                                                                                    |
| ceritinib    | capsule     | Lung                    | treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with ceritinib                                                                                                                        | LUAVCER                                                      | I     |                                                                                                    |
| cetuximab    | injectable  | Gastrointestinal        | palliative third line treatment of metastatic colorectal cancer with wild-type KRAS using cetuximab and irinotecan                                                                                          | GIAVCETIR                                                    | I     |                                                                                                    |
|              |             | Head and Neck           | combined cetuximab and radiation treatment for locally advanced squamous cell carcinoma of the head and neck                                                                                                | HNLACETRT                                                    | I     |                                                                                                    |
|              |             | Skin & Melanoma         | Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cetuximab                                                                                                               | SMAVCET                                                      | I     |                                                                                                    |
| chlorambucil | tablet      | Lymphoma                | low grade lymphoma and chronic lymphocytic leukemia                                                                                                                                                         | LYCHLOR                                                      | I     |                                                                                                    |
|              |             |                         | treatment of indolent B-cell lymphoma with chlorambucil and rituximab                                                                                                                                       | LYCHLRR                                                      | I     |                                                                                                    |
|              |             |                         | treatment of chronic lymphocytic leukemia with chlorambucil and rituximab                                                                                                                                   | LYCLLCHLR                                                    | I     |                                                                                                    |
|              |             |                         | lymphoma palliative chemotherapy                                                                                                                                                                            | LYPALL                                                       | I     |                                                                                                    |
|              |             |                         | treatment of previously untreated chronic lymphocytic leukemia using obinutuzumab in combination with chlorambucil                                                                                          | LYOBCHLOR                                                    | I     |                                                                                                    |
|              |             | Not Otherwise Specified |                                                                                                                                                                                                             | Other tumour site code followed by 'NOS' (e.g. LKNOS, LYNOS) | I     |                                                                                                    |
| chlormethine | topical gel | Lymphoma                | topical chlormethine in cutaneous T-Cell lymphoma                                                                                                                                                           | LYMECHLOR                                                    | I     |                                                                                                    |
| cisplatin    | injectable  | Breast                  | palliative therapy for metastatic breast cancer using cisplatin and gemcitabine                                                                                                                             | BRAVGEMP                                                     | I     |                                                                                                    |
|              |             | Neuro-Oncology          | adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour                                                                                  | CNCCV                                                        | I     |                                                                                                    |
|              |             | Gastrointestinal        | First-Line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum                                                                                                 | GIAVDURPG                                                    | I     |                                                                                                    |
|              |             |                         | First-Line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum                                                                                              | GIAVPEMPG                                                    | I     |                                                                                                    |
|              |             |                         | First-Line Palliative Chemotherapy for Advanced Gallbladder or Pancreatic Carcinoma and Cholangiocarcinoma using Gemcitabine and Cisplatin                                                                  | GIAVPG                                                       | I     |                                                                                                    |
|              |             |                         | curative-intent combined modality therapy for cancer of the anal canal, using cisplatin, capecitabine and radiation therapy                                                                                 | GICPART                                                      | I     |                                                                                                    |
|              |             |                         | hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis                                                                                                                       | GIEMBOL                                                      | I     | Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital |
|              |             |                         | palliative chemotherapy for upper gastrointestinal tract cancer (gastric, esophageal, gall bladder carcinoma and cholangiocarcinoma) and metastatic anal cancer using infusional fluorouracil and cisplatin | GIFUC                                                        | I     |                                                                                                    |
|              |             |                         | combined modality curative therapy for carcinoma of the anal canal using cisplatin, infusional fluorouracil and radiation therapy                                                                           | GIFUPART                                                     | I     |                                                                                                    |
|              |             |                         | adjuvant chemotherapy of gastric cancer patients with completely resected gastric cancer using cisplatin and capecitabine and radiation therapy                                                             | GIGAJCPRT                                                    | I     |                                                                                                    |
|              |             |                         | palliative therapy of metastatic or locally advanced anal squamous cell carcinoma using cisplatin and capecitabine                                                                                          | GIGAVCC                                                      | I     |                                                                                                    |
|              |             |                         | Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab                                        | GIGAVCCT                                                     | I     |                                                                                                    |
|              |             |                         | palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab                             | GIGAVCFT                                                     | I     |                                                                                                    |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG               | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                         | PROTOCOL CODES | CLASS | NOTES |
|--------------------|-------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| cisplatin (cont'd) | injectable  | Gastrointestinal | treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine | GIGECC         | I     |       |
|                    |             |                  | palliative therapy of neuroendocrine tumours using cisplatin and etoposide                                                                                                   | GIPE           | I     |       |
|                    |             |                  | hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel                                      | GIPMHIPEC      | I     |       |
|                    |             | Gynecology       | therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide and cisplatin                                                                            | GOBEP          | I     |       |
|                    |             |                  | alternative treatment of gynecological malignancies using cisplatin and paclitaxel                                                                                           | GOCISP         | I     |       |
|                    |             |                  | Alternative Treatment of Gynecological Malignancies using Bevacizumab, Cisplatin and Paclitaxel                                                                              | GOCISPBEV      | I     |       |
|                    |             |                  | treatment of high risk squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix with concurrent cisplatin and radiation                                  | GOCXCRT        | I     |       |
|                    |             |                  | therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide                                                                                           | GOEP           | I     |       |
|                    |             |                  | invasive epithelial ovarian cancer                                                                                                                                           | GOOVCIS        | I     |       |
|                    |             |                  | treatment of small-cell gynecologic cancer with cisplatin and etoposide                                                                                                      | GOSCPE         | I     |       |
|                    |             |                  | treatment of small-cell gynecologic cancer with cisplatin and etoposide with radiation therapy                                                                               | GOSCPERT       | I     |       |
|                    |             | Genitourinary    | adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine                                                                                                    | GUAJPG         | I     |       |
|                    |             |                  | palliative therapy for urothelial carcinoma using cisplatin and gemcitabine                                                                                                  | GUAVPG         | I     |       |
|                    |             |                  | Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin                                                             | GUBDDMVAC      | I     |       |
|                    |             |                  | curative therapy for germ cell cancer using bleomycin, etoposide and cisplatin                                                                                               | GUBEP          | I     |       |
|                    |             |                  | treatment of locally advanced bladder cancer with weekly cisplatin and concurrent radiation                                                                                  | GUBPWRT        | I     |       |
|                    |             |                  | treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane                                                                           | GUEDPM         | I     |       |
|                    |             |                  | therapy for nonseminoma germ cell cancer using etoposide-cisplatin                                                                                                           | GUEP           | I     |       |
|                    |             |                  | combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation                                               | GUFUPRT        | I     |       |
|                    |             |                  | therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin                                                           | GUMVAC         | I     |       |
|                    |             |                  | neo-adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine                                                                                                | GUNAJPG        | I     |       |
|                    |             | Head and Neck    | therapy of genitourinary small cell tumors with a platin and etoposide                                                                                                       | GUSCPE         | I     |       |
|                    |             |                  | Therapy of Genitourinary Small Cell Tumors with a Platinum and Etoposide with Radiation                                                                                      | GUSCPERT       | I     |       |
|                    |             |                  | advanced therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin                                                                         | GUTIP          | I     |       |
|                    |             |                  | consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna                                                                     | GUVEIP         | I     |       |
|                    |             |                  | nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna                                                                                     | GUVIP2         | I     |       |
|                    |             |                  | treatment of advanced squamous cell carcinoma of the head and neck cancer using fluorouracil and platinum                                                                    | HNAVFUP        | I     |       |
|                    |             |                  | palliative chemotherapy for advanced head and neck squamous cell carcinoma with weekly cisplatin                                                                             | HNAVP          | I     |       |
|                    |             |                  | treatment for unresectable, locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin                | HNAVPC         | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG               | DOSAGE FORM | TUMOUR SITE   | APPROVED INDICATIONS                                                                                                                | PROTOCOL CODES | CLASS | NOTES |
|--------------------|-------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| cisplatin (cont'd) | injectable  | Head and Neck | treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with platinum and docetaxel                       | HNAVPD         | I     |       |
|                    |             |               | treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide                                              | HNAVPE         | I     |       |
|                    |             |               | First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab        | HNAVPFPMB      | I     |       |
|                    |             |               | treatment of locally advanced (alternate) head and neck cancer using cisplatin during radiation therapy                             | HNLAALTPRT     | I     |       |
|                    |             |               | treatment of locally advanced squamous cell carcinoma of the head and neck with docetaxel, cisplatin and infusional fluorouracil    | HNLADCF        | I     |       |
|                    |             |               | combined chemotherapy (cisplatin) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck         | HNLPART        | I     |       |
|                    |             |               | treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil                                   | HNNAVFUP       | I     |       |
|                    |             |               | palliative chemotherapy for advanced head and neck nasopharyngeal carcinoma with weekly cisplatin                                   | HNNAVP         | I     |       |
|                    |             |               | treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide                                          | HNNAVPE        | I     |       |
|                    |             |               | treatment of locoregionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine                         | HNNAVPG        | I     |       |
|                    |             |               | induction treatment of locally advanced nasopharyngeal cancer with cisplatin and gemcitabine                                        | HNNLAPG        | I     |       |
|                    |             |               | treatment of locally advanced nasopharyngeal cancer with concurrent cisplatin and radiation                                         | HNNLAPRT       | I     |       |
|                    |             |               | treatment of advanced head and neck cancer using cisplatin and fluorouracil                                                         | HNSAVFUP       | I     |       |
|                    |             |               | treatment of advanced salivary gland cancers with cisplatin and vinorelbine                                                         | HNSAVNP        | I     |       |
|                    |             |               | treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide                                        | HNSAVPAC       | I     |       |
|                    |             | Lung          | Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum                            | LUAJNIVPP      | I     |       |
|                    |             |               | adjuvant cisplatin and vinorelbine following resection of non-small cell lung cancer                                                | LUAJNP         | I     |       |
|                    |             |               | Adjuvant Cisplatin and Pemetrexed Following Resection of Non-Small Cell Lung Cancer                                                 | LUAJPP         | I     |       |
|                    |             |               | first-line treatment of advanced non-small cell lung cancer with cisplatin and docetaxel                                            | LUAVDC         | I     |       |
|                    |             |               | treatment for advanced non-small cell lung cancer with cisplatin and vinorelbine                                                    | LUAVNP         | I     |       |
|                    |             |               | treatment of advanced non-small cell lung cancer with platinum and gemcitabine                                                      | LUAVPG         | I     |       |
|                    |             |               | first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab                   | LUAVPGPMB      | I     |       |
|                    |             |               | first-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed                                            | LUAVPP         | I     |       |
|                    |             |               | First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab        | LUAVPIPNI      | I     |       |
|                    |             |               | treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation therapy                       | LULAPERT       | I     |       |
|                    |             |               | treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy | LULAPE2RT      | I     |       |
|                    |             |               | treatment of malignant mesothelioma with platinum and gemcitabine                                                                   | LUMMPG         | I     |       |
|                    |             |               | treatment of malignant mesothelioma with platinum and pemetrexed                                                                    | LUMMPP         | I     |       |
|                    |             |               | treatment of thymoma with platinum, doxorubicin and cyclophosphamide                                                                | LUOTPAC        | I     |       |
|                    |             |               | treatment of thymoma with cisplatin and etoposide                                                                                   | LUOTPE         | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG               | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                  | PROTOCOL CODES                                        | CLASS | NOTES                            |
|--------------------|-------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|----------------------------------|
| cisplatin (cont'd) | injectable  | Lung                    | treatment of thymoma using cisplatin and etoposide with radiation therapy                                                                                                                                             | LUOTPERT                                              | I     |                                  |
|                    |             |                         | treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide                                                                                                                              | LUPUPE                                                | I     |                                  |
|                    |             |                         | Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide                                                                                                                  | LUSCATPE                                              | I     |                                  |
|                    |             |                         | Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide                                                                                                                    | LUSCDURPE                                             | I     |                                  |
|                    |             |                         | Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide                                                                                                                                | LUSCPE                                                | I     |                                  |
|                    |             |                         | Treatment of Extensive Stage Small Cell Lung Cancer with Platinum and Oral Etoposide                                                                                                                                  | LUSCPEPO                                              | I     |                                  |
|                    |             |                         | Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy                                                                                                            | LUSCPEPORT                                            | I     |                                  |
|                    |             |                         | Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide with Radiation Therapy                                                                                                                 | LUSCPERT                                              | I     |                                  |
|                    |             |                         | second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum                                                                                                       | LUSCPI                                                | I     |                                  |
|                    |             | Lymphoma                | Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXimab                                                                                                                                          | LYDHAPR                                               | I     |                                  |
|                    |             |                         | treatment of lymphoma with gemcitabine, dexamethasone and platinum                                                                                                                                                    | LYGDP                                                 | I     |                                  |
|                    |             |                         | Treatment of ritUXimab-refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and oBINutuzumab                                                                                                      | LYGDPO                                                | I     |                                  |
|                    |             |                         | treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab                                                                                                                                     | LYGDPR                                                | I     |                                  |
|                    |             | Sarcoma                 | Treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone | LYVIPDRT                                              | I     |                                  |
|                    |             |                         | adjuvant therapy for osteosarcoma using doxorubicin and cisplatin                                                                                                                                                     | SAAJAP                                                | I     |                                  |
|                    |             |                         | therapy of advanced osteosarcoma using doxorubicin and cisplatin                                                                                                                                                      | SAAVAP                                                | I     |                                  |
|                    |             |                         | hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal desmoplastic small round cell tumour (DSRCT)                                                                                           | SAHIPEC                                               | I     |                                  |
|                    |             | Skin & Melanoma         | treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide                                                                                                                               | SMMCCPE                                               | I     |                                  |
|                    |             | Not Otherwise Specified |                                                                                                                                                                                                                       | Other tumour site code followed by 'NOS' (e.g.        | I     |                                  |
| cladribine         | injectable  | Lymphoma                | hairy cell leukemia                                                                                                                                                                                                   | LYCDA                                                 | I     |                                  |
|                    |             | Pediatric               | salvage treatment of pediatric patients with Langerhans cell histiocytosis (LCH) who are risk organ positive (RO+) or with chronic reactivating disease                                                               |                                                       | I     |                                  |
| clodronate         | capsule     | Breast                  | bony metastases associated with breast cancer or acute bone pain secondary to metastatic breast cancer                                                                                                                | BRAVCLOD                                              | I     | Not reimbursed for hypercalcemia |
| cobimetinib        | tablet      | Skin & Melanoma         | treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib and cobimetinib                                                                                                        | SMAVVC                                                | I     |                                  |
| cortisone          | tablet      | Genitourinary           | treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane                                                                                                                    | GUEDPM                                                | I     |                                  |
|                    |             |                         | treatment of adrenal cortical cancer using mitotane                                                                                                                                                                   | GUMITO                                                | I     |                                  |
|                    |             | Not Otherwise Specified |                                                                                                                                                                                                                       | Other tumour site code followed by 'NOS' (e.g. GUNOS) | I     |                                  |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                               | DOSAGE FORM        | TUMOUR SITE              | APPROVED INDICATIONS                                                                                                                                                                                | PROTOCOL CODES | CLASS | NOTES |
|------------------------------------|--------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| crisantaspase recombinant (RYLAZE) | injectable         | Leukemia & BMT, Lymphoma | Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Adult Patients Allergic to Asparaginase (KIDROLASE) or Pegaspargase (ONCASPAR) using Crisantaspase Recombinant (RYLAZE)     | LKNOS, LYNOS   | I     |       |
|                                    |                    | Pediatric                | Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in Pediatric Patients Allergic to Asparaginase (KIDROLASE) or Pegaspargase (ONCASPAR) using Crisantaspase Recombinant (RYLAZE) |                | I     |       |
|                                    |                    |                          | Treatment of Children with Low-Risk Acute Myeloid Leukemia Who Require Short-Acting Asparaginase per COG AAML 1831 Study using Crisantaspase Recombinant (RYLAZE)                                   |                | I     |       |
| crizotinib                         | tablet             | Lung                     | second-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with crizotinib                                                                                                   | LUAVCRIZ       | I     |       |
|                                    |                    |                          | first-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with crizotinib                                                                                                    | LUAVCRIZF      | I     |       |
|                                    |                    |                          | first-line treatment of ROS1-positive advanced non-small cell lung cancer with crizotinib                                                                                                           | LUAVCRIZR      | I     |       |
| cyclophosphamide                   | tablet, injectable | Leukemia & BMT           | myeloablative conditioning therapy prior to autologous and allogeneic hematopoietic stem cell transplantation for myeloid malignancies using IV busulfan and cyclophosphamide                       | BMTIVBUCY      | I     |       |
|                                    |                    | Breast                   | adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide                                                                                                                           | BRAJAC         | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel                                                                                     | BRAJACT        | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel                                                                 | BRAJACTG       | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab                                                                     | BRAJACTT       | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab                                                 | BRAJACTTG      | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel                                                                        | BRAJACTW       | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and docetaxel                                                                                                 | BRAJDAC        | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for breast cancer using docetaxel and cyclophosphamide                                                                                                              | BRAJDC         | I     |       |
|                                    |                    |                          | adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide                                                                                                              | BRAJFEC        | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel                                                                                 | BRAJFECD       | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab                                                         | BRAJFECDT      | I     |       |
|                                    |                    |                          | neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel and cyclophosphamide                                                                                                 | BRAJTDC        | I     |       |
|                                    |                    |                          | palliative therapy for metastatic breast cancer using doxorubicin and cyclophosphamide                                                                                                              | BRAVAC         | I     |       |
|                                    |                    |                          | palliative therapy for advanced breast cancer using cyclophosphamide, methotrexate and fluorouracil                                                                                                 | BRAVCMF        | I     |       |
|                                    |                    |                          | palliative therapy for metastatic breast cancer using metronomic low-dose oral cyclophosphamide and methotrexate                                                                                    | BRAVCMPO       | I     |       |
|                                    |                    |                          | treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel                                                                                            | BRLAACD        | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                      | DOSAGE FORM        | TUMOUR SITE   | APPROVED INDICATIONS                                                                                                                                                               | PROTOCOL CODES | CLASS | NOTES |
|---------------------------|--------------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| cyclophosphamide (cont'd) | tablet, injectable | Breast        | treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab                                                           | BRLAACDT       | I     |       |
|                           |                    |               | Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide                     | BRLACPNAC      | I     |       |
|                           |                    |               | Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide | BRLACPNACG     | I     |       |
|                           |                    |               | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide                                         | BRLACTWAC      | I     |       |
|                           |                    |               | Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide                     | BRLACTWACG     | I     |       |
|                           |                    |               | Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide                                    | BRLAPNAC       | I     |       |
|                           |                    |               | Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide                                 | BRLAPNACG      | I     |       |
|                           |                    |               | neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel followed by doxorubicin and cyclophosphamide                                                            | BRLATACG       | I     |       |
|                           |                    |               | treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel                                                                   | BRLATWAC       | I     |       |
|                           |                    |               | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide                     | BRPCTAC        | I     |       |
|                           |                    |               | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide                  | BRPCWTAC       | I     |       |
|                           |                    | Gynecology    | palliative therapy for relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using metronomic low-dose oral cyclophosphamide                    | GOOVCYCPO      | I     |       |
|                           |                    |               | therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine           | GOTDEMACO      | I     |       |
|                           |                    | Head and Neck | palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil                                                                        | HNSAVFAC       | I     |       |
|                           |                    |               | treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide                                                                                       | HNSAVPAC       | I     |       |
|                           |                    | Lung          | treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine                                                                                           | LUOTCAV        | I     |       |
|                           |                    |               | treatment of thymoma with platinum, doxorubicin and cyclophosphamide                                                                                                               | LUOTPAC        | I     |       |
|                           |                    | Lymphoma      | treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine                                                                                   | LUSCCAV        | I     |       |
|                           |                    |               | treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone                                                                                               | LYCHOP         | I     |       |
|                           |                    |               | Treatment of ritUXImab-refractory Follicular Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRiStine, predniSONE, and oBINutuzumab                                                | LYCHOPO        | I     |       |
|                           |                    |               | treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab                                                                                    | LYCHOPR        | I     |       |
|                           |                    |               | treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin                                          | LYCHPBV        | I     |       |
|                           |                    |               | treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab                                                                   | LYCLLCVPR      | I     |       |



**BC Cancer Benefit Drug List  
May 2025**

| DRUG                      | DOSAGE FORM        | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                                 | PROTOCOL CODES                                        | CLASS | NOTES |
|---------------------------|--------------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-------|
| cyclophosphamide (cont'd) | tablet, injectable | Lymphoma                | treatment of Burkitt's Lymphoma and Leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab                                                                                                 | LYCODOXMR                                             | I     |       |
|                           |                    |                         | advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone                                                                                                                                                        | LYCVP                                                 | I     |       |
|                           |                    |                         | Treatment of nTUXImab-refractory Follicular Lymphoma with Cyclophosphamide, vinCRISine, predniSONE and oBINutuzumab                                                                                                                  | LYCVPO                                                | I     |       |
|                           |                    |                         | treatment of Hodgkin's disease with cyclophosphamide, vinblastine, procarbazine and prednisone                                                                                                                                       | LYCVPPABO                                             | I     |       |
|                           |                    |                         | treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab                                                                                                                                | LYCVPR                                                | I     |       |
|                           |                    |                         | therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia or multiple myeloma using cyclophosphamide                                                                                                                      | LYCYCLO                                               | I     |       |
|                           |                    |                         | Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone                                                                | LYDARCBD                                              | I     |       |
|                           |                    |                         | treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate                                                                               | LYEPOCHR                                              | I     |       |
|                           |                    |                         | treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab                                                                                                          | LYFCR                                                 | I     |       |
|                           |                    |                         | lymphoma palliative chemotherapy                                                                                                                                                                                                     | LYPALL                                                | I     |       |
|                           |                    | Myeloma                 | Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant                                                                                                 | MYBORPRE                                              | I     |       |
|                           |                    |                         | Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide                                                                                                                              | MYBORREL                                              | I     |       |
|                           |                    |                         | Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide                                                                                                                        | MYBSD                                                 | I     |       |
|                           |                    |                         | Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide                                                                                                                                     | MYCARDEX                                              | I     |       |
|                           |                    |                         | treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide                                                                             | MYDARBD                                               | I     |       |
|                           |                    |                         | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone                                                                       | MYDARCBD                                              | I     |       |
|                           |                    |                         | Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide                                                                                                                         | UMYISACARD                                            | R     |       |
|                           |                    |                         | Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide                                                                                                                        | UMYISAPOMD                                            | R     |       |
|                           |                    |                         | treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan                                                                                       | MYMPBOR                                               | I     |       |
|                           |                    |                         | single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant                                                                                                                           | MYHDC                                                 | I     |       |
|                           |                    | Pediatric               | treatment of recurrent/refractory rhabdomyosarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol                                                                            |                                                       | I     |       |
|                           |                    |                         | <b>Brentuximab Vedotin in Combination with Doxorubicin, Vincristine, Etoposide and Cyclophosphamide for First Line High Risk Pediatric Hodgkin's Lymphoma</b>                                                                        |                                                       | I     |       |
|                           |                    | Sarcoma                 | SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma   | SAALT2W                                               | I     |       |
|                           |                    |                         | SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma | SAALT3W                                               | I     |       |
|                           |                    |                         | summary for treatment of recurrent/refractory neuroblastoma, ewing's sarcoma, osteogenic sarcoma or rhabdomyosarcoma with topotecan/cyclophosphamide                                                                                 | SAAVTC                                                | I     |       |
|                           |                    |                         | treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide                                                                                                                                                             | SAVAC                                                 | I     |       |
|                           |                    |                         | Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna                                                                                             | SAVACM                                                | I     |       |
|                           |                    |                         | Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide                                                                                                                                           | SAVDC                                                 | I     |       |
|                           |                    | Not Otherwise Specified |                                                                                                                                                                                                                                      | Other tumour site code followed by 'NOS' (e.g. BRNOS) | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG         | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                        | PROTOCOL CODES                                         | CLASS | NOTES |
|--------------|-------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|-------|-------|
| cyclosporine | capsule     | Lymphoma                | cytopenias associated with lymphoproliferative disorder of large granular lymphocytes                                                                                       | LYCSPA                                                 | I     |       |
|              |             |                         | treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cyclosporine                                                                              | HLHETCSPA                                              | I     |       |
| cytarabine   | injectable  | Leukemia & BMT          | therapy of acute myeloid leukemia using low dose cytarabine                                                                                                                 | LKAMLCYT                                               | I     |       |
|              |             |                         | Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy                                                               | LKGEMOZ                                                | I     |       |
|              |             | Lymphoma                | treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab                                        | LYCODOXMR                                              | I     |       |
|              |             |                         | Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXimab                                                                                                | LYDHAPR                                                | I     |       |
|              |             |                         | treatment of lymphoma using intrathecal methotrexate and cytarabine                                                                                                         | LYIT                                                   | I     |       |
|              |             |                         | treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab                                                                    | LYIVACR                                                | I     |       |
|              |             | Miscellaneous Origins   | therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine                                                                                  | MOIT                                                   | I     |       |
|              |             | Not Otherwise Specified |                                                                                                                                                                             | Other tumour site code followed by 'NOS' (e.g. LYNNOS) | I     |       |
| dabrafenib   | capsule     | Skin & Melanoma         | adjuvant treatment of stage III and IV, BRAF-mutated, fully resected melanoma using dabrafenib and trametinib                                                               | SMAJDT                                                 | I     |       |
|              |             |                         | treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib                                                                               | SMAVDAB                                                | I     |       |
|              |             |                         | treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib and trametinib                                                                | SMAVDT                                                 | I     |       |
| dacarbazine  | injectable  | Lymphoma                | treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine                                                                                     | LYABVD                                                 | I     |       |
|              |             |                         | <a href="#">Treatment of Previously Untreated, Stage III or IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin</a>                      | LYAVDBV                                                | I     |       |
|              |             |                         | Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients 60 Years or Older | LYBVAVDVBV                                             | I     |       |
|              |             |                         | adjuvant treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine                                                                                   | SAAJADIC                                               | I     |       |
|              |             | Sarcoma                 | treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine                                                                                            | SAAVADIC                                               | I     |       |
|              |             |                         | high dose single agent dacarbazine for metastatic soft tissue sarcoma                                                                                                       | SADTIC                                                 | I     |       |
|              |             |                         | therapy for metastatic malignant melanoma using high dose single agent dacarbazine                                                                                          | SMDTIC                                                 | I     |       |
|              |             | Not Otherwise Specified |                                                                                                                                                                             | Other tumour site code followed by 'NOS' (e.g. SMNOS)  | I     |       |
| dactinomycin | injectable  | Gynecology              | therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine    | GOTDEMACO                                              | I     |       |
|              |             |                         | Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate                                                                          | GOTDMR (previously GOTDLR)                             | I     |       |
|              |             | Gynecology              | Therapy for Low-Risk Gestational Trophoblastic Cancer using Dactinomycin                                                                                                    | GOTDLRA                                                | I     |       |
|              |             | Sarcoma                 | Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide                                                                                  | SAVDC                                                  | I     |       |
|              |             | Not Otherwise Specified |                                                                                                                                                                             | Other tumour site code followed by 'NOS' (e.g. SANOS)  | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                                                  | DOSAGE FORM        | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                  | PROTOCOL CODES                                        | CLASS | NOTES                                                                                                              |
|-------------------------------------------------------|--------------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------|
| daratumumab                                           | SC injectable only | Lymphoma                | Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone | LYDARCBDF                                             | I     |                                                                                                                    |
|                                                       | IV/SC injectable   | Myeloma                 | Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide              | MYDARBD                                               | I     |                                                                                                                    |
|                                                       | IV/SC injectable   |                         | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone        | MYDARCBDF                                             | I     |                                                                                                                    |
|                                                       | IV/SC injectable   |                         | Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone                                             | MYDARLD                                               | I     |                                                                                                                    |
|                                                       | IV/SC injectable   |                         | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone                        | MYDARLDF                                              | I     |                                                                                                                    |
| darolutamide                                          | tablet             | Genitourinary           | Treatment of Metastatic Castration Sensitive Prostate Cancer using Darolutamide and Docetaxel                                                                         | UGUMCSPDD                                             | R     |                                                                                                                    |
|                                                       |                    |                         | Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using Darolutamide                                                                                   | UGUNMPDAR                                             | R     |                                                                                                                    |
| dasatinib                                             | tablet             | Leukemia & BMT          | treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia                                                                                            | LKCMDL                                                | I     |                                                                                                                    |
| daunorubicin                                          | injectable         | Leukemia & BMT          | first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin                                     | LKATOP                                                | I     |                                                                                                                    |
|                                                       |                    |                         | Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy                                                         | LKGEMOZ                                               | I     |                                                                                                                    |
|                                                       |                    | Not Otherwise Specified |                                                                                                                                                                       | Other tumour site code followed by 'NOS' (e.g. KSNOS) | I     |                                                                                                                    |
| daunorubicin liposomal-cytarabine liposomal (Vyxeos®) | injectable         | Leukemia & BMT          | Therapy of Acute Myeloid Leukemia using Daunorubicin Liposomal-Cytarabine Liposomal                                                                                   | LKAMLDCYT                                             | I     |                                                                                                                    |
| decitabine-cedazuridine                               | tablet             | Leukemia & BMT          | Therapy of Myelodysplastic Syndrome using Decitabine-Cedazuridine                                                                                                     | ULKMDSDC                                              | R     |                                                                                                                    |
| denosumab (XGEVA, WYOST)                              | injectable         | Sarcoma                 | neoadjuvant use in patients with non-metastatic operable giant cell tumour of the bone                                                                                | SANADENO                                              | I     | Not reimbursed for hypercalcemia                                                                                   |
| dexamethasone                                         | tablet             | Genitourinary           | Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone                                                                          | GUMCSPABI                                             | I     | Not reimbursed for:<br>anti-emetic treatment, steroid replacement therapy, pre-taxane use, or appetite stimulation |
|                                                       |                    |                         | Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and prednisone                                                               | UGUPABI                                               | R     |                                                                                                                    |
|                                                       |                    |                         | Treatment for Metastatic Castration-Resistant Prostate Cancer using Olaparib with Abiraterone and prednisone                                                          | UGUPAVOABI                                            | R     |                                                                                                                    |
|                                                       |                    |                         | palliative therapy for metastatic hormone refractory prostate cancer                                                                                                  | GUPDOC                                                | I     |                                                                                                                    |
|                                                       |                    |                         | treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cyclosporine                                                                        | HLHETCSA                                              | I     |                                                                                                                    |
|                                                       |                    | Lymphoma                | treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone                                  | LYASPMEDX                                             | I     |                                                                                                                    |
|                                                       |                    |                         | Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone | LYDARCBDF                                             | I     |                                                                                                                    |
|                                                       |                    |                         | treatment of lymphoma with gemcitabine, dexamethasone and platinum                                                                                                    | LYGDP                                                 | I     |                                                                                                                    |
|                                                       |                    |                         | Treatment of rituximab-refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and obinutuzumab                                                      | LYGDPO                                                | I     |                                                                                                                    |
|                                                       |                    |                         | treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab                                                                                     | LYGDPR                                                | I     |                                                                                                                    |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                   | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                  | PROTOCOL CODES                                            | CLASS | NOTES                                                                                                                    |
|------------------------|-------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------|
| dexamethasone (cont'd) | tablet      | Lymphoma                | Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXImab                                                                                                                                          | LYDHAPR                                                   | I     | Not reimbursed for:<br>anti-emetic treatment, steroid<br>replacement therapy, pre-taxane use, or<br>appetite stimulation |
|                        |             |                         | lymphoma palliative chemotherapy                                                                                                                                                                                      | LYPALL                                                    | I     |                                                                                                                          |
|                        |             |                         | treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide                                                                                              | LYSMILE                                                   | I     |                                                                                                                          |
|                        |             | Myeloma                 | treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone | LYVIPDRT                                                  | I     |                                                                                                                          |
|                        |             |                         | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone                                                                         | MYBLDF                                                    | I     |                                                                                                                          |
|                        |             |                         | Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant                                                                                                  | MYBLDPRE                                                  | I     |                                                                                                                          |
|                        |             |                         | Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant                                                                                  | MYBORPRE                                                  | I     |                                                                                                                          |
|                        |             |                         | Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide                                                                                                               | MYBORREL                                                  | I     |                                                                                                                          |
|                        |             |                         | Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide                                                                                                         | MYBSD                                                     | I     |                                                                                                                          |
|                        |             |                         | Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide                                                                                                                      | MYCARDEX                                                  | I     |                                                                                                                          |
|                        |             |                         | Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone                                                                                                                                        | MYCARLD                                                   | I     |                                                                                                                          |
|                        |             |                         | treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide                                                              | MYDARBD                                                   | I     |                                                                                                                          |
|                        |             |                         | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone                                                        | MYDARCBD                                                  | I     |                                                                                                                          |
|                        |             |                         | treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone                                                                                             | MYDARLD                                                   | I     |                                                                                                                          |
|                        |             |                         | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone                                                                        | MYDARLDF                                                  | I     |                                                                                                                          |
|                        |             |                         | Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide                                                                                                          | UMYISACARD                                                | R     |                                                                                                                          |
|                        |             |                         | treatment of previously untreated multiple myeloma and not eligible for stem cell transplant using lenalidomide with low-dose dexamethasone                                                                           | UMYLDF                                                    | R     |                                                                                                                          |
|                        |             |                         | therapy of relapsed multiple myeloma using lenalidomide with dexamethasone                                                                                                                                            | MYLDREL                                                   | I     |                                                                                                                          |
|                        |             |                         | treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan                                                                        | MYMPBOR                                                   | I     |                                                                                                                          |
|                        |             |                         | therapy of multiple myeloma using pomalidomide with dexamethasone                                                                                                                                                     | UMYPOMDEX                                                 | R     |                                                                                                                          |
|                        |             | Miscellaneous Origins   | patients with primary or metastatic disease exhibiting cerebral edema or CNS swelling; management of malignant brain tumours; management of CNS lymphoma                                                              | MODEXA                                                    | I     |                                                                                                                          |
|                        |             | Not Otherwise Specified |                                                                                                                                                                                                                       | Other tumour site code followed by 'NOS' (for e.g. CNNOS) | I     |                                                                                                                          |
|                        | injectable  | Not Otherwise Specified |                                                                                                                                                                                                                       | Other tumour site code followed by 'NOS' (e.g. BRNOS)     | I     |                                                                                                                          |
|                        |             | Pediatric               | Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Tretnoin and with or without Idarubicin and Dexamethasone on the COG AAML1331 Study              |                                                           | I     |                                                                                                                          |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG        | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                                                                 | PROTOCOL CODES | CLASS | NOTES |
|-------------|-------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| dexrazoxane | injectable  | Pediatric        | Pediatric patients with acute myeloid leukemia receiving anthracycline on the COG AAML1031 protocol                                                                                                                                  |                | I     |       |
|             |             |                  | Pediatric patients with neuroblastoma treated on the COG AEWS1031 protocol                                                                                                                                                           |                | I     |       |
|             |             |                  | Pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol                                                                                                                                                        |                | I     |       |
|             |             |                  | Dexrazoxane for pediatric patients with anticipated cumulative anthracycline dose >150 mg/m2 or with past or anticipated radiotherapy including the pericardium (including whole-abdomen or left flank irradiation)                  |                | I     |       |
| dinutuximab | injectable  | Pediatric        | treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in combination with sargramostim, aldesleukin and tretinoin                |                | I     |       |
|             |             |                  | dinutuximab in combination with irinotecan, temozolomide and sargramostim for high-risk neuroblastoma in first relapse or determination of refractory disease                                                                        |                | I     |       |
| docetaxel   | injectable  | Breast           | neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and docetaxel                                                                                                                                  | BRAJDAC        | I     |       |
|             |             |                  | neoadjuvant or adjuvant therapy for breast cancer using docetaxel and cyclophosphamide                                                                                                                                               | BRAJDC         | I     |       |
|             |             |                  | neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and trastuzumab                                                                                                                                       | BRAJDCARBT     | I     |       |
|             |             |                  | neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel                                                                                                                  | BRAJFECD       | I     |       |
|             |             |                  | neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab                                                                                          | BRAJFECDT      | I     |       |
|             |             |                  | neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel and cyclophosphamide                                                                                                                                  | BRAJTDC        | I     |       |
|             |             |                  | combination with doxorubicin and cyclophosphamide as treatment of locally advanced breast cancer                                                                                                                                     | BRLAACD        | I     |       |
|             |             |                  | treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab                                                                                                             | BRLAACDT       | I     |       |
|             |             |                  | first, second, or third line treatment of metastatic breast cancer patients with ECOG performance status 0, 1, or 2 and greater than 3 month life expectancy                                                                         | BRAVDOC        | I     |       |
|             |             |                  | weekly docetaxel regimen for metastatic breast cancer patients with poor tolerance to 3-weekly docetaxel regimen (BRAVDOC) or high doses of dexamethasone used in BRAVDOC                                                            | BRAVDOC7       | I     |       |
|             |             |                  | palliative therapy for metastatic breast cancer using gemcitabine and docetaxel                                                                                                                                                      | BRAVGEMD       | I     |       |
|             |             |                  | palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab and docetaxel as first-line treatment for advanced breast cancer                                                                                       | BRAVPTRAD      | I     |       |
|             |             | Gastrointestinal | palliative treatment of metastatic esophagogastric adenocarcinoma with docetaxel                                                                                                                                                     | GIAVDOC        | I     |       |
|             |             |                  | perioperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin                                          | GIGFLODOC      | I     |       |
|             |             | Gynecology       | combination with carboplatin as primary treatment of advanced/recurrent non-small cell cancer of the cervix in ambulatory care settings                                                                                              | GOCXCAD        | I     |       |
|             |             |                  | treatment of primarily advanced or recurrent endometrial cancer using carboplatin and docetaxel                                                                                                                                      | GOENDCAD       | I     |       |
|             |             |                  | primary treatment with visible or no visible residual tumour (moderate, high, or extreme risk) or treatment at relapse of invasive epithelial ovarian, fallopian tube, and primary peritoneal cancer using carboplatin and docetaxel | GOOVCAD        | I     |       |
|             |             |                  | treatment of progressive, platinum-refractory epithelial ovarian carcinoma, primary peritoneal                                                                                                                                       | GOOVDOC        | I     |       |
|             |             |                  | combination with gemcitabine for advanced or recurrent uterine sarcoma cancer                                                                                                                                                        | GOSADG         | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG               | DOSAGE FORM | TUMOUR SITE   | APPROVED INDICATIONS                                                                                                                                                                                                | PROTOCOL CODES | CLASS | NOTES |
|--------------------|-------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| docetaxel (cont'd) | injectable  | Genitourinary | Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Gemcitabine and Docetaxel                                                                                                                         | GUBGEMDOC      | I     |       |
|                    |             |               | Treatment of Metastatic Castration Sensitive Prostate Cancer using Darolutamide and Docetaxel                                                                                                                       | UGUMCSPDD      | R     |       |
|                    |             |               | intravesical use for bladder cancer if BCG and mitomycin C not available                                                                                                                                            | GUNOS          | I     |       |
|                    |             |               | palliative therapy for metastatic hormone refractory prostate cancer                                                                                                                                                | GUPDOC         | I     |       |
|                    |             | Head and Neck | first-line treatment of castration sensitive, metastatic prostate cancer using docetaxel and androgen deprivation therapy with LHRH agonist or LHRH antagonist with or without antiandrogen, or surgical castration | GUPDOCADT      | I     |       |
|                    |             |               | treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with docetaxel                                                                                                                    | HNAVDOC        | I     |       |
|                    |             |               | treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with platinum and docetaxel                                                                                                       | HNAVPD         | I     |       |
|                    |             |               | treatment of locally advanced squamous cell carcinoma of the head and neck with docetaxel, cisplatin and infusional fluorouracil                                                                                    | HNLACF         | I     |       |
|                    |             | Lung          | combination with cisplatin as first line treatment of advanced non-small lung cancer                                                                                                                                | LUAVDC         | I     |       |
|                    |             |               | second-line treatment of non-small cell lung cancer                                                                                                                                                                 | LUAVDOC        | I     |       |
|                    |             | Sarcoma       | combination with gemcitabine as second or third line therapy for soft tissue sarcomas                                                                                                                               | SAAVGEMD       | I     |       |
| dostarlimab        | injectable  | Gynecology    | Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel                                                                      | UGOEAVDCAT     | R     |       |
| dostarlimab        | injectable  | Gynecology    | Alternative Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin                                                      | UGOEAVDPNC     | R     |       |
| doxorubicin        | injectable  | Breast        | adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide                                                                                                                                           | BRAJAC         | I     |       |
|                    |             |               | neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel                                                                                                     | BRAJACT        | I     |       |
|                    |             |               | neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel                                                                                 | BRAJACTG       | I     |       |
|                    |             |               | neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab                                                                                     | BRAJACTT       | I     |       |
|                    |             |               | neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab                                                                 | BRAJACTTG      | I     |       |
|                    |             |               | neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel                                                                                        | BRAJACTW       | I     |       |
|                    |             |               | neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide, doxorubicin and docetaxel                                                                                                                 | BRAJDAC        | I     |       |
|                    |             |               | palliative therapy for metastatic breast cancer using weekly doxorubicin                                                                                                                                            | BRAVA7         | I     |       |
|                    |             |               | palliative therapy for metastatic breast cancer using doxorubicin and cyclophosphamide                                                                                                                              | BRAVAC         | I     |       |
|                    |             |               | treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel                                                                                                            | BRLAACD        | I     |       |
|                    |             |               | treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab                                                                                            | BRLAACDT       | I     |       |
|                    |             |               | Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide                                                      | BRLACPNAC      | I     |       |
|                    |             |               | Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide                                  | BRLACPNACG     | I     |       |
|                    |             |               | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide                                                                          | BRLACTWAC      | I     |       |
|                    |             |               | Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide                                                      | BRLACTWACG     | I     |       |
|                    |             |               | Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide                                                                     | BRLAPNAC       | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                 | DOSAGE FORM | TUMOUR SITE   | APPROVED INDICATIONS                                                                                                                                                        | PROTOCOL CODES | CLASS | NOTES                                                                                              |
|----------------------|-------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|----------------------------------------------------------------------------------------------------|
| doxorubicin (cont'd) | injectable  | Breast        | Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PAClitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide                          | BRLAPNACG      | I     |                                                                                                    |
|                      |             |               | neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel followed by doxorubicin and cyclophosphamide                                                     | BRLATACG       | I     |                                                                                                    |
|                      |             |               | treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel                                                            | BRLATWAC       | I     |                                                                                                    |
|                      |             |               | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide              | BRPCTAC        | I     |                                                                                                    |
|                      |             |               | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide           | BRPCWTAC       | I     |                                                                                                    |
|                      |             |               | transarterial chemoembolization (TACE) of hepatocellular carcinoma using drug-eluting bead (DEB) loaded with doxorubicin                                                    | GIDEBTACE      | I     |                                                                                                    |
|                      |             |               | hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis                                                                                       | GIEMBOL        | I     | Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital |
|                      |             |               | palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin                                                                                      | GIENDO2        | I     |                                                                                                    |
|                      |             |               | hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel                                     | GIPMHIPEC      | I     |                                                                                                    |
|                      |             | Genitourinary | palliative therapy for advanced adrenal cortical cancer using doxorubicin                                                                                                   | GUAVD          | I     |                                                                                                    |
|                      |             |               | Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin                                                            | GUBDDMVAC      | I     | Not reimbursed for bladder instillations                                                           |
|                      |             |               | treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane                                                                          | GUEDPM         | I     |                                                                                                    |
|                      |             |               | therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin                                                          | GUMVAC         | I     |                                                                                                    |
|                      |             |               |                                                                                                                                                                             |                |       |                                                                                                    |
|                      |             | Gynecology    | for use in patients with advanced endometrial cancer                                                                                                                        | GOENDD         | I     |                                                                                                    |
|                      |             |               | for use in patients with advanced uterine sarcoma                                                                                                                           | GOSAD          | I     |                                                                                                    |
|                      |             | Head and Neck | palliative therapy for advanced thyroid cancers using doxorubicin                                                                                                           | HNOTAVD        | I     |                                                                                                    |
|                      |             |               | palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil                                                                 | HNSAVFAC       | I     |                                                                                                    |
|                      |             | Lung          | treatment of advanced salivary gland cancers with platinum, doxorubicin and cyclophosphamide                                                                                | HNSAVPAC       | I     |                                                                                                    |
|                      |             |               | treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine                                                                                    | LUOTCAV        | I     |                                                                                                    |
|                      |             |               | treatment of thymoma with platinum, doxorubicin, and cyclophosphamide                                                                                                       | LUOTPAC        | I     |                                                                                                    |
|                      |             |               | treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine                                                                            | LUSCCAV        | I     |                                                                                                    |
|                      |             | Lymphoma      | treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine                                                                                     | LYABVD         | I     |                                                                                                    |
|                      |             |               | Treatment of Previously Untreated, Stage III or IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin                                      | LYAVDBV        | I     |                                                                                                    |
|                      |             |               | Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin, vinBLASTine and Dacarbazine in Patients 60 Years or Older | LYBVAVDBV      | I     |                                                                                                    |
|                      |             |               | treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone                                                                                        | LYCHOP         | I     |                                                                                                    |
|                      |             |               | Treatment of rITUXimab-refractory Follicular Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISTine, predniSONE, and oBINutuzumab                                         | LYCHOPO        | I     |                                                                                                    |
|                      |             |               | treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab                                                                             | LYCHOPR        | I     |                                                                                                    |
|                      |             |               |                                                                                                                                                                             |                |       |                                                                                                    |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                                                                      | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                                 | PROTOCOL CODES                                        | CLASS | NOTES                                    |
|---------------------------------------------------------------------------|-------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|------------------------------------------|
| doxorubicin (cont'd)                                                      | injectable  | Lymphoma                | central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma                                                                                                                  | LYCHOPRMTX                                            | I     |                                          |
|                                                                           |             |                         | treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin                                                                                            | LYCHPBV                                               | I     |                                          |
|                                                                           |             |                         | treatment of burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab                                                                                                 | LYCODOXMR                                             | I     |                                          |
|                                                                           |             |                         | treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone                                                                                                                                       | LYCVPPABO                                             | I     |                                          |
|                                                                           |             |                         | treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate                                                                               | LYEPOCHR                                              | I     |                                          |
|                                                                           |             |                         | lymphoma palliative chemotherapy                                                                                                                                                                                                     | LYPALL                                                | I     |                                          |
|                                                                           |             | Pediatric               | Brentuximab Vedotin in Combination with Doxorubicin, Vincristine, Etoposide and Cyclophosphamide for First Line High Risk Pediatric Hodgkin's Lymphoma                                                                               |                                                       | I     |                                          |
|                                                                           |             | Sarcoma                 | therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna                                                                                                                                                         | SAAI                                                  | I     |                                          |
|                                                                           |             |                         | 3-day doxorubicin, ifosfamide and mesna for use in patients with advanced soft tissue sarcoma                                                                                                                                        | SAAI3                                                 | I     |                                          |
|                                                                           |             |                         | doxorubicin for adjuvant use for patients with non-metastatic operable large high grade soft tissue sarcoma                                                                                                                          | SAAJA                                                 | I     |                                          |
|                                                                           |             |                         | adjuvant treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine                                                                                                                                            | SAAJADIC                                              | I     |                                          |
|                                                                           |             |                         | adjuvant therapy for osteosarcoma using doxorubicin and cisplatin                                                                                                                                                                    | SAAJAP                                                | I     |                                          |
|                                                                           |             |                         | SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma   | SAALT2W                                               | I     |                                          |
|                                                                           |             |                         | SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma | SAALT3W                                               | I     |                                          |
|                                                                           |             |                         | therapy for advanced soft tissue sarcoma using doxorubicin                                                                                                                                                                           | SAAVA                                                 | I     |                                          |
|                                                                           |             |                         | treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine                                                                                                                                                     | SAAVADIC                                              | I     |                                          |
|                                                                           |             |                         | therapy of advanced osteosarcoma using doxorubicin and cisplatin                                                                                                                                                                     | SAAVAP                                                | I     |                                          |
|                                                                           |             |                         | treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide                                                                                                                                                             | SAVAC                                                 | I     |                                          |
|                                                                           |             |                         | Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna                                                                                             | SAVACM                                                | I     |                                          |
|                                                                           |             | Not Otherwise Specified |                                                                                                                                                                                                                                      | Other tumour site code followed by 'NOS' (e.g. BRNOS) | I     | Not reimbursed for bladder instillations |
| doxorubicin pegylated liposomal                                           | injectable  | Gynecology              | Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and DOXOrubicin Pegylated Liposomal                                                                                                                               | GOOVBEVLD                                             | I     |                                          |
|                                                                           |             |                         | first line treatment of epithelial ovarian cancer using doxorubicin pegylated liposomal and carboplatin                                                                                                                              | GOOVFLDC                                              | I     |                                          |
|                                                                           |             |                         | treatment of epithelial ovarian cancer relapsing after primary treatment using pegylated liposomal doxorubicin                                                                                                                       | GOOVLDOX                                              | I     |                                          |
|                                                                           |             |                         | treatment of epithelial ovarian cancer relapsing after primary treatment using pegylated liposomal doxorubicin and carboplatin                                                                                                       | GOOVPLDC                                              | I     |                                          |
|                                                                           |             | Kaposi's Sarcoma        | Kaposi's sarcoma                                                                                                                                                                                                                     | KSLDO                                                 | I     |                                          |
|                                                                           |             | Lymphoma                | Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and Doxorubicin Pegylated Liposomal                                                                                                               | LYGVLD                                                | I     |                                          |
| drug-eluting bead (DEB) loaded with doxorubicin (DC Bead® or HepaSphere™) | other       | Gastrointestinal        | transarterial chemoembolization (TACE) of hepatocellular carcinoma using drug-eluting bead (DEB) loaded with doxorubicin                                                                                                             | GIDEBTACE                                             | I     |                                          |



**BC Cancer Benefit Drug List  
May 2025**

| DRUG               | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                         | PROTOCOL CODES                                        | CLASS | NOTES |
|--------------------|-------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-------|
| durvalumab         | injectable  | Gastrointestinal        | Treatment of Advanced Biliary Tract Cancer using Durvalumab                                                                                                                  | GIAVDUR4                                              | I     |       |
|                    |             |                         | First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum                                                                  | GIAVDURPG                                             | I     |       |
|                    |             |                         | First-Line Treatment of Advanced Hepatocellular Carcinoma using Tremelimumab and Durvalumab                                                                                  | GITREMDUR                                             | I     |       |
|                    |             | Lung                    | Locally Advanced Non-Small Cell Lung Cancer Using Durvalumab                                                                                                                 | LULADUR                                               | I     |       |
|                    |             |                         | Treatment of Locally Advanced Non-Small Cell Lung Cancer Using 4-Weekly Durvalumab                                                                                           | LULADUR4                                              | I     |       |
|                    |             |                         | Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide                                                                           | LUSCDURPE                                             | I     |       |
| encorafenib        | capsule     | Gastrointestinal        | Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer using Panitumumab and Encorafenib                                                                               | UGIAVPANEN                                            | R     |       |
|                    |             | Skin & Melanoma         | Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Encorafenib and Binimetinib                                                               | SMAVEB                                                | I     |       |
| enfortumab vedotin | injectable  | Genitourinary           | Palliative Therapy for Urothelial Carcinoma using Enfortumab Vedotin                                                                                                         | GUAVEV                                                | I     |       |
| entrectinib        | capsule     | Lung                    | First-Line Treatment of ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Entrectinib                                                                           | LUAVENT                                               | I     |       |
|                    |             | Tumour Agnostic         | Treatment of Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion using Entrectinib                                                                              | UTAAVENT                                              | R     |       |
| enzalutamide       | tablet      | Genitourinary           | Therapy for Metastatic Castration Sensitive Prostate Cancer using Enzalutamide                                                                                               | GUMCSPENZ                                             | I     |       |
|                    |             |                         | Therapy for Non-Metastatic Castration Resistant Prostate Cancer Using Enzalutamide                                                                                           | UGUNMPENZ                                             | R     |       |
|                    |             |                         | Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Enzalutamide                                                                                    | UGUPENZ                                               | R     |       |
| epcoritamab        | injectable  | Lymphoma                | Treatment of Lymphoma using Epcoritamab                                                                                                                                      | ULYEPCOR                                              | R     |       |
| epirubicin         | injectable  | Breast                  | adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide                                                                                       | BRAJFEC                                               | I     |       |
|                    |             |                         | neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel                                                          | BRAJFECD                                              | I     |       |
|                    |             |                         | neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab                                  | BRAJFECDT                                             | I     |       |
|                    |             | Gastrointestinal        | treatment of operable cancer of the stomach, stomach-esophagus junction or lower 1/3 esophagus, given before and after surgery, using epirubicin, cisplatin and capecitabine | GIGECC                                                | I     |       |
|                    |             | Genitourinary           | intravesical use for bladder cancer if BCG and mitomycin C not available                                                                                                     | GUNOS                                                 | I     |       |
|                    |             | Not Otherwise Specified |                                                                                                                                                                              | Other tumour site code followed by 'NOS' (e.g. BRNOS) | I     |       |
| eribulin           | injectable  | Breast                  | Palliative Therapy for Metastatic Breast Cancer using Eribulin                                                                                                               | BRAVERIB                                              | I     |       |
|                    |             | Sarcoma                 | Palliative Therapy for Metastatic Sarcoma using Eribulin                                                                                                                     | SAAVERIB                                              | I     |       |
| erlotinib          | tablet      | Lung                    | second or third line treatment of advanced non-small cell lung cancer                                                                                                        | LUAVERL                                               | I     |       |
|                    |             |                         | maintenance therapy of advanced non-small cell lung cancer after first-line chemotherapy                                                                                     | LUAVMTNE                                              | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG      | DOSAGE FORM         | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                     | PROTOCOL CODES | CLASS | NOTES |
|-----------|---------------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| etoposide | capsule/ injectable | Neuro-Oncology   | carboplatin and etoposide in the treatment of recurrent ependymoma                                                                                                       | CNCARV         | I     |       |
|           |                     |                  | palliative treatment of patients with recurrent malignant gliomas and ependymoma using low dose etoposide                                                                | CNETO          | I     |       |
|           |                     |                  | therapy for recurrent malignant brain tumours using temozolomide and etoposide                                                                                           | CNTMZETO       | I     |       |
|           |                     | Gastrointestinal | palliative therapy of neuroendocrine tumours using cisplatin and etoposide                                                                                               | GIPE           | I     |       |
|           |                     | Gynecology       | therapy of non-dysgerminomatous ovarian germ cell cancer using bleomycin, etoposide and cisplatin                                                                        | GOBEP          | I     |       |
|           |                     |                  | therapy of dysgerminomatous ovarian germ cell cancer using cisplatin and etoposide                                                                                       | GOEP           | I     |       |
|           |                     |                  | treatment of relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using etoposide                                                    | GOOVETO        | I     |       |
|           |                     |                  | treatment of small-cell gynecologic cancer with cisplatin and etoposide                                                                                                  | GOSCPE         | I     |       |
|           |                     |                  | treatment of small-cell gynecologic cancer with cisplatin and etoposide with radiation therapy                                                                           | GOSCPERT       | I     |       |
|           |                     | Genitourinary    | therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine | GOTDEMACO      | I     |       |
|           |                     |                  | curative therapy for germ cell cancer using bleomycin, etoposide and cisplatin                                                                                           | GUBEP          | I     |       |
|           |                     |                  | treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane                                                                       | GUEDPM         | I     |       |
|           |                     |                  | therapy for nonseminoma germ cell cancer using etoposide-cisplatin                                                                                                       | GUEP           | I     |       |
|           |                     |                  | therapy of genitourinary small cell tumours with a platin and etoposide                                                                                                  | GUSCPE         | I     |       |
|           |                     |                  | Therapy of Genitourinary Small Cell Tumors with a Platinum and Etoposide with Radiation                                                                                  | GUSCPERT       | I     |       |
|           |                     |                  | nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna                                                                                 | GUVIP2         | I     |       |
|           |                     |                  | treatment of recurrent and metastatic squamous cell cancer with platinum and etoposide                                                                                   | HNAVPE         | I     |       |
|           |                     | Head and Neck    | treatment of recurrent and/or metastatic nasopharyngeal cancer with platinum and etoposide                                                                               | HNAVPE         | I     |       |
|           |                     | Lung             | treatment of locally advanced non-small cell lung cancer using cisplatin and etoposide with radiation                                                                    | LULAPERT       | I     |       |
|           |                     |                  | treatment of locally advanced non-small cell lung cancer using alternative dosing of cisplatin and etoposide with radiation therapy                                      | LULAPE2RT      | I     |       |
|           |                     |                  | treatment of thymoma with cisplatin and etoposide                                                                                                                        | LUOTPE         | I     |       |
|           |                     |                  | treatment of thymoma using cisplatin and etoposide with radiation therapy                                                                                                | LUOTPERT       | I     |       |
|           |                     |                  | treatment of cancer of unknown primary involving the thorax with cisplatin and etoposide                                                                                 | LUPUPE         | I     |       |
|           |                     |                  | Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Atezolizumab, Platinum and Etoposide                                                                     | LUSCATPE       | I     |       |
|           |                     |                  | Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) with Durvalumab, Platinum and Etoposide                                                                       | LUSCDURPE      | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                      | DOSAGE FORM         | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                                 | PROTOCOL CODES                                        | CLASS | NOTES                                                                             |
|---------------------------|---------------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-----------------------------------------------------------------------------------|
| etoposide (cont'd)        | capsule/ injectable | Lung                    | Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Platinum and Etoposide                                                                                                                                               | LUSCPE                                                | I     |                                                                                   |
|                           | capsule             |                         | Treatment of Extensive Stage Small Cell Lung Cancer with Platinum and Oral Etoposide                                                                                                                                                 | LUSCPEPO                                              | I     |                                                                                   |
|                           | capsule             |                         | Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Oral Etoposide with Radiation Therapy                                                                                                                           | LUSCPEPORT                                            | I     |                                                                                   |
|                           | capsule/ injectable |                         | Treatment of Limited Stage Small Cell Lung Cancer using Platinum and Etoposide with Radiation Therapy                                                                                                                                | LUSCPERT                                              | I     |                                                                                   |
|                           | capsule             |                         | palliative therapy of extensive stage small cell lung cancer with oral etoposide                                                                                                                                                     | LUSCPOE                                               | I     |                                                                                   |
|                           | capsule/ injectable | Lymphoma                | treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE                                                                                                                                       | HLHETCSPA                                             | I     |                                                                                   |
|                           |                     |                         | treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate                                                                               | LYEPOCHR                                              | I     |                                                                                   |
|                           |                     |                         | treatment of burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab                                                                                                                             | LYIVACR                                               | I     |                                                                                   |
|                           |                     |                         | lymphoma palliative chemotherapy                                                                                                                                                                                                     | LYPALL                                                | I     |                                                                                   |
|                           |                     |                         | treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab                                                                                    | LYRICE                                                | I     |                                                                                   |
|                           |                     |                         | treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide                                                                                                             | LYSMILE                                               | I     |                                                                                   |
|                           |                     |                         | treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone                | LYVIPDRT                                              | I     |                                                                                   |
|                           |                     | Pediatric               | Brentuximab Vedotin in Combination with Doxorubicin, Vincristine, Etoposide and Cyclophosphamide for First Line High Risk Pediatric Hodgkin's Lymphoma                                                                               |                                                       | I     |                                                                                   |
|                           |                     | Sarcoma                 | SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma   | SAALT2W                                               | I     |                                                                                   |
|                           |                     |                         | SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma | SAALT3W                                               | I     |                                                                                   |
|                           |                     |                         | 3-Day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas                                                                                                                                           | SAAVIME3                                              | I     |                                                                                   |
|                           |                     |                         | etoposide, ifosfamide-mesna (SAIME) for use in sarcomas                                                                                                                                                                              | SAIME                                                 | I     |                                                                                   |
|                           |                     | Skin & Melanoma         | treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin and etoposide                                                                                                                                              | SMMCCPE                                               | I     |                                                                                   |
|                           |                     | Not Otherwise Specified |                                                                                                                                                                                                                                      | Other tumour site code followed by 'NOS' (e.g. HNNQS) | I     |                                                                                   |
| etoposide phosphate (SAP) | injectable          | Genitourinary           | Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and CISplatin                                                                                                                                                       | GUBEP                                                 | I     | Approval from Health Canada Special Access Programme is required for each patient |
|                           |                     |                         | Etoposide-CISplatin Protocol for Germ Cell Cancers                                                                                                                                                                                   | GUEP                                                  | I     |                                                                                   |
|                           |                     |                         | Consolidation and Salvage Therapy for Nonseminoma Using Etoposide, CISplatin, Ifosfamide, Mesna                                                                                                                                      | GUVIP2                                                | I     |                                                                                   |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                                        | DOSAGE FORM        | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                                                                                                      | PROTOCOL CODES | CLASS | NOTES                                           |
|---------------------------------------------|--------------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------------------------------------------------|
| everolimus                                  | tablet             | Breast           | therapy for advanced breast cancer using everolimus and exemestane                                                                                                                                                                                                        | BRAVEVEX       | I     | Note: AFINITOR® DISPERZ™ formulation not funded |
|                                             |                    | Gastrointestinal | treatment of advanced neuroendocrine tumours of gastrointestinal origin (non-functional) using everolimus                                                                                                                                                                 | UGINETEV       | R     |                                                 |
|                                             |                    |                  | palliative treatment of advanced pancreatic neuroendocrine tumours                                                                                                                                                                                                        | GIPNEVER       | I     |                                                 |
|                                             |                    | Genitourinary    | therapy for advanced renal cancer using everolimus                                                                                                                                                                                                                        | GUEVER         | I     |                                                 |
|                                             |                    |                  | Therapy for Tuberous Sclerosis Complex-Associated High Risk Renal Angiomyolipomas using Everolimus                                                                                                                                                                        | GUOTEVER       | I     |                                                 |
|                                             |                    | Lung             | treatment of advanced neuroendocrine tumours of lung origin (non-functional) using everolimus                                                                                                                                                                             | LUNETEV        | I     |                                                 |
| exemestane                                  | tablet             | Breast           | Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist                                                                                                                                                                | UBRAJABEI      | R     |                                                 |
|                                             |                    |                  | neoadjuvant or adjuvant therapy for breast cancer using exemestane in postmenopausal women                                                                                                                                                                                | BRAJEXE        | I     |                                                 |
|                                             |                    |                  | Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer                                                                                                                             | BRAJLHRHAI     | I     |                                                 |
|                                             |                    |                  | therapy for advanced breast cancer using everolimus and exemestane                                                                                                                                                                                                        | BRAVEVEX       | I     |                                                 |
|                                             |                    |                  | first or second line hormonal treatment for advanced breast cancer in postmenopausal women                                                                                                                                                                                | BRAVEXE        | I     |                                                 |
|                                             |                    |                  | therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor                                                                                                                                                                                        | BRAVLHRHAI     | I     |                                                 |
|                                             |                    | Gynecology       | hormonal treatment for advanced endometrial cancer in postmenopausal women                                                                                                                                                                                                | GOENDAI        | I     |                                                 |
|                                             |                    |                  |                                                                                                                                                                                                                                                                           |                |       |                                                 |
| fedratinib                                  | capsule            | Leukemia & BMT   | Treatment of Symptomatic Myelofibrosis with Fedratinib                                                                                                                                                                                                                    | ULKMFED        | R     |                                                 |
| filgrastim (GRASTIFIL®, NIVESTYM®, NYPOZI®) | injectable         |                  | for inpatient administration only - see BC PharmaCare Special Authority Form for indications covered                                                                                                                                                                      | FILGRASTIM     |       |                                                 |
| fludarabine                                 | injectable/ tablet | Leukemia & BMT   | Fludarabine for patients ineligible for conventional conditioning therapy with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation                                                                                                                       | BMTNOS         | I     |                                                 |
|                                             |                    |                  | Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia or myelodysplastic syndromes at increased risk for standard conditioning therapies | BMTNOS         | I     |                                                 |
|                                             |                    |                  |                                                                                                                                                                                                                                                                           | LKNOS          | I     |                                                 |
|                                             |                    | Lymphoma         | treatment of chronic lymphocytic leukemia or prolymphocytic leukemia with fludarabine and rituximab                                                                                                                                                                       | LYCLLFLUDR     | I     |                                                 |
|                                             |                    |                  | treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab                                                                                                                                               | LYFCR          | I     |                                                 |
|                                             |                    |                  | chronic lymphocytic leukemia or low grade lymphoma                                                                                                                                                                                                                        | LYFLU          | I     |                                                 |
|                                             |                    |                  | treatment of relapsed indolent lymphoma with fludarabine and rituximab                                                                                                                                                                                                    | LYFLUDR        | I     |                                                 |
|                                             |                    |                  |                                                                                                                                                                                                                                                                           | LYNOS          | I     |                                                 |
|                                             |                    |                  |                                                                                                                                                                                                                                                                           |                | I     |                                                 |
|                                             |                    | Pediatric        | pediatric patients with AML treated on the CCG-2961 study                                                                                                                                                                                                                 |                | I     |                                                 |
| fludrocortisone                             | tablet             | Genitourinary    | treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane                                                                                                                                                                        | GUEDPM         | I     |                                                 |
|                                             |                    |                  | mineralocorticoid deficiency associated with mitotane use                                                                                                                                                                                                                 | GUMITO         | I     |                                                 |
| fluorouracil                                | injectable         | Breast           | adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide                                                                                                                                                                                    | BRAJFEC        | I     |                                                 |
|                                             |                    |                  | neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide and docetaxel                                                                                                                                                       | BRAJFECD       | I     |                                                 |
|                                             |                    |                  | neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab                                                                                                                               | BRAJFECDT      | I     |                                                 |
|                                             |                    |                  | palliative therapy for advanced breast cancer using cyclophosphamide, methotrexate and fluorouracil                                                                                                                                                                       | BRAVCMF        | I     |                                                 |
|                                             |                    | Gastrointestinal | adjuvant combination chemotherapy for stage III and stage IIB colon cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin)                                                                                                                                  | GIAJFFOX       | I     |                                                 |
|                                             |                    |                  | adjuvant therapy of colon cancer using fluorouracil injection and infusion and leucovorin infusion                                                                                                                                                                        | GIAJFL         | I     |                                                 |
|                                             |                    |                  | Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Fluorouracil and Leucovorin                                                                                                                                                                    | GIAVFL         | I     |                                                 |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG         | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                                        | PROTOCOL CODES | CLASS | NOTES                                                                                              |
|--------------|-------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|----------------------------------------------------------------------------------------------------|
| fluorouracil | injectable  | Gastrointestinal | combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy                                                                         | GIEFFOXR       | I     | Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital |
|              |             |                  | hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis                                                                                                                       | GIEMBOL        | I     |                                                                                                    |
|              |             |                  | palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin                                                                                                                      | GIENDO2        | I     |                                                                                                    |
|              |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab                                                              | GIFFIRB        | I     |                                                                                                    |
|              |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab                                                                            | GIFFIRPAN      | I     |                                                                                                    |
|              |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab                                                                           | GIFFOXB        | I     |                                                                                                    |
|              |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab                                                                           | GIFFOXPAN      | I     |                                                                                                    |
|              |             |                  | palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)                                                        | GIFIRINOX      | I     |                                                                                                    |
|              |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)                                                                           | GIFOLFIRI      | I     |                                                                                                    |
|              |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin)                                                                          | GIFOLFOX       | I     |                                                                                                    |
|              |             |                  | combined modality curative therapy for carcinoma of the anal canal using mitomycin, fluorouracil and radiation therapy                                                                                      | GIFUART        | I     |                                                                                                    |
|              |             |                  | palliative chemotherapy for upper gastrointestinal tract cancer (gastric, esophageal, gall bladder carcinoma and cholangiocarcinoma) and metastatic anal cancer using infusional fluorouracil and cisplatin | GIFUC          | I     |                                                                                                    |
|              |             |                  | Chemotherapy of Pseudomyxoma Peritonei Using Intraperitoneal Mitomycin and Fluorouracil                                                                                                                     | GIFUIP         | I     |                                                                                                    |
|              |             |                  | combined modality curative therapy for carcinoma of the anal canal using cisplatin, infusional fluorouracil and radiation therapy                                                                           | GIFUPART       | I     |                                                                                                    |
|              |             |                  | adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin                                | GIGAJFFOX      | I     |                                                                                                    |
|              |             |                  | palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab                             | GIGAVCFT       | I     |                                                                                                    |
|              |             |                  | Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin                                            | GIGAVFFOX      | I     |                                                                                                    |
|              |             |                  | First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab                                            | GIGAVFFOXN     | I     |                                                                                                    |
|              |             |                  | First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab                                                                | GIGAVFFOXP     | I     |                                                                                                    |
|              |             |                  | palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab         | GIGAVFFOXT     | I     |                                                                                                    |
|              |             |                  | Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab                                            | GIGAVPFOXT     | I     |                                                                                                    |
|              |             |                  | perioperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin                 | GIGFLODOC      | I     |                                                                                                    |
|              |             |                  | Second or Third Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma or Esophageal Squamous Cell Carcinoma using Irinotecan, Fluorouracil and Leucovorin            | GIGFOLFIRI     | I     |                                                                                                    |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                  | DOSAGE FORM   | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                         | PROTOCOL CODES                                 | CLASS | NOTES                                               |
|-----------------------|---------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|-------|-----------------------------------------------------|
| fluorouracil (cont'd) | injectable    | Gastrointestinal        | hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using oxaliplatin and fluorouracil | GIHIPEC                                        | I     |                                                     |
|                       |               |                         | adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin                                                                      | GIPAJFIROX                                     | I     |                                                     |
|                       |               |                         | Treatment of Metastatic Pancreatic or Biliary Tract Cancer using Irinotecan, Fluorouracil and Leucovorin                                                                                     | GIPAVFFIRI                                     | I     |                                                     |
|                       |               |                         | Palliative Combination Chemotherapy for Metastatic Pancreatic or Biliary Tract Cancer using Oxaliplatin, Fluorouracil, and Leucovorin                                                        | GIPAVFFOX                                      | I     |                                                     |
|                       |               |                         | Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin                                                                  | GIRAJFFOX                                      | I     |                                                     |
|                       |               |                         | combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine, infusional fluorouracil and radiation therapy                                                          | GIRINFRT                                       | I     |                                                     |
|                       |               |                         | combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation                                                               | GUFUPRT                                        | I     |                                                     |
|                       |               | Genitourinary           | fluorouracil and leucovorin for recurrent head and neck cancer (squamous cell carcinoma)                                                                                                     | HNAVFUFA                                       | I     |                                                     |
|                       |               | Head and Neck           | treatment of advanced squamous cell carcinoma of the head and neck cancer using fluorouracil and platinum                                                                                    | HNAVFUP                                        | I     |                                                     |
|                       |               |                         | First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab                                                                 | HNAVPFPMB                                      | I     |                                                     |
|                       |               |                         | combined chemotherapy (carboplatin and fluorouracil) and radiation treatment for locally advanced squamous cell carcinoma of the head and neck                                               | HNLACAFRT                                      | I     |                                                     |
|                       |               |                         | treatment of locally advanced squamous cell carcinoma of the head and neck with docetaxel, cisplatin and infusional fluorouracil                                                             | HNLADCF                                        | I     |                                                     |
|                       |               |                         | fluorouracil and leucovorin for recurrent head and neck cancer (nasopharyngeal)                                                                                                              | HNNAVFUFA                                      | I     |                                                     |
|                       |               |                         | treatment for advanced nasopharyngeal cancer of the head and neck using platinum and fluorouracil                                                                                            | HNNAVFUP                                       | I     |                                                     |
|                       |               |                         | palliative therapy for advanced salivary gland cancers using cyclophosphamide, doxorubicin and fluorouracil                                                                                  | HNSAVFAC                                       | I     |                                                     |
|                       |               |                         | treatment of advanced head and neck cancer using cisplatin and fluorouracil                                                                                                                  | HNSAVFUP                                       | I     |                                                     |
|                       |               | Not Otherwise Specified |                                                                                                                                                                                              | Other tumour site code followed by 'NOS' (e.g. | I     |                                                     |
|                       | eyedrops      | Ocular                  | Topical Therapy for Ocular Malignancies using Fluorouracil Eye Drops                                                                                                                         | OCFU                                           | I     |                                                     |
|                       | topical cream | Skin & Melanoma         | skin cancer                                                                                                                                                                                  | SMNOS                                          | I     |                                                     |
| flutamide             | tablet        | Genitourinary           | Androgen Deprivation Therapy for Prostate Cancer                                                                                                                                             | GUPADT                                         | I     | Not reimbursed for vasomotor symptoms (hot flashes) |
| fulvestrant           | injectable    | Breast                  | Therapy of Advanced Breast Cancer using Capivasertib and Fulvestrant With or Without LHRH Agonist                                                                                            | UBRAVCAFLV                                     | R     |                                                     |
|                       |               |                         | Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist                                                                                             | BRAVPBFLV                                      | I     |                                                     |
|                       |               |                         | Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist                                                                                              | BRAVRBFLV                                      | I     |                                                     |
| gefitinib             | tablet        | Lung                    | first-line treatment of epidermal growth factor receptor mutation-positive advanced NSCLC                                                                                                    | LUAVGEFF                                       | I     |                                                     |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG        | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                       | PROTOCOL CODES | CLASS | NOTES |
|-------------|-------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| gemcitabine | injectable  | Breast           | palliative therapy for metastatic breast cancer using gemcitabine                                                                          | BRAVGEM        | I     |       |
|             |             |                  | palliative therapy for metastatic breast cancer using gemcitabine and docetaxel                                                            | BRAVGEMD       | I     |       |
|             |             |                  | as palliative therapy for metastatic breast cancer using cisplatin and gemcitabine                                                         | BRAVGEMP       | I     |       |
|             |             |                  | treatment of metastatic breast cancer using gemcitabine and paclitaxel                                                                     | BRAVGEMT       | I     |       |
|             |             | Gastrointestinal | Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin                                          | BRAVPGC        | I     |       |
|             |             |                  | First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum                                | GIAVDURPG      | I     |       |
|             |             |                  | First-line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum                             | GIAVPEMPG      | I     |       |
|             |             |                  | First-Line Palliative Chemotherapy for Advanced Gallbladder or Pancreatic Carcinoma and Cholangiocarcinoma using Gemcitabine and Cisplatin | GIAVPG         | I     |       |
|             |             |                  | adjuvant chemotherapy for resected pancreatic adenocarcinoma using capecitabine and gemcitabine                                            | GIPAJGCAP      | I     |       |
|             |             |                  | adjuvant chemotherapy for pancreatic adenocarcinoma using gemcitabine                                                                      | GIPAJGEM       | I     |       |
|             |             |                  | palliative chemotherapy for pancreatic adenocarcinoma, gallbladder cancer, and cholangiocarcinoma using gemcitabine                        | GIPGEM         | I     |       |
|             |             |                  | first line treatment of locally advanced and metastatic pancreatic cancer with paclitaxel NAB (ABRAXANE) and gemcitabine                   | GIPGEMABR      | I     |       |
|             |             | Gynecology       | Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine                                   | GOOVBEVG       | I     |       |
|             |             |                  | carboplatin and gemcitabine for the treatment of recurrent platinum-sensitive ovarian cancer                                               | GOOVCAG        | I     |       |
|             |             |                  | palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer using gemcitabine                                        | GOOVGEM        | I     |       |
|             |             |                  | combination with docetaxel for advanced or recurrent uterine sarcoma cancer                                                                | GOSADG         | I     |       |
|             |             | Genitourinary    | adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine                                                                  | GUAJPG         | I     |       |
|             |             |                  | combination with cisplatin for advanced transitional cell carcinoma of the bladder                                                         | GUAVPG         | I     |       |
|             |             |                  | intravesical therapy for non-muscle invasive bladder cancer using gemcitabine                                                              | GUBGEM         | I     |       |
|             |             |                  | Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using Gemcitabine and Docetaxel                                                | GUBGEMDOC      | I     |       |
|             |             | Head and Neck    | combination with cisplatin as neoadjuvant therapy for urothelial carcinoma                                                                 | GUNAJPG        | I     |       |
|             |             |                  | palliative therapy for germ cell cancers using paclitaxel and gemcitabine                                                                  | GUTAXGEM       | I     |       |
|             |             |                  | treatment of loco-regionally recurrent and/or metastatic nasopharyngeal cancer with gemcitabine                                            | HNNAVGEM       | I     |       |
|             |             |                  | treatment of local-regionally recurrent and/or metastatic nasopharyngeal cancer with platinum and gemcitabine                              | HNNAVPG        | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                  | DOSAGE FORM            | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                               | PROTOCOL CODES                                        | CLASS | NOTES                              |
|-----------------------|------------------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|------------------------------------|
| gemcitabine (cont'd)  | injectable             | Head and Neck           | as induction treatment of locally advanced nasopharyngeal cancer with cisplatin and gemcitabine                                                                                                                                    | HNNLAPG                                               | I     |                                    |
|                       |                        | Lung                    | combination with cisplatin or carboplatin as treatment of advanced non-small cell lung cancer                                                                                                                                      | LUAVPG                                                | I     |                                    |
|                       |                        |                         | first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab                                                                                                                  | LUAVPGPMB                                             | I     |                                    |
|                       |                        |                         | treatment of malignant mesothelioma with platinum and gemcitabine                                                                                                                                                                  | LUMMPG                                                | I     |                                    |
|                       |                        | Lymphoma                | treatment of lymphoma with gemcitabine, dexamethasone and platinum                                                                                                                                                                 | LYGDP                                                 | I     |                                    |
|                       |                        |                         | Treatment of rTUXImab-refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and cBINutuzumab                                                                                                                    | LYGDPO                                                | I     |                                    |
|                       |                        |                         | treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab                                                                                                                                                  | LYGDPR                                                | I     |                                    |
|                       |                        |                         | Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase                                                                                              | LYGEMOXPEG                                            | I     |                                    |
|                       |                        |                         | Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and Doxorubicin Pegylated Liposomal                                                                                                             | LYGVLD                                                | I     |                                    |
|                       |                        |                         | palliative chemotherapy of lymphomas                                                                                                                                                                                               | LYPALL                                                | I     |                                    |
| gemtuzumab ozogamicin | injectable             | Leukemia & BMT          | Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy                                                                                                                      | LKGEMOZ                                               | I     |                                    |
|                       |                        | Pediatric               | Pediatric patients with de novo acute myeloid leukemia (AML) in the first induction chemotherapy cycle, in combination with standard chemotherapy                                                                                  |                                                       | R     |                                    |
|                       |                        | Sarcoma                 | combination with docetaxel as second or third line therapy for soft tissue sarcomas                                                                                                                                                | SAAVGEMD                                              | I     |                                    |
| gilteritinib          | tablet                 | Leukemia & BMT          | Therapy of Relapsed or Refractory FLT3+ Acute Myeloid Leukemia using Gilteritinib                                                                                                                                                  | ULKAMLGIL                                             | R     |                                    |
| glofitamab            | injectable             | Lymphoma                | Treatment of Lymphoma using Glofitamab                                                                                                                                                                                             | ULYOGLOFIT                                            | R     |                                    |
| goserelin             | long acting injectable | Breast                  | Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist                                                                                                                         | UBRAJABEI                                             | R     |                                    |
|                       |                        |                         | Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist                                                                                                                                   | UBRAJABET                                             | R     |                                    |
|                       |                        |                         | Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen | BRAJLHRHAI                                            | I     |                                    |
|                       |                        |                         | Therapy of Advanced Breast Cancer using Capivasertib and Fulvestrant With or Without LHRH Agonist                                                                                                                                  | UBRAVCAFLV                                            | R     |                                    |
|                       |                        |                         | therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor                                                                                                                                                 | BRAVLHRHAI                                            | I     |                                    |
|                       |                        |                         | combination therapy with tamoxifen palliative therapy for metastatic breast cancer                                                                                                                                                 | BRAVLHRHT                                             | I     |                                    |
|                       |                        |                         | therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist                                                                                                                           | BRAVPALAI                                             | I     |                                    |
|                       |                        |                         | Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist                                                                                                                                   | BRAVPBFLV                                             | I     |                                    |
|                       |                        |                         | Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist                                                                                                                                    | BRAVRBFLV                                             | I     |                                    |
|                       |                        |                         | therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist                                                                                                                            | BRAVRIBAI                                             | I     |                                    |
|                       |                        | Genitourinary           | Androgen Deprivation Therapy for Prostate Cancer                                                                                                                                                                                   | GUPADT                                                | I     |                                    |
|                       |                        |                         |                                                                                                                                                                                                                                    |                                                       |       | Not reimbursed for endometriosis   |
| hydrocortisone        | tablet, injectable     | Lymphoma                | treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE                                                                                                                                     | HLHETCSPA                                             | I     |                                    |
|                       |                        | Not Otherwise Specified |                                                                                                                                                                                                                                    | Other tumour site code followed by 'NOS' (e.g. LYNOS) | I     | Not reimbursed for supportive care |
| hydroxyurea           | capsule                | Leukemia & BMT          | Myeloid neoplasms, including but not limited to: Acute myeloid leukemia, Myelodysplastic syndromes (e.g. Refractory anemia), Myeloproliferative disease (e.g. Chronic myeloid leukemia, Polycythemia, Essential thrombocythemia)   | LKNOS                                                 | I     |                                    |
|                       |                        | Lymphoma                | Lymphoid neoplasms, including but not limited to: Lymphoproliferative disease, Myeloma                                                                                                                                             | LYNOS                                                 | I     |                                    |



**BC Cancer Benefit Drug List  
May 2025**

| DRUG                                | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                                 | PROTOCOL CODES                                        | CLASS | NOTES |
|-------------------------------------|-------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-------|
| ibritumomab tiuxetan 90Y (ZEVALIN®) | injectable  | Lymphoma                | Palliative Therapy For Lymphoma Using Radioimmunotherapy: ritUXImab-Priming for 90Y-Ibritumomab tiuxetan (ZEVALIN®)                                                                                                                  | LYRITZ                                                | I     |       |
| ibrutinib                           | capsule     | Lymphoma                | treatment of previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma using ibrutinib                                                                                                                         | LYFIBRU                                               | I     |       |
|                                     |             |                         | treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using ibrutinib                                                                                                                       | LYIBRU                                                | I     |       |
|                                     |             |                         | treatment of relapsed/refractory mantle-cell lymphoma using ibrutinib                                                                                                                                                                | LYMIBRU                                               | I     |       |
| idarubicin                          | injectable  | Not Otherwise Specified |                                                                                                                                                                                                                                      | Tumour site code followed by 'NOS' (e.g. BRNOS)       | I     |       |
|                                     |             | Pediatric               | Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Trelinoin and with or without Idarubicin and Dexamethasone on the COG AAML1331 Study                            |                                                       | I     |       |
| idelalisib                          | tablet      | Lymphoma                | treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab                                                                                                           | LYIDELAR                                              | I     |       |
| ifosfamide                          | injectable  | Genitourinary           | advanced therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin                                                                                                                                 | GUTIP                                                 | I     |       |
|                                     |             |                         | consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna                                                                                                                             | GUVEIP                                                | I     |       |
|                                     |             |                         | nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna                                                                                                                                             | GUVIP2                                                | I     |       |
|                                     |             | Lymphoma                | treatment of burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab                                                                                                                             | LYIVACR                                               | I     |       |
|                                     |             |                         | treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab                                                                                    | LYRICE                                                | I     |       |
|                                     |             |                         | treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide                                                                                                             | LYSMILE                                               | I     |       |
|                                     |             |                         | treatment of newly diagnosed nasal, extranodal natural killer (NK) or T-cell lymphoma, stage IE to IIE using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone                | LYVIPDRT                                              | I     |       |
|                                     |             | Pediatric               | treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)                                                                                           |                                                       | I     |       |
|                                     |             | Sarcoma                 | therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna                                                                                                                                                         | SAAI                                                  | I     |       |
|                                     |             |                         | 3-day doxorubicin, ifosfamide and mesna for use in patients with advanced soft tissue sarcoma                                                                                                                                        | SAAI3                                                 | I     |       |
|                                     |             |                         | SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma   | SAALT2W                                               | I     |       |
|                                     |             |                         | SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma | SAALT3W                                               | I     |       |
|                                     |             |                         | therapy for advanced soft tissue sarcoma using ifosfamide                                                                                                                                                                            | SAAVI                                                 | I     |       |
|                                     |             |                         | 3-day ifosfamide for use in patients with advanced soft tissue sarcoma                                                                                                                                                               | SAAVI3                                                | I     |       |
|                                     |             |                         | 3-Day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas                                                                                                                                           | SAAVIME3                                              | I     |       |
|                                     |             |                         | etoposide, ifosfamide-mesna (SAIME) for use in sarcomas                                                                                                                                                                              | SAIME                                                 | I     |       |
|                                     |             | Not Otherwise Specified |                                                                                                                                                                                                                                      | Other tumour site code followed by 'NOS' (e.g. LYNOS) | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                  | DOSAGE FORM   | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                             | PROTOCOL CODES | CLASS | NOTES |
|-----------------------|---------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| imatinib              | tablet        | Leukemia & BMT   | therapy for chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia                                                                                                                        | LKCMLI         | I     |       |
|                       |               | Pediatric        | pediatric patients with Philadelphia chromosome positive acute lymphoblastic leukemia                                                                                                            |                | I     |       |
|                       |               | Sarcoma          | adjuvant therapy of C-Kit positive high risk gastrointestinal stromal cell tumours                                                                                                               | SAAJGI         | I     |       |
|                       |               |                  | advanced c-kit positive and c-kit negative gastrointestinal stromal cell tumours                                                                                                                 | SAAVGI         | I     |       |
|                       |               |                  | advanced c-kit positive gastrointestinal stromal cell tumors using 800 mg dosing of imatinib                                                                                                     | SAAVGIDD       | I     |       |
|                       |               | Skin & Melanoma  | treatment of advanced c-kit melanoma using imatinib                                                                                                                                              | SMAVI          | I     |       |
| imiquimod             | topical cream | Skin & Melanoma  | topical immunotherapy for in-transit melanoma metastases, cutaneous lymphoma, basal cell carcinoma using imiquimod                                                                               | SMIMI          | I     |       |
| inotuzumab ozogamicin | injectable    | Leukemia & BMT   | treatment of relapsed or refractory pre-B-cell acute lymphoblastic leukemia with inotuzumab ozogamicin                                                                                           | ULKINOZ        | R     |       |
| ipilimumab            | injectable    | Genitourinary    | treatment of metastatic or advanced renal cell carcinoma using ipilimumab and nivolumab                                                                                                          | GUAVIPNI       | I     |       |
|                       |               | Lung             | First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab                                                                      | LUAVPCIPNI     | I     |       |
|                       |               |                  | First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab                                                                     | LUAVPPIPNI     | I     |       |
|                       |               |                  | Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab                                                                                                                               | LUMMIPNI       | I     |       |
|                       |               |                  | Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab                                                                                                                      | LUMMIPNI3      | I     |       |
|                       |               | Skin & Melanoma  | Treatment of Unresectable or Metastatic Melanoma Using Alternative Dosing Regimen of Ipilimumab and Nivolumab                                                                                    | SMAVALIPNI     | I     |       |
|                       |               |                  | first-line treatment of unresectable or metastatic melanoma using ipilimumab                                                                                                                     | SMAVFIPI       | I     |       |
|                       |               |                  | treatment of advanced and metastatic melanoma after prior systemic therapy                                                                                                                       | SMAVIPI        | I     |       |
|                       |               |                  | treatment of unresectable or metastatic melanoma using ipilimumab and nivolumab                                                                                                                  | SMAVIPNI       | I     |       |
|                       |               |                  |                                                                                                                                                                                                  |                |       |       |
| irinotecan            | injectable    | Gastrointestinal | palliative third line treatment of metastatic colorectal cancer with wild-type KRAS using cetuximab and irinotecan                                                                               | GIAVCETIR      | I     |       |
|                       |               |                  | Palliative Therapy of Metastatic Colorectal Cancer using Irinotecan and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine                                                       | GIAVRALIR      | I     |       |
|                       |               |                  | Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Irinotecan and Capecitabine in Patients Unsuitable for GEOFIRI                                       | GICAPIRI       | I     |       |
|                       |               |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, bevacizumab and capecitabine                                                                              | GICIRB         | I     |       |
|                       |               |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab                                                   | GIFFIRB        | I     |       |
|                       |               |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab                                                                 | GIFFIRPAN      | I     |       |
|                       |               |                  | palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)                                             | GIFIRINOX      | I     |       |
|                       |               |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)                                                                | GIFOLFIRI      | I     |       |
|                       |               |                  | Second or Third Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma or Esophageal Squamous Cell Carcinoma using Irinotecan, Fluorouracil and Leucovorin | GIGOLFIRI      | I     |       |
|                       |               |                  |                                                                                                                                                                                                  |                |       |       |
|                       |               |                  |                                                                                                                                                                                                  |                |       |       |
|                       |               |                  |                                                                                                                                                                                                  |                |       |       |
|                       |               |                  |                                                                                                                                                                                                  |                |       |       |
|                       |               |                  |                                                                                                                                                                                                  |                |       |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                | DOSAGE FORM            | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                           | PROTOCOL CODES | CLASS | NOTES |
|---------------------|------------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| irinotecan (cont'd) | injectable             | Gastrointestinal | palliative chemotherapy of metastatic colorectal cancer using irinotecan                                                                       | GIIR           | I     |       |
|                     |                        |                  | palliative therapy of metastatic colorectal cancer in patients who may not tolerate the 3-weekly irinotecan schedule of GIIR                   | GIIRINALT      | I     |       |
|                     |                        |                  | adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin                        | GIPAJFIROX     | I     |       |
|                     |                        |                  | Treatment of Metastatic Pancreatic or Biliary Tract Cancer using Irinotecan, Fluorouracil and Leucovorin                                       | GIPAVFFIRI     | I     |       |
|                     |                        |                  | second line treatment of extensive stage small cell lung cancer (SCLC) with irinotecan with or without platinum                                | LUSCPI         | I     |       |
|                     |                        | Pediatric        | pediatric patients treated on the COG protocol ARST0531 for intermediate-risk rhabdomyosarcoma                                                 |                | I     |       |
|                     |                        |                  | pediatric patients with recurrent pediatric neuroblastoma treated on the COG protocol ANBL0421                                                 |                | I     |       |
|                     |                        |                  | pediatric patients with high risk renal tumors treated on the COG protocol AREN0321                                                            |                | I     |       |
|                     |                        |                  | pediatric patients with high risk rhabdomyosarcoma treated on the COG protocol ARST0431                                                        |                | I     |       |
|                     |                        |                  | pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol                                                                  |                | I     |       |
| isatuximab          | injectable             | Myeloma          | Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide                                   | UMYISACARD     | R     |       |
|                     |                        |                  | Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide                                  | UMYISAPOMD     | R     |       |
| isotretinoin        | capsule                | Pediatric        | pediatric patients with high risk neuroblastoma                                                                                                |                | I     |       |
|                     |                        |                  | pediatric patients treated on the COG protocol ACNS0332 for above average risk medulloblastoma/PNE                                             |                | I     |       |
| lanreotide          | injectable             | Neuro-Oncology   | treatment of growth hormone secreting pituitary adenoma using lanreotide                                                                       | CNLAN          | I     |       |
|                     |                        | Gastrointestinal | symptomatic management of functional carcinoid and neuroendocrine tumours of the GI Tract using lanreotide                                     | UGILAN         | R     |       |
| lapatinib           | tablet                 | Breast           | therapy for metastatic breast cancer using capecitabine and lapatinib                                                                          | BRAVLCAP       | I     |       |
| larotrectinib       | capsule, oral solution | Tumour Agnostic  | Treatment of Solid Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion using Larotrectinib                                        | UTAAVLAR       | R     |       |
|                     |                        | Pediatric        | Treatment of Solid Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion using Larotrectinib                                        |                | R     |       |
| lenalidomide        | capsule                | Leukemia & BMT   | therapy of myelodysplastic syndrome using lenalidomide                                                                                         | LKMDSL         | I     |       |
|                     |                        | Myeloma          | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone  | MYBLDF         | I     |       |
|                     |                        |                  | Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant                           | MYBLDPRE       | I     |       |
|                     |                        |                  | Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone                                                                 | MYCARLD        | I     |       |
|                     |                        |                  | treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone                      | MYDARLD        | I     |       |
|                     |                        |                  | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone | MYDARLDF       | I     |       |
|                     |                        |                  | treatment of previously untreated multiple myeloma and not eligible for stem cell transplant using lenalidomide with low-dose dexamethasone    | UMYLDF         | R     |       |
|                     |                        |                  | therapy of relapsed multiple myeloma using lenalidomide with dexamethasone                                                                     | MYLDREL        | I     |       |
|                     |                        |                  | Maintenance Therapy of Multiple Myeloma using Lenalidomide                                                                                     | MYLENMTN       | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG               | DOSAGE FORM        | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                         | PROTOCOL CODES | CLASS | NOTES |
|--------------------|--------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| lenvatinib         | capsule            | Gastrointestinal | Therapy of Advanced Hepatocellular Carcinoma using Lenvatinib                                                                                                                | GILEN          | I     |       |
|                    |                    | Gynecology       | Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using Pembrolizumab and Lenvatinib                                              | GOENDAVPL      | I     |       |
|                    |                    |                  | Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using 6-weekly Pembrolizumab and Lenvatinib                                     | GOENDAVPL6     | I     |       |
|                    |                    | Genitourinary    | Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Lenvatinib                                                                                              | GUAVPEML       | I     |       |
|                    |                    |                  | Treatment of Metastatic Renal Cell Carcinoma using 6-weekly Pembrolizumab and Lenvatinib                                                                                     | GUAVPEML6      | I     |       |
|                    |                    | Head and Neck    | therapy for locally recurrent or metastatic, RAI-refractory differentiated thyroid cancer using lenvatinib                                                                   | HNOTLEN        | I     |       |
|                    |                    |                  |                                                                                                                                                                              |                |       |       |
| letrozole          | tablet             | Breast           | Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist                                                                   | UBRAJABEI      | R     |       |
|                    |                    |                  | neoadjuvant or adjuvant therapy for breast cancer using letrozole in postmenopausal women                                                                                    | BRAJLET        | I     |       |
|                    |                    |                  | Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer                                | BRAJLHRHAI     | I     |       |
|                    |                    |                  | first or second line hormonal treatment for advanced breast cancer in postmenopausal women                                                                                   | BRAVLET        | I     |       |
|                    |                    |                  | therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor                                                                                           | BRAVLHRHAI     | I     |       |
|                    |                    |                  | therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist                                                                     | BRAVPALAI      | I     |       |
|                    |                    |                  | therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist                                                                      | BRAVRIBAI      | I     |       |
|                    |                    | Gynecology       | hormonal treatment for advanced endometrial cancer in postmenopausal women with contraindications to tamoxifen or intolerant of tamoxifen                                    | GOENDAI        | I     |       |
|                    |                    |                  | hormonal treatment for advanced ovarian cancer in postmenopausal women                                                                                                       | GOOVAI         | I     |       |
|                    |                    |                  |                                                                                                                                                                              |                |       |       |
| leucovorin calcium | tablet, injectable | Breast           | treatment of meningeal disease using high-dose methotrexate with leucovorin rescue                                                                                           | BRAVHDMTX      | I     |       |
|                    |                    | Gastrointestinal | adjuvant combination chemotherapy for Stage III and Stage IIB colon cancer using oxaliplatin, fluorouracil and folinic acid (Leucovorin)                                     | GIAJFFOX       | I     |       |
|                    |                    |                  | adjuvant therapy of colon cancer using fluorouracil injection and infusion and leucovorin infusion                                                                           | GIAJFL         | I     |       |
|                    |                    |                  | Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Fluorouracil and Leucovorin                                                                       | GIAVFL         | I     |       |
|                    |                    |                  | combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy                                          | GIEFFOXRT      | I     |       |
|                    |                    |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab                               | GIFFIRB        | I     |       |
|                    |                    |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab                                             | GIFFIRPAN      | I     |       |
|                    |                    |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab                                            | GIFFOXB        | I     |       |
|                    |                    |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab                                            | GIFFOXPAN      | I     |       |
|                    |                    |                  | palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)                         | GIFIRINOX      | I     |       |
|                    |                    |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil and folinic acid (leucovorin)                                            | GIFOLFIRI      | I     |       |
|                    |                    |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin)                                           | GIFOLFOX       | I     |       |
|                    |                    |                  |                                                                                                                                                                              |                |       |       |
|                    |                    |                  | adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin | GIGAJFFOX      | I     |       |
|                    |                    |                  |                                                                                                                                                                              |                |       |       |
|                    |                    |                  |                                                                                                                                                                              |                |       |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                        | DOSAGE FORM        | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                | PROTOCOL CODES                                        | CLASS | NOTES |
|-----------------------------|--------------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-------|
| leucovorin calcium (cont'd) | tablet, injectable | Gastrointestinal        | Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin                                    | GIGAVFFOX                                             | I     |       |
|                             |                    |                         | First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab                                    | GIGAVFFOXN                                            | I     |       |
|                             |                    |                         | First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab                                                        | GIGAVFFOXP                                            | I     |       |
|                             |                    |                         | palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab | GIGAVFFOXT                                            | I     |       |
|                             |                    |                         | Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab                                    | GIGAVPFOXT                                            | I     |       |
|                             |                    |                         | perioperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin         | GIGFLODOC                                             | I     |       |
|                             |                    |                         | Second or Third Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma or Esophageal Squamous Cell Carcinoma using Irinotecan, Fluorouracil and Leucovorin    | GIGFOLFIRI                                            | I     |       |
|                             |                    |                         | adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin                                                                             | GIPAJFIROX                                            | I     |       |
|                             |                    |                         | Treatment of Metastatic Pancreatic or Biliary Tract Cancer using Irinotecan, Fluorouracil and Leucovorin                                                                                            | GIPAVFFIRI                                            | I     |       |
|                             |                    |                         | Palliative Combination Chemotherapy for Metastatic Pancreatic or Biliary Tract Cancer using Oxaliplatin, Fluorouracil, and Leucovorin                                                               | GIPAVFFOX                                             | I     |       |
|                             |                    |                         | Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin                                                                         | GIRAJFFOX                                             | I     |       |
|                             |                    | Gynecology              | therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine                            | GOTDEMACO                                             | I     |       |
|                             |                    |                         | Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate                                                                                                  | GOTDMR (previously GOTDLR)                            | I     |       |
|                             |                    | Head and Neck           | fluorouracil and leucovorin for recurrent head and neck cancer (squamous cell carcinoma)                                                                                                            | HNAVFUFA                                              | I     |       |
|                             |                    |                         | fluorouracil and leucovorin for recurrent head and neck cancer (nasopharyngeal)                                                                                                                     | HNNAVFUFA                                             | I     |       |
|                             |                    | Lymphoma                | treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone                                                                | LYASPMDEX                                             | I     |       |
|                             |                    |                         | central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma                                                                                 | LYCHOPRMTX                                            | I     |       |
|                             |                    |                         | treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab                                                                | LYCODOXMR                                             | I     |       |
|                             |                    |                         | Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide                                                                                             | LYHDMRTEM                                             | I     |       |
|                             |                    |                         | Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) with Pralatrexate                                                                                                             | LYPRA                                                 | I     |       |
|                             |                    |                         | treatment of natural killer or T-Cell lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide                                                                            | LYSMILE                                               | I     |       |
|                             |                    |                         |                                                                                                                                                                                                     |                                                       |       |       |
|                             |                    | Not Otherwise Specified |                                                                                                                                                                                                     | Other tumour site code followed by 'NOS' (e.g. LYNOS) | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                | DOSAGE FORM            | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                        | PROTOCOL CODES                                        | CLASS | NOTES                                                                                                                                               |
|---------------------|------------------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| leuprolide          | long acting injectable | Breast                  | Treatment of Adjuvant Breast Cancer using Abemaciclib and Aromatase Inhibitor With or Without LHRH Agonist                                                                  | UBRAJABEI                                             | R     | Not reimbursed for endometriosis. Leuprolide acetate IM (LUPRON®) and SC (ELIGARD®) are both reimbursable for prostate cancer indications (GUPADT). |
|                     |                        |                         | Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist                                                                            | UBRAJABET                                             | R     |                                                                                                                                                     |
|                     |                        |                         | Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibitor in Premenopausal Women or In Men with High Risk Early Stage Breast Cancer                               | BRAJLHRHAI                                            | I     |                                                                                                                                                     |
|                     |                        |                         | neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist and tamoxifen                                                                                        | BRAJLHRHT                                             | I     |                                                                                                                                                     |
|                     |                        |                         | Therapy of Advanced Breast Cancer using Capivasertib and Fulvestrant With or Without LHRH Agonist                                                                           | UBRAVCAFLV                                            | R     |                                                                                                                                                     |
|                     |                        |                         | therapy for advanced breast cancer using a LHRH agonist and an aromatase inhibitor                                                                                          | BRAVLHRHAI                                            | I     |                                                                                                                                                     |
|                     |                        |                         | combination therapy with tamoxifen palliative therapy for metastatic breast cancer                                                                                          | BRAVLHRHT                                             | I     |                                                                                                                                                     |
|                     |                        |                         | therapy of advanced breast cancer using palbociclib and aromatase inhibitor with or without LHRH agonist                                                                    | BRAVPALAI                                             | I     |                                                                                                                                                     |
|                     |                        |                         | Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist                                                                            | BRAVPBFLV                                             | I     |                                                                                                                                                     |
|                     |                        |                         | Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist                                                                             | BRAVRBFLV                                             | I     |                                                                                                                                                     |
| lomustine           | capsule                | Neuro-Oncology          | therapy of advanced breast cancer using ribociclib and aromatase inhibitor with or without LHRH agonist                                                                     | BRAVRIBAI                                             | I     |                                                                                                                                                     |
|                     |                        |                         |                                                                                                                                                                             |                                                       |       |                                                                                                                                                     |
|                     |                        |                         |                                                                                                                                                                             |                                                       |       |                                                                                                                                                     |
|                     |                        |                         |                                                                                                                                                                             |                                                       |       |                                                                                                                                                     |
|                     |                        | Genitourinary           | Androgen Deprivation Therapy for Prostate Cancer                                                                                                                            | GUPADT                                                | I     |                                                                                                                                                     |
|                     |                        |                         |                                                                                                                                                                             |                                                       |       |                                                                                                                                                     |
|                     |                        |                         |                                                                                                                                                                             |                                                       |       |                                                                                                                                                     |
|                     |                        |                         |                                                                                                                                                                             |                                                       |       |                                                                                                                                                     |
| 177Lu-Dotatate      | radio-pharmaceutical   | Gastrointestinal        | Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Neuroendocrine Tumours | UGIPRRT                                               | R     |                                                                                                                                                     |
|                     |                        |                         |                                                                                                                                                                             |                                                       |       |                                                                                                                                                     |
|                     |                        |                         |                                                                                                                                                                             |                                                       |       |                                                                                                                                                     |
|                     |                        |                         |                                                                                                                                                                             |                                                       |       |                                                                                                                                                     |
| lorlatinib          | tablet                 | Lung                    | Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Lorlatinib                                                                                       | LUAVLOR                                               | I     |                                                                                                                                                     |
| medroxyprogesterone | tablet                 | Gynecology              | non-aromatase inhibitor hormonal treatment of endometrial cancer                                                                                                            | GOENDH                                                | I     | Not reimbursed for appetite stimulation or replacement therapy.                                                                                     |
| megestrol           | tablet                 | Breast                  | breast cancer                                                                                                                                                               | BRAVMEG                                               | I     | Not reimbursed for appetite stimulation or symptom management                                                                                       |
|                     |                        | Gynecology              | non-aromatase inhibitor hormonal treatment of endometrial cancer                                                                                                            | GOENDH                                                | I     |                                                                                                                                                     |
| melphalan           | tablet, injectable     | Leukemia & BMT          | conditioning therapy for autologous stem cell transplant using high dose melphalan in the treatment of multiple myeloma                                                     | BMTMM0301                                             | I     |                                                                                                                                                     |
|                     |                        | Myeloma                 | Treatment of Multiple Myeloma using Melphalan and Prednisone                                                                                                                | MYMP                                                  | I     |                                                                                                                                                     |
|                     |                        |                         | treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan                              | MYMPBOR                                               | I     |                                                                                                                                                     |
|                     |                        | Not Otherwise Specified |                                                                                                                                                                             | Other tumour site code followed by 'NOS' (e.g. LKNOS) | I     |                                                                                                                                                     |
| 6-mercaptopurine    | tablet                 | Not Otherwise Specified |                                                                                                                                                                             | Tumour site code followed by 'NOS' (e.g. LKNOS)       | I     |                                                                                                                                                     |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG         | DOSAGE FORM        | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                                 | PROTOCOL CODES                                        | CLASS | NOTES                                                                                  |
|--------------|--------------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|----------------------------------------------------------------------------------------|
| mesna        | injectable         | Genitourinary           | therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin (TIP)                                                                                                                                    | GUTIP                                                 | I     | Approved for use ONLY as an uro-protector for ifosfamide or high dose cyclophosphamide |
|              |                    |                         | consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna                                                                                                                             | GUVEIP                                                | I     |                                                                                        |
|              |                    | Lymphoma                | nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide, mesna                                                                                                                                             | GUVIP2                                                | I     |                                                                                        |
|              |                    |                         | Treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab                                                                                                                             | LYIVACR                                               | I     |                                                                                        |
|              |                    |                         | treatment of relapsed or refractory advanced stage aggressive B-Cell Non-Hodgkin's Lymphoma with ifosfamide, carboplatin, etoposide, and rituximab                                                                                   | LYRICE                                                | I     |                                                                                        |
|              |                    |                         | treatment of Natural Killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide                                                                                                             | LYSMILE                                               | I     |                                                                                        |
|              |                    |                         | treatment of newly diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using concurrent radiation and weekly cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone                                | LYVIPDRT                                              | I     |                                                                                        |
|              |                    |                         | treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)                                                                                           |                                                       | I     |                                                                                        |
|              |                    | Sarcoma                 | therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide-mesna                                                                                                                                                         | SAAI                                                  | I     |                                                                                        |
|              |                    |                         | 3-day doxorubicin, ifosfamide and mesna for use in patients with advanced soft tissue sarcoma                                                                                                                                        | SAAI3                                                 | I     |                                                                                        |
|              |                    |                         | SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma   | SAALT2W                                               | I     |                                                                                        |
|              |                    |                         | SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma | SAALT3W                                               | I     |                                                                                        |
|              |                    |                         | therapy for advanced soft tissue sarcoma using ifosfamide                                                                                                                                                                            | SAAVI                                                 | I     |                                                                                        |
|              |                    |                         | 3-day ifosfamide for use in patients with advanced soft tissue sarcoma                                                                                                                                                               | SAAVI3                                                | I     |                                                                                        |
|              |                    |                         | 3-day etoposide & ifosfamide-mesna for patients with advanced soft tissue or bony sarcomas                                                                                                                                           | SAAVIME3                                              | I     |                                                                                        |
|              |                    |                         | etoposide, ifosfamide-mesna (SAIME) for use in sarcomas                                                                                                                                                                              | SAIME                                                 | I     |                                                                                        |
|              |                    |                         | Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna                                                                                             | SAVACM                                                | I     |                                                                                        |
|              |                    | Supportive Care         | mesna dosage modification for hematuria secondary to oxazaphosphorines                                                                                                                                                               | SCMESNA                                               | I     |                                                                                        |
|              |                    | Not Otherwise Specified |                                                                                                                                                                                                                                      | Other tumour site code followed by 'NOS' (e.g. SANOS) | I     |                                                                                        |
| methotrexate | tablet, injectable | Breast                  | Palliative Therapy for Advanced Breast Cancer Using Cyclophosphamide, Methotrexate and Fluorouracil                                                                                                                                  | BRAVCMF                                               | I     |                                                                                        |
|              |                    |                         | Palliative Therapy for Metastatic Breast Cancer Using Metronomic Low-Dose Oral Cyclophosphamide and Methotrexate                                                                                                                     | BRAVCMPO                                              | I     |                                                                                        |
|              |                    | Gynecology              | Treatment of Meningeal Disease using High-Dose Methotrexate with Leucovorin Rescue                                                                                                                                                   | BRAVHDMTX                                             | I     |                                                                                        |
|              |                    |                         | Therapy for High Risk Gestational Trophoblastic Neoplasia (GTN) Using Etoposide, Methotrexate, Leucovorin (Folinic Acid), DACTINomycin, Cyclophosphamide and vinCRiStine                                                             | GOTDEMACO                                             | I     |                                                                                        |
|              |                    |                         | Therapy for Low-Risk Gestational Trophoblastic Cancer using Methotrexate                                                                                                                                                             | GOTDLRM                                               | I     |                                                                                        |
|              |                    |                         | Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate                                                                                                                                   | GOTDMR (previously GOTDLR)                            | I     |                                                                                        |
|              |                    | Genitourinary           | Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin                                                                                                                     | GUBDDMVAC                                             | I     |                                                                                        |
|              |                    |                         | therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin                                                                                                                   | GUMVAC                                                | I     |                                                                                        |
|              |                    |                         |                                                                                                                                                                                                                                      |                                                       |       |                                                                                        |
|              |                    |                         |                                                                                                                                                                                                                                      |                                                       |       |                                                                                        |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                             | DOSAGE FORM        | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                         | PROTOCOL CODES                                        | CLASS | NOTES                                                                                                                        |
|----------------------------------|--------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|------------------------------------------------------------------------------------------------------------------------------|
| methotrexate (cont'd)            | tablet, injectable | Head and Neck           | treatment of head and neck cancer using methotrexate as standard therapy                                                                                                                     | HNAVM                                                 | I     |                                                                                                                              |
|                                  |                    | Kaposi's Sarcoma        | therapy for Kaposi's Sarcoma using vinblastine-vincristine                                                                                                                                   | KSVB                                                  | I     |                                                                                                                              |
|                                  |                    | Lymphoma                | treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone and cycloSPORINE                                                                                               | HLHETCSPA                                             | I     |                                                                                                                              |
|                                  |                    |                         | treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone                                                         | LYASPMEDX                                             | I     |                                                                                                                              |
|                                  |                    |                         | central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma                                                                          | LYCHOPRMTX                                            | I     |                                                                                                                              |
|                                  |                    |                         | treatment of burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab                                                         | LYCODOXMR                                             | I     |                                                                                                                              |
|                                  |                    |                         | treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate                                       | LYEPOCHR                                              | I     |                                                                                                                              |
|                                  |                    |                         | Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide                                                                                      | LYHDMRTEM                                             | I     |                                                                                                                              |
|                                  |                    |                         | Central Nervous System Prophylaxis with High-Dose Methotrexate in Diffuse Large B-Cell Lymphoma                                                                                              | LYHDMTXPRO                                            | I     |                                                                                                                              |
|                                  |                    |                         | treatment of lymphoma using intrathecal methotrexate and cytarabine                                                                                                                          | LYIT                                                  | I     |                                                                                                                              |
|                                  |                    |                         | treatment of Burkitt's Lymphoma and Leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab                                                                                     | LYIVACR                                               | I     |                                                                                                                              |
|                                  |                    |                         | lymphoma palliative chemotherapy                                                                                                                                                             | LYPALL                                                | I     |                                                                                                                              |
|                                  |                    |                         | treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide                                                                     | LYSMILE                                               | I     |                                                                                                                              |
|                                  |                    | Miscellaneous Origins   | therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine                                                                                                   | MOIT                                                  | I     |                                                                                                                              |
|                                  |                    | Sarcoma                 | palliative therapy for aggressive fibromatosis using weekly or alternate week methotrexate and vinblastine intravenously                                                                     | SAMV                                                  | I     |                                                                                                                              |
|                                  |                    | Not Otherwise Specified |                                                                                                                                                                                              | Other tumour site code followed by 'NOS' (e.g. MYNOS) | I     |                                                                                                                              |
| methoxsalen                      | injectable         | Lymphoma                | Treatment of Cutaneous T-Cell Lymphoma (Sézary Syndrome) with Extracorporeal Photopheresis                                                                                                   | LYMFECP                                               | I     |                                                                                                                              |
| methyl aminolevulinate (METVIX®) | topical cream      | Skin & Melanoma         | topical therapy for skin cancer with PDT (Photodynamic Therapy)                                                                                                                              | SMPDT                                                 | I     | Only reimbursable when prescribed by physicians in the Skin Tumour Group within the Skin PDT Program of the BC Cancer Agency |
| midostaurin                      | capsule            | Leukemia & BMT          | therapy of FLT3+ acute myeloid leukemia using midostaurin in combination with induction and consolidation chemotherapy                                                                       | LKAMLMIDO                                             | I     |                                                                                                                              |
| mitomycin                        | injectable         | Gastrointestinal        | combined modality therapy for carcinoma of the anal canal using mitomycin, capecitabine and radiation therapy                                                                                | GICART                                                | I     |                                                                                                                              |
|                                  |                    |                         | hepatic trans-arterial chemoembolization for primary liver cancer or liver metastasis                                                                                                        | GIEMBOL                                               | I     | Note: only funded when prescribed by specialists at BC Cancer Vancouver and Royal Jubilee Hospital                           |
|                                  |                    |                         | combined modality curative therapy for carcinoma of the anal canal using mitomycin, fluorouracil and radiation therapy                                                                       | GIFUART                                               | I     |                                                                                                                              |
|                                  |                    |                         | chemotherapy of pseudomyxoma peritonei using intraperitoneal mitomycin and fluorouracil                                                                                                      | GIFUIP                                                | I     |                                                                                                                              |
|                                  |                    |                         | hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using oxaliplatin and fluorouracil | GIHIPEC                                               | I     |                                                                                                                              |
|                                  |                    | Genitourinary           | combined modality therapy for squamous cell cancer of the genitourinary system using fluorouracil and cisplatin with radiation                                                               | GUFUPRT                                               | I     |                                                                                                                              |
|                                  |                    |                         | intravesical therapy for non-muscle invasive cell bladder cancer using mitomycin                                                                                                             | GUBMITO                                               | I     |                                                                                                                              |
|                                  | eye drops          | Ocular                  | eye drops as topical therapy for ocular malignancies                                                                                                                                         | OCMITO                                                | I     |                                                                                                                              |
|                                  | injectable         | Not Otherwise Specified |                                                                                                                                                                                              | Other tumour site code followed by 'NOS' (e.g. GUNOS) | I     |                                                                                                                              |



**BC Cancer Benefit Drug List  
May 2025**

| DRUG                  | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                    | PROTOCOL CODES                                 | CLASS | NOTES |
|-----------------------|-------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|-------|-------|
| mitotane              | tablet      | Genitourinary           | treatment of advanced adrenal cortical cancer                                                                                                                           | GUMITO                                         | I     |       |
|                       |             |                         | treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide, cisplatin and mitotane                                                                      | GUEDPM                                         | I     |       |
| mitoxantrone          | injectable  | Genitourinary           | palliative therapy for hormone-refractory prostate cancer using mitoxantrone and prednisone                                                                             | GUPMX                                          | I     |       |
|                       |             | Not Otherwise Specified |                                                                                                                                                                         | Other tumour site code followed by 'NOS' (e.g. | I     |       |
| mogamulizumab         | injectable  | Lymphoma                | Treatment of Mycosis Fungoides and Sézary Syndrome with Mogamulizumab                                                                                                   | ULYMOGA                                        | R     |       |
| nelarabine            | injectable  | Pediatric               | Nelarabine for addition to front-line multi-agent therapy of pediatric, adolescent, and young adult patients with intermediate- or high-risk T-cell acute lymphoblastic |                                                | I     |       |
| nilotinib             | tablet      | Leukemia & BMT          | Treatment of Chronic Myeloid Leukemia using Nilotinib                                                                                                                   | LKCLMLN                                        | I     |       |
| niraparib             | capsule     | Gynecology              | Maintenance Treatment of Newly Diagnosed Platinum Responsive Epithelial Ovarian Cancer using Niraparib                                                                  | GOOVFNIRM                                      | I     |       |
|                       |             |                         | Maintenance Treatment of Relapsed Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Niraparib                                                           | GOOVNIRAM                                      | I     |       |
| niraparib-abiraterone | tablet      | Genitourinary           | Treatment for Metastatic Castration-Resistant Prostate Cancer using Niraparib-Abiraterone and Prednisone                                                                | UGUPAVNABI                                     | R     |       |
| nivolumab             | injectable  | Gastrointestinal        | Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer using Nivolumab                                                                           | GIAJNIV                                        | I     |       |
|                       |             |                         | First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab                    | GIGAVCOXN                                      | I     |       |
|                       |             |                         | First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab        | GIGAVFFOXN                                     | I     |       |
|                       |             | Genitourinary           | Adjuvant Treatment of Resected Urothelial Carcinoma using Nivolumab                                                                                                     | UGUAJNIV                                       | R     |       |
|                       |             |                         | Adjuvant Treatment of Resected Urothelial Carcinoma using 4-Weekly Nivolumab                                                                                            | UGUAJNIV4                                      | R     |       |
|                       |             |                         | treatment of metastatic or advanced renal cell carcinoma using ipilimumab and nivolumab                                                                                 | GUAVIPNI                                       | I     |       |
|                       |             |                         | treatment of metastatic or advanced renal cell carcinoma using nivolumab                                                                                                | GUAVNIV                                        | I     |       |
|                       |             |                         | treatment of metastatic or advanced renal cell carcinoma using 4-weekly nivolumab                                                                                       | GUAVNIV4                                       | I     |       |
|                       |             |                         | Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab and Cabozantinib                                                                               | GUAVNIVC                                       | I     |       |
|                       |             |                         | Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-weekly Nivolumab and Cabozantinib                                                                      | GUAVNIVC4                                      | I     |       |
|                       |             | Head and Neck           | Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using Nivolumab                             | HNAVIV                                         | I     |       |
|                       |             |                         | Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab                    | HNAVIV4                                        | I     |       |
|                       |             | Lung                    | Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PACLitaxel                                                                          | LUAJNIVPC                                      | I     |       |
|                       |             |                         | Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum                                                                | LUAJNIVPP                                      | I     |       |
|                       |             |                         | treatment of advanced non-small cell lung cancer using nivolumab                                                                                                        | LUAVNIV                                        | I     |       |
|                       |             |                         | treatment of advanced non-small cell lung cancer using 4-weekly nivolumab                                                                                               | LUAVNIV4                                       | I     |       |
|                       |             |                         | First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab                                             | LUAVPCIPNI                                     | I     |       |
|                       |             |                         | First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab                                            | LUAVPPIPNI                                     | I     |       |
|                       |             |                         | Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab                                                                                                      | LUMMIPNI                                       | I     |       |
|                       |             |                         | Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab                                                                                             | LUMMIPNI3                                      | I     |       |
|                       |             | Lymphoma                | treatment of relapsed or refractory Hodgkin lymphoma using nivolumab                                                                                                    | LYNIV                                          | I     |       |
|                       |             |                         | treatment of relapsed or refractory Hodgkin lymphoma using 4-weekly nivolumab                                                                                           | LYNIV4                                         | I     |       |
|                       |             | Skin & Melanoma         | adjuvant treatment of resected stage III-IV NED melanoma using nivolumab                                                                                                | SMAJNIV                                        | I     |       |
|                       |             |                         | adjuvant treatment of resected stage III-IV NED melanoma using 4-weekly nivolumab                                                                                       | SMAJNIV4                                       | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                 | DOSAGE FORM             | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                           | PROTOCOL CODES | CLASS | NOTES |
|----------------------|-------------------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| nivolumab (cont'd)   | injectable              | Skin & Melanoma  | Treatment of Unresectable or Metastatic Melanoma Using Alternative Dosing Regimen of Ipilimumab and Nivolumab                                                  | SMAVALIPNI     | I     |       |
|                      |                         |                  | treatment of unresectable or metastatic melanoma using ipilimumab and nivolumab                                                                                | SMAVIPNI       | I     |       |
|                      |                         |                  | treatment of unresectable or metastatic melanoma using nivolumab                                                                                               | SMAVNIV        | I     |       |
|                      |                         |                  | treatment of unresectable or metastatic melanoma using 4-weekly nivolumab                                                                                      | SMAVNIV4       | I     |       |
| nivolumab-relatlimab | injectable              | Skin & Melanoma  | Treatment of Unresectable or Metastatic Melanoma using Nivolumab-Relatlimab                                                                                    | USMAVNIVRE     | R     |       |
| obinutuzumab         | injectable              | Lymphoma         | Treatment of Rituximab-refractory Follicular Lymphoma with Bendamustine in Combination with Obinutuzumab                                                       | LYBENDO        | I     |       |
|                      |                         |                  | Treatment of ritUXImab-refractory Follicular Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISine, predniSONE, and oBINutuzumab                             | LYCHOPO        | I     |       |
|                      |                         |                  | Treatment of ritUXImab-refractory Follicular Lymphoma with Cyclophosphamide, vinCRISine, predniSONE and oBINutuzumab                                           | LYCVPO         | I     |       |
|                      |                         |                  | Treatment of ritUXImab-refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and oBINutuzumab                                               | LYGDPO         | I     |       |
|                      |                         |                  | treatment of previously untreated chronic lymphocytic leukemia using obinutuzumab in combination with chlorambucil                                             | LYOBCHLOR      | I     |       |
|                      |                         |                  | Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Obinutuzumab                                 | LYVENOB        | I     |       |
| octreotide           | short acting injectable | Neuro-Oncology   | treatment of growth hormone secreting pituitary adenoma                                                                                                        | CNNOS          | I     |       |
|                      |                         | Gastrointestinal | management of non-functional neuroendocrine tumours of the GI tract; symptomatic management of functional carcinoid and neuroendocrine tumours of the GI tract | GINOS          | I     |       |
|                      | long acting injectable  | Neuro-Oncology   | Treatment of Growth Hormone Secreting Pituitary Adenoma using Octreotide Long Acting                                                                           | CNOCTLAR       | I     |       |
|                      |                         | Gastrointestinal | Management of Non-Functional Neuroendocrine Tumours of the GI Tract using Octreotide Long Acting                                                               | GINFOCLAR      | I     |       |
|                      |                         |                  | Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumors of the GI Tract using Octreotide Long Acting                                          | GIOCTLAR       | I     |       |
| olaparib             | tablet                  | Breast           | Treatment of BRCA-Mutated High-Risk Early Breast Cancer using Olaparib                                                                                         | UBRAJOLA       | R     |       |
|                      |                         | Genitourinary    | Treatment for Metastatic Castration-Resistant Prostate Cancer using Olaparib with Abiraterone and predniSONE                                                   | UGUPAVOABI     | R     |       |
|                      |                         |                  | Metastatic Castration-Resistant Prostate Cancer using Olaparib                                                                                                 | UGUPOLAP       | R     |       |
|                      |                         | Gynecology       | Maintenance Treatment of Newly Diagnosed BRCA-Mutated Platinum Responsive Epithelial Ovarian Cancer using Olaparib                                             | GOOVFOLAM      | I     |       |
|                      |                         |                  | Maintenance Treatment of Relapsed, BRCA-Mutated, Platinum Sensitive and Responsive Epithelial Ovarian Cancer using Olaparib                                    | GOOVOLAPM      | I     |       |
| osimertinib          | tablet                  | Lung             | Adjuvant Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) with Osimertinib                            | LUAJOSI        | I     |       |
|                      |                         |                  | treatment of EGFR T790M mutation-positive advanced non-small cell lung cancer with osimertinib                                                                 | LUAVOSI        | I     |       |
|                      |                         |                  | first-line treatment of EGFR mutation-positive advanced non-small cell lung cancer with osimertinib                                                            | LUAVOSIF       | I     |       |
| oxaliplatin          | injectable              | Gastrointestinal | adjuvant combination chemotherapy for stage III and IIB colon cancer with capecitabine                                                                         | GIAJCAPOX      | I     |       |
|                      |                         |                  | adjuvant combination chemotherapy for stage III and IIB colon cancer with fluorouracil and folinic acid                                                        | GIAJFFOX       | I     |       |
|                      |                         |                  | adjuvant combination chemotherapy for node-positive colon cancer using oxaliplatin and raltitrexed in patients intolerant to fluorouracil or capecitabine      | GIAJRALOX      | I     |       |
|                      |                         |                  | Palliative Therapy of Metastatic Colorectal Cancer using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine                    | GIAVRALOX      | I     |       |
|                      |                         |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin and capecitabine                                                        | GICAPOX        | I     |       |
|                      |                         |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, bevacizumab and capecitabine                                           | GICOXB         | I     |       |
|                      |                         |                  | combined modality therapy for locally advanced esophageal cancer using oxaliplatin, fluorouracil, leucovorin, and radiation therapy                            | GIEFFOXRT      | I     |       |
|                      |                         |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and bevacizumab                              | GIFFOXB        | I     |       |
|                      |                         |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab                              | GIFFOXPAN      | I     |       |
|                      |                         |                  |                                                                                                                                                                |                |       |       |
|                      |                         |                  |                                                                                                                                                                |                |       |       |
|                      |                         |                  |                                                                                                                                                                |                |       |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                 | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                                | PROTOCOL CODES | CLASS | NOTES |
|----------------------|-------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| oxaliplatin (cont'd) | injectable  | Gastrointestinal | palliative combination chemotherapy for advanced pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid (leucovorin)                                                | GIFIRINOX      | I     |       |
|                      |             |                  | palliative combination chemotherapy for metastatic colorectal cancer with fluorouracil and folinic acid                                                                                             | GIFOLFOX       | I     |       |
|                      |             |                  | adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin and capecitabine                                     | GIGAJCOX       | I     |       |
|                      |             |                  | adjuvant chemotherapy in gastric cancer patients with D2 resection (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, fluorouracil, and leucovorin                        | GIGAJFFOX      | I     |       |
|                      |             |                  | Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin                                                | GIGAVCOX       | I     |       |
|                      |             |                  | First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab                                                | GIGAVCOXN      | I     |       |
|                      |             |                  | First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab                                                                    | GIGAVCOXP      | I     |       |
|                      |             |                  | palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab                             | GIGAVCOXT      | I     |       |
|                      |             |                  | Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin                                    | GIGAVFFOX      | I     |       |
|                      |             |                  | First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab                                    | GIGAVFFOXN     | I     |       |
|                      |             |                  | First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab                                                        | GIGAVFFOXP     | I     |       |
|                      |             |                  | palliative treatment of metastatic or locally advanced HER-2 positive gastric, gastroesophageal junction, or esophageal adenocarcinoma using oxaliplatin, fluorouracil, leucovorin, and trastuzumab | GIGAVFFOXT     | I     |       |
|                      |             |                  | Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab                                                | GIGAVPCOXT     | I     |       |
|                      |             |                  | Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab                                    | GIGAVPFOXT     | I     |       |
|                      |             |                  | perioperative treatment of resectable adenocarcinoma of the stomach, gastroesophageal junction or lower 1/3 esophagus using docetaxel, oxaliplatin, infusional fluorouracil, and leucovorin         | GIGFLODOC      | I     |       |
|                      |             |                  | hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis from limited advanced colorectal and appendiceal carcinomas using oxaliplatin and fluorouracil        | GIHIPEC        | I     |       |
|                      |             |                  | adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and leucovorin                                                                             | GIPAJFIROX     | I     |       |
|                      |             |                  | Palliative Combination Chemotherapy for Metastatic Pancreatic or Biliary Tract Cancer using Oxaliplatin, Fluorouracil, and Leucovorin                                                               | GIPAVFFOX      | I     |       |
|                      |             |                  | Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin and Capecitabine                                                                                     | GIRAJCOX       | I     |       |
|                      |             |                  | Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin                                                                         | GIRAJFFOX      | I     |       |
|                      |             | Lymphoma         | Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase                                                               | LYGEMOXPEG     | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG       | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                              | PROTOCOL CODES | CLASS | NOTES |
|------------|-------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| paclitaxel | injectable  | Breast           | neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel                                                   | BRAJACT        | I     |       |
|            |             |                  | neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel                               | BRAJACTG       | I     |       |
|            |             |                  | neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab                                   | BRAJACTT       | I     |       |
|            |             |                  | neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab               | BRAJACTTG      | I     |       |
|            |             |                  | neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel                                      | BRAJACTW       | I     |       |
|            |             |                  | adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab                                                                                        | BRAJTTW        | I     |       |
|            |             |                  | treatment of metastatic breast cancer using gemcitabine and paclitaxel                                                                                            | BRAVGEMT       | I     |       |
|            |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with PACLitaxel                                                                               | BRAVPP         | I     |       |
|            |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Paclitaxel as First-Line Treatment for Advanced Breast Cancer                   | BRAVPTRAT      | I     |       |
|            |             |                  | palliative therapy for metastatic breast cancer using paclitaxel                                                                                                  | BRAVTAX        | I     |       |
|            |             |                  | palliative therapy for metastatic breast cancer using weekly paclitaxel (given weekly for 3 weeks out of 4 weeks) (replaces BRAVT7)                               | BRAVTW         | I     |       |
|            |             |                  | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide                        | BRLACTWAC      | I     |       |
|            |             |                  | Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide    | BRLACTWACG     | I     |       |
|            |             |                  | neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel followed by doxorubicin and cyclophosphamide                                           | BRLATACG       | I     |       |
|            |             |                  | treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by weekly paclitaxel                                                  | BRLATWAC       | I     |       |
|            |             |                  | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide    | BRPCTAC        | I     |       |
|            |             |                  | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide | BRPCWTAC       | I     |       |
|            |             | Gastrointestinal | First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using Carboplatin and Weekly Paclitaxel                                                | GIAAVCT        | I     |       |
|            |             |                  | neoadjuvant treatment of esophageal and gastroesophageal carcinomas using carboplatin, paclitaxel and radiation therapy                                           | GIENACTRT      | I     |       |
|            |             |                  | Second-Line Therapy for Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer using Weekly PACLitaxel and Ramucirumab                        | GIGAVRAMT      | I     |       |
|            |             |                  | hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel                           | GIPMHIPEC      | I     |       |
|            |             | Gynecology       | alternative treatment of gynecological malignancies using cisplatin and paclitaxel                                                                                | GOCISP         | I     |       |
|            |             |                  | Alternative Treatment of Gynecological Malignancies using Bevacizumab, Cisplatin and Paclitaxel                                                                   | GOCISPBEV      | I     |       |
|            |             |                  | combination with carboplatin as primary treatment of advanced/recurrent non-small cell cancer of the cervix in ambulatory care settings                           | GOCXCAT        | I     |       |
|            |             |                  | Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Carboplatin and Paclitaxel                    | UGOEAVDCAT     | R     |       |
|            |             |                  | Neoadjuvant or Adjuvant Treatment of Endometrial Cancer using CARBOplatin and PACLitaxel                                                                          | GOENDAJCAT     | I     |       |
|            |             |                  | Treatment of Advanced or Recurrent Endometrial Cancer using CARBOplatin and PACLitaxel                                                                            | GOENDAVCAT     | I     |       |
|            |             |                  |                                                                                                                                                                   |                |       |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                | DOSAGE FORM | TUMOUR SITE     | APPROVED INDICATIONS                                                                                                                                                                           | PROTOCOL CODES | CLASS | NOTES |
|---------------------|-------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| paclitaxel (cont'd) | injectable  | Gynecology      | primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer with high risk of relapse using bevacizumab, carboplatin and paclitaxel                         | GOOVCATB       | I     |       |
|                     |             |                 | primary treatment of invasive epithelial ovarian, fallopian tube and primary peritoneal cancer, with no visible residual tumour (moderate-high risk)                                           | GOOVCATM       | I     |       |
|                     |             |                 | ovarian cancer relapsing after complete remission of at least 4 months' duration in response to primary treatment with carboplatin and paclitaxel                                              | GOOVCATR       | I     |       |
|                     |             |                 | primary treatment of visible residual (extreme risk) invasive epithelial ovarian cancer                                                                                                        | GOOVCATX       | I     |       |
|                     |             |                 | primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab, carboplatin and paclitaxel                                                                                    | GOCXCATB       | I     |       |
|                     |             |                 | Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab                                               | UGOCXCATBP     | R     |       |
|                     |             |                 | Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel, and Pembrolizumab                                                           | UGOCXCATP      | R     |       |
|                     |             |                 | Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel                                                                                                     | GOOVBEVP       | I     |       |
|                     |             |                 | primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using carboplatin and weekly paclitaxel                                                      | GOOVDDCAT      | I     |       |
|                     |             |                 | primary treatment of stage III less than or equal to 1 cm visible residual invasive epithelial ovarian cancer using intravenous and intraperitoneal paclitaxel and intraperitoneal carboplatin | GOOVIPPC       | I     |       |
|                     |             |                 | progressive, platinum-refractory ovarian carcinoma, primary peritoneal carcinoma or fallopian tube carcinoma                                                                                   | GOOV TAX3      | I     |       |
|                     |             | Genitourinary   | palliative therapy for germ cell cancers using paclitaxel and gemcitabine                                                                                                                      | GUTAXGEM       | I     |       |
|                     |             |                 | advanced therapy for relapsed testicular germ cell cancer using paclitaxel, ifosfamide and cisplatin                                                                                           | GUTIP          | I     |       |
|                     |             | Head and Neck   | treatment for unresectable, locoregionally recurrent or metastatic squamous cell carcinoma of the head and neck using paclitaxel and cisplatin or carboplatin                                  | HNAVPC         | I     |       |
|                     |             |                 | First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Paclitaxel, Carboplatin and Pembrolizumab                                                                   | HNAVPCPMB      | I     |       |
|                     |             | Lung            | treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin and paclitaxel                                                                                                  | HNAVPC         | I     |       |
|                     |             |                 | Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PACLitaxel                                                                                                 | LUAJNIVPC      | I     |       |
|                     |             |                 | adjuvant carboplatin and paclitaxel following resection of stage I, II and IIIA non-small cell lung cancer                                                                                     | LUAJPC         | I     |       |
|                     |             |                 | combination with carboplatin as first line treatment of advanced non-small cell lung cancer                                                                                                    | LUAVPC         | I     |       |
|                     |             |                 | First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab                                                                    | LUAVPCIPNI     | I     |       |
|                     |             |                 | first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel, carboplatin and pembrolizumab                                                                            | LUAVPCPMB      | I     |       |
|                     |             |                 | treatment of locally advanced non-small cell lung cancer using carboplatin and paclitaxel with radiation therapy                                                                               | LULACATRT      | I     |       |
|                     |             | Primary Unknown | primary treatment of cancer of unknown primary origin using carboplatin and paclitaxel                                                                                                         | PUCAT          | I     |       |
|                     |             | Pediatric       | treatment of recurrent or resistant pediatric malignant germ cell tumors with paclitaxel, ifosfamide and carboplatin (COG protocol AGCT0521)                                                   |                | I     |       |
|                     |             | Sarcoma         | Metastatic or Unresectable Angiosarcoma using Weekly Paclitaxel (3 Weeks out of 4 Weeks Schedule)                                                                                              | SAAVTW         | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                      | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                               | PROTOCOL CODES | CLASS | NOTES                            |
|---------------------------|-------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|----------------------------------|
| paclitaxel NAB (ABRAXANE) | injectable  | Breast           | Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE)                                                                                                     | BRAJPN         | I     |                                  |
|                           |             |                  | Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PAClitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab                                                         | BRAJPNCT       | I     |                                  |
|                           |             |                  | Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE) and Trastuzumab                                                                                     | BRAJPNNT       | I     |                                  |
|                           |             |                  | Palliative Therapy for Metastatic Breast Cancer using PACLitaxel NAB (ABRAXANE)                                                                                                    | BRAVABR        | I     |                                  |
|                           |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and PACLitaxel NAB (ABRAXANE)                                                                                  | BRAVPPN        | I     |                                  |
|                           |             |                  | Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide                     | BRLACPNAC      | I     |                                  |
|                           |             |                  | Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide | BRLACPNACG     | I     |                                  |
|                           |             |                  | Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide                                    | BRLAPNAC       | I     |                                  |
|                           |             |                  | Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide                                 | BRLAPNACG      | I     |                                  |
|                           |             | Gastrointestinal | First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PACLitaxel NAB (ABRAXANE) and Gemcitabine                                                           | GIPGEMABR      | I     |                                  |
|                           |             | Gynecology       | Alternative Treatment of Gynecological Malignancies Using CARBOplatin and PACLitaxel NAB (ABRAXANE)                                                                                | GOCABR         | I     |                                  |
|                           |             |                  | Alternative Treatment of Gynecological Malignancies Using Bevacizumab, CARBOplatin and PACLitaxel NAB (ABRAXANE)                                                                   | GOCABRBEV      | I     |                                  |
|                           |             |                  | Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and Pembrolizumab                | GOCXCPNBP      | I     |                                  |
|                           |             |                  | Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel NAB (ABRAXANE), and Pembrolizumab                            | GOCXCPNP       | I     |                                  |
|                           |             |                  | Alternative Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Dostarlimab with Paclitaxel NAB and Carboplatin                     | UGOEAVDPNC     | R     |                                  |
| palbociclib               | tablet      | Breast           | Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor with or without LHRH Agonist                                                                           | BRAVPAI        | I     |                                  |
|                           |             |                  | Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant with or without LHRH Agonist                                                                                   | BRAVPBFLV      | I     |                                  |
| pamidronate               | injectable  | Breast           | adjuvant therapy for breast cancer in post-menopausal women using pamidronate bony metastases associated with breast cancer for patients who do not tolerate oral clodronate       | BRAJPAM        | I     | Not reimbursed for hypercalcemia |
|                           |             |                  | prevention of skeletal related events secondary to breast cancer using pamidronate                                                                                                 | BRAVPAM        | I     |                                  |
|                           |             | Myeloma          | multiple myeloma                                                                                                                                                                   | MYPAM          | I     |                                  |
|                           |             |                  |                                                                                                                                                                                    |                |       |                                  |
| panitumumab               | injectable  | Gastrointestinal | Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer using Panitumumab and Encorafenib                                                                                     | UGIAVPANEN     | R     |                                  |
|                           |             |                  | palliative third-line treatment of metastatic colorectal cancer using panitumumab with wild type KRAS                                                                              | GIAVPANI       | I     |                                  |
|                           |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using irinotecan, fluorouracil, leucovorin, and panitumumab                                                   | GIFFIRPAN      | I     |                                  |
|                           |             |                  | palliative combination chemotherapy for metastatic colorectal cancer using oxaliplatin, fluorouracil, leucovorin, and panitumumab                                                  | GIFFOXPAN      | I     |                                  |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                     | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                | PROTOCOL CODES | CLASS | NOTES |
|--------------------------|-------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| pazopanib                | tablet      | Genitourinary    | palliative therapy for renal cell carcinoma using pazopanib                                                                                                         | GUPAZO         | I     |       |
| pegaspargase (ONCASPAR®) | injectable  | Lymphoma         | treatment of refractory or relapsing extranodal natural killer or T-Cell lymphoma using pegaspargase, methotrexate and dexamethasone                                | LYASPMEDX      | I     |       |
|                          |             |                  | Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase                               | LYGEMOXPEG     | I     |       |
|                          |             |                  | treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide                                            | LYSMILE        | I     |       |
|                          |             |                  | treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma using pegaspargase (ONCASPAR)                                                                  | LKNOS, LYNOS   | I     |       |
|                          |             | Pediatric        | pediatric patients with leukemia or lymphoma                                                                                                                        |                | I     |       |
| peginterferon alfa-2a    | injectable  | Leukemia & BMT   | therapy of chronic myeloid neoplasms and hypereosinophilic syndrome                                                                                                 | LKPEGIFN       | I     |       |
| pembrolizumab            | injectable  | Breast           | Adjuvant Treatment of Resected Triple Negative Breast Cancer using Pembrolizumab                                                                                    | BRAJPEM        | I     |       |
|                          |             |                  | Treatment of Metastatic Breast Cancer using Pembrolizumab                                                                                                           | BRAVPEM        | I     |       |
|                          |             |                  | Treatment of Metastatic Breast Cancer using 6-Weekly Pembrolizumab                                                                                                  | BRAVPEM6       | I     |       |
|                          |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin                                                                   | BRAVPGC        | I     |       |
|                          |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with PACLitaxel                                                                                 | BRAVPP         | I     |       |
|                          |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and PACLitaxel NAB (ABRAXANE)                                                                   | BRAVPPN        | I     |       |
|                          |             |                  | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide      | BRPCTAC        | I     |       |
|                          |             |                  | NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide   | BRPCWTAC       | I     |       |
|                          |             | Gastrointestinal | First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using Pembrolizumab                                                                                 | UGIAVPEM       | R     |       |
|                          |             |                  | First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using 6-Weekly Pembrolizumab                                                                        | UGIAVPEM6      | R     |       |
|                          |             |                  | First-line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum                                                      | GIAVPEMPG      | I     |       |
|                          |             |                  | First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab                                    | GIGAVCOXP      | I     |       |
|                          |             |                  | First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab                        | GIGAVFFOXP     | I     |       |
|                          |             |                  | Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab                | GIGAVPCOXT     | I     |       |
|                          |             |                  | Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab    | GIGAVPFOXT     | I     |       |
|                          |             | Gynecology       | Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Pembrolizumab with or without Bevacizumab                               | GOCXBP         | I     |       |
|                          |             |                  | Maintenance Therapy of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with 6-Weekly Pembrolizumab with or without Bevacizumab                      | GOCXBP6        | I     |       |
|                          |             |                  | Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel and Pembrolizumab                    | UGOCXCATBP     | R     |       |
|                          |             |                  | Primary Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with CARBOplatin, PACLitaxel, and Pembrolizumab                                | UGOCXCATP      | R     |       |
|                          |             |                  | Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and Pembrolizumab | GOCXCPNBP      | I     |       |
|                          |             |                  | Alternative Treatment of Squamous, Adenocarcinoma, or Adenosquamous Cancer of the Cervix with Bevacizumab, CARBOplatin, PACLitaxel NAB (ABRAXANE) and Pembrolizumab | GOCXCPNP       | I     |       |
|                          |             |                  | Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using Pembrolizumab                                                    | UGOENDAVP      | R     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                   | DOSAGE FORM | TUMOUR SITE   | APPROVED INDICATIONS                                                                                                                     | PROTOCOL CODES | CLASS | NOTES |
|------------------------|-------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| pembrolizumab (cont'd) | injectable  | Gynecology    | Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using Pembrolizumab and Lenvatinib          | GOENDAVPL      | I     |       |
|                        |             |               | Treatment of Endometrial Cancer With Microsatellite Stability or Mismatch Repair Proficiency using 6-weekly Pembrolizumab and Lenvatinib | GOENDAVPL6     | I     |       |
|                        |             |               | Treatment of Microsatellite Instability-High or Mismatch Repair Deficient Endometrial Cancer using 6-Weekly Pembrolizumab                | UGOENDAVP6     | R     |       |
|                        |             | Genitourinary | Adjuvant Treatment of Resected Renal Cell Carcinoma using Pembrolizumab                                                                  | GUAJPEM        | I     |       |
|                        |             |               | Adjuvant Treatment of Resected Renal Cell Carcinoma using 6-Weekly Pembrolizumab                                                         | GUAJPEM6       | I     |       |
|                        |             |               | treatment of locally advanced or metastatic urothelial carcinoma using pembrolizumab                                                     | GUAVPEM        | I     |       |
|                        |             |               | Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Lenvatinib                                                          | GUAVPEML       | I     |       |
|                        |             |               | Treatment of Metastatic Renal Cell Carcinoma using 6-weekly Pembrolizumab and Lenvatinib                                                 | GUAVPEML6      | I     |       |
|                        |             |               | treatment of locally advanced or metastatic urothelial carcinoma using 6-weekly pembrolizumab                                            | GUAVPEM6       | I     |       |
|                        |             |               | Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Axitinib                                                            | GUAVPEMAX      | I     |       |
|                        |             | Head and Neck | First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Paclitaxel, Carboplatin and Pembrolizumab             | HNAVPCPMB      | I     |       |
|                        |             |               | First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab             | HNAVFPMB       | I     |       |
|                        |             |               | First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Pembrolizumab                                         | HNAVPMBF       | I     |       |
|                        |             |               | First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using 6-Weekly Pembrolizumab                               | HNAVPMBF6      | I     |       |
|                        |             |               | Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Pembrolizumab                                        | HNAVPMBM       | I     |       |
|                        |             |               | Maintenance Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using 6-Weekly Pembrolizumab                              | HNAVPMBM6      | I     |       |
|                        |             | Lung          | first-line treatment of advanced squamous non-small cell lung cancer with paclitaxel, carboplatin and pembrolizumab                      | LUAVPCPMB      | I     |       |
|                        |             |               | first-line treatment of advanced squamous non-small cell lung cancer with platinum, gemcitabine and pembrolizumab                        | LUAVGPMB       | I     |       |
|                        |             |               | second-line treatment of advanced non-small cell lung cancer using pembrolizumab                                                         | LUAVPMB        | I     |       |
|                        |             |               | treatment of advanced non-small cell lung cancer using 6-weekly pembrolizumab                                                            | LUAVPMB6       | I     |       |
|                        |             |               | first-line treatment of advanced non-small cell lung cancer using pembrolizumab                                                          | LUAVPMBF       | I     |       |
|                        |             |               | first-line treatment of advanced non-small cell lung cancer using 6-weekly pembrolizumab                                                 | LUAVPMBF6      | I     |       |
|                        |             |               | maintenance therapy of advanced non-small cell lung cancer with pembrolizumab                                                            | LUAVPMBM       | I     |       |
|                        |             |               | maintenance therapy of advanced non-small cell lung cancer with 6-weekly pembrolizumab                                                   | LUAVPMBM6      | I     |       |
|                        |             |               | maintenance therapy of advanced non-squamous non-small cell lung cancer with pemetrexed and pembrolizumab                                | LUAVPPMBM      | I     |       |
|                        |             |               | first-line treatment of advanced non-squamous non-small cell lung cancer with platinum, pemetrexed and pembrolizumab                     | LUAVPPMB       | I     |       |
|                        |             | Lymphoma      | treatment of relapsed or refractory hodgkin lymphoma using pembrolizumab                                                                 | LYPEM          | I     |       |
|                        |             |               | treatment of relapsed or refractory hodgkin lymphoma using 6-weekly pembrolizumab                                                        | LYPEM6         | I     |       |



**BC Cancer Benefit Drug List  
May 2025**

| DRUG                   | DOSAGE FORM | TUMOUR SITE     | APPROVED INDICATIONS                                                                                                                                    | PROTOCOL CODES | CLASS | NOTES |
|------------------------|-------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|-------|
| pembrolizumab (cont'd) | injectable  | Skin & Melanoma | Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using Pembrolizumab                                                                         | SMAJPEM        | I     |       |
|                        |             |                 | Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using 6-Weekly Pembrolizumab                                                                | SMAJPEM6       | I     |       |
|                        |             |                 | treatment of unresectable or metastatic melanoma using pembrolizumab                                                                                    | SMAVPEM        | I     |       |
|                        |             |                 | treatment of unresectable or metastatic melanoma using 6-weekly pembrolizumab                                                                           | SMAVPEM6       | I     |       |
|                        |             |                 | Neoadjuvant-Adjuvant Treatment of Stage IIIB to IV Melanoma using Pembrolizumab                                                                         | SMNAPEM        | I     |       |
| pemetrexed             | injectable  | Lung            | Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum                                                | LUAJNIVPP      | I     |       |
|                        |             |                 | Adjuvant Cisplatin and Pemetrexed Following Resection of Non-Small Cell Lung Cancer                                                                     | LUAJPP         | I     |       |
|                        |             |                 | second-line treatment of advanced non-small cell lung cancer                                                                                            | LUAVPEM        | I     |       |
|                        |             |                 | maintenance therapy of advanced non-small cell lung cancer after first-line chemotherapy                                                                | LUAVPMTN       | I     |       |
|                        |             |                 | first-line treatment of advanced non-small cell lung cancer with platinum and pemetrexed                                                                | LUAVPP         | I     |       |
|                        |             |                 | First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab                            | LUAVPPIPNI     | I     |       |
|                        |             |                 | maintenance therapy of advanced non-squamous non-small cell lung cancer with pemetrexed and pembrolizumab                                               | LUAVPPMBM      | I     |       |
|                        |             |                 | first-line treatment of advanced non-squamous non-small cell lung cancer with platinum, pemetrexed and pembrolizumab                                    | LUAVPPMB       | I     |       |
|                        |             |                 | treatment of malignant mesothelioma with platinum and pemetrexed                                                                                        | LUMMPP         | I     |       |
| pertuzumab             | injectable  | Breast          | Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Docetaxel as First-Line Treatment for Advanced Breast Cancer          | BRAVPTRAD      | I     |       |
|                        |             |                 | Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Paclitaxel as First-Line Treatment for Advanced Breast Cancer         | BRAVPTRAT      | I     |       |
|                        |             |                 | Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer       | BRAVPTRVIN     | I     |       |
| plerixafor             | injectable  |                 | hematopoietic stem cell mobilization                                                                                                                    | PLERIXAFOR     | I     |       |
| polatuzumab vedotin    | injectable  | Lymphoma        | Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab | LYPOLABR       | I     |       |
| pomalidomide           | capsule     | Myeloma         | Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide                                           | UMYISAPOMD     | R     |       |
|                        |             |                 | therapy of multiple myeloma using pomalidomide with dexamethasone                                                                                       | UMYPOMDEX      | R     |       |
| ponatinib              | tablet      | Leukemia & BMT  | treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia using ponatinib                                                              | ULKCMLP        | R     |       |
| pralatrexate           | injectable  | Lymphoma        | Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) with Pralatrexate                                                                 | LYPRA          | I     |       |
| prednisolone           | suspension  | Pediatric       | pediatric patients                                                                                                                                      |                | I     |       |
| prednisone             | tablet      | Genitourinary   | palliative therapy for metastatic castration resistant prostate cancer sing cabazitaxel and prednisone                                                  | GUPCABA        | I     |       |
|                        |             |                 | Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone                                                            | GUMCSPABI      | I     |       |
|                        |             |                 | Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and prednisone                                                 | UGUPABI        | R     |       |
|                        |             |                 | Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer using Abiraterone and predniSONE                                         | UGUPAJABI      | R     |       |
|                        |             |                 | Treatment for Metastatic Castration-Resistant Prostate Cancer using Niraparib-Abiraterone and Prednisone                                                | UGUPAVNABI     | R     |       |
|                        |             |                 | Treatment for Metastatic Castration-Resistant Prostate Cancer using Olaparib with Abiraterone and predniSONE                                            | UGUPAVOABI     | R     |       |
|                        |             |                 | palliative therapy for metastatic hormone refractory prostate cancer                                                                                    | GUPDOC         | I     |       |
|                        |             |                 | palliative therapy for hormone-refractory prostate cancer using mitoxantrone and prednisone                                                             | GUPMX          | I     |       |
|                        |             |                 |                                                                                                                                                         |                |       |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                  | PROTOCOL CODES                                        | CLASS | NOTES |
|---------------------|-------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-------|
| prednisone (cont'd) | tablet      | Lymphoma                | treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone                                                                                  | LYCHOP                                                | I     |       |
|                     |             |                         | Treatment of ritUXImab-refractory Follicular Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine, predniSONE, and oBINutuzumab                                   | LYCHOPO                                               | I     |       |
|                     |             |                         | treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab                                                                       | LYCHOPR                                               | I     |       |
|                     |             |                         | central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma                                                   | LYCHOPRMTX                                            | I     |       |
|                     |             |                         | treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab vedotin                             | LYCHPBV                                               | I     |       |
|                     |             |                         | treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab                                                      | LYCLLCVPR                                             | I     |       |
|                     |             |                         | advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone                                                                                         | LYCVP                                                 | I     |       |
|                     |             |                         | Treatment of ritUXImab-refractory Follicular Lymphoma with Cyclophosphamide, vinCRIStine, predniSONE and oBINutuzumab                                                 | LYCVPO                                                | I     |       |
|                     |             |                         | treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone                                                                        | LYCVPPABO                                             | I     |       |
|                     |             |                         | treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab                                                                 | LYCVPR                                                | I     |       |
|                     |             |                         | therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia or multiple myeloma using cyclophosphamide                                                       | LYCYCLO                                               | I     |       |
|                     |             |                         | Treatment of Previously Untreated Light Chain Amyloidosis and Not-Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone | LYDARCBD                                              | I     |       |
|                     |             |                         | treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate                | LYEPOCHR                                              | I     |       |
|                     |             |                         | lymphoma palliative chemotherapy                                                                                                                                      | LYPALL                                                | I     |       |
|                     |             | Myeloma                 | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone                         | MYBLDF                                                | I     |       |
|                     |             |                         | Treatment of Multiple Myeloma using Lenalidomide, Bortezomib and Dexamethasone as Induction Pre-Stem Cell Transplant                                                  | MYBLDPRE                                              | I     |       |
|                     |             |                         | Treatment of Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant                                  | MYBORPRE                                              | I     |       |
|                     |             |                         | Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone With or Without Cyclophosphamide                                                               | MYBORREL                                              | I     |       |
|                     |             |                         | treatment of relapsed and refractory multiple myeloma with daratumumab in combination with bortezomib and dexamethasone with or without cyclophosphamide              | MYDARBD                                               | I     |       |
|                     |             |                         | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone        | MYDARCBD                                              | I     |       |
|                     |             |                         | treatment of relapsed and refractory multiple myeloma with daratumumab in combination with lenalidomide and dexamethasone                                             | MYDARLD                                               | I     |       |
|                     |             |                         | Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Daratumumab, Lenalidomide and Dexamethasone                        | MYDARLDF                                              | I     |       |
|                     |             |                         | Treatment of Multiple Myeloma using Melphalan and Prednisone                                                                                                          | MYMP                                                  | I     |       |
|                     |             |                         | treatment of multiple myeloma using melphalan, prednisone and weekly bortezomib with the option of substituting cyclophosphamide for melphalan                        | MYMPBOR                                               | I     |       |
|                     |             | Not Otherwise Specified |                                                                                                                                                                       | Other tumour site code followed by 'NOS' (e.g. LKNOS) | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG         | DOSAGE FORM                | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                    | PROTOCOL CODES                                        | CLASS | NOTES                                                                                                                                                                                                                          |
|--------------|----------------------------|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| procarbazine | capsule                    | Neuro-Oncology          | modified PCV chemotherapy of brain tumours using procarbazine, lomustine and vincristine                                                                                                                | CNMODPCV                                              | I     |                                                                                                                                                                                                                                |
|              |                            |                         | standard procarbazine for second-line treatment of recurrent brain tumor                                                                                                                                | CNPROC                                                | I     |                                                                                                                                                                                                                                |
|              |                            | Lymphoma                | treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone                                                                                                          | LYCVPPABO                                             | I     |                                                                                                                                                                                                                                |
|              |                            |                         | lymphoma palliative chemotherapy                                                                                                                                                                        | LYPALL                                                | I     |                                                                                                                                                                                                                                |
|              |                            | Not Otherwise Specified |                                                                                                                                                                                                         | Other tumour site code followed by 'NOS' (e.g. CNNOS) | I     |                                                                                                                                                                                                                                |
| radium-223   | radio-pharmaceutical       | Genitourinary           | therapy for metastatic castration resistant prostate cancer using radium-223                                                                                                                            | GUPRAD                                                | I     |                                                                                                                                                                                                                                |
| raltitrexed  | injectable                 | Gastrointestinal        | adjuvant combination chemotherapy for node-positive colon cancer using oxaliplatin and raltitrexed in patients intolerant to fluorouracil or capecitabine                                               | GIAJRALOX                                             | I     |                                                                                                                                                                                                                                |
|              |                            |                         | Palliative Therapy of Metastatic Colorectal Cancer using Irinotecan and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine                                                              | GIAVRALIR                                             | I     |                                                                                                                                                                                                                                |
|              |                            |                         | Palliative Therapy of Metastatic Colorectal Cancer using Oxaliplatin and Raltitrexed in Patients Intolerant to Fluorouracil or Capecitabine                                                             | GIAVRALOX                                             | I     |                                                                                                                                                                                                                                |
|              |                            |                         | unresectable or metastatic colorectal adenocarcinoma for patients with previous fluorouracil toxicity                                                                                                   | GIRALT                                                | I     |                                                                                                                                                                                                                                |
| ramucirumab  | injectable                 | Gastrointestinal        | Second-Line Therapy for Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer using Weekly PACLitaxel and Ramucirumab                                                              | GIGAVRAMT                                             | I     |                                                                                                                                                                                                                                |
| regorafenib  | tablet                     | Sarcoma                 | third line treatment of advanced gastrointestinal stromal cell tumours (GIST's) using regorafenib                                                                                                       | SAAVGR                                                | I     |                                                                                                                                                                                                                                |
|              |                            |                         | Treatment of Relapsed or Refractory Advanced Osteosarcoma using Regorafenib                                                                                                                             | SAAVOR                                                | I     |                                                                                                                                                                                                                                |
|              |                            | Gastrointestinal        | treatment of advanced hepatocellular carcinoma using regorafenib                                                                                                                                        | GIREGO                                                | I     |                                                                                                                                                                                                                                |
| ribociclib   | tablet                     | Breast                  | Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant with or without LHRH Agonist                                                                                                         | BRAVRBFLV                                             | I     |                                                                                                                                                                                                                                |
|              |                            |                         | Therapy of Advanced Breast Cancer using Ribociclib and Aromatase Inhibitor with or without LHRH Agonist                                                                                                 | BRAVRIBAI                                             | I     |                                                                                                                                                                                                                                |
| ripretinib   | tablet                     | Sarcoma                 | Fourth-Line Therapy of Advanced Gastrointestinal Stromal Cell Tumours (GIST) Using Ripretinib                                                                                                           | SAAVGRIP                                              | I     |                                                                                                                                                                                                                                |
| rituximab    | IV injectable only         | Leukemia & BMT          | pre-emptive rituximab therapy of Epstein-Barr virus related post-transplant lymphoproliferative disease                                                                                                 | BMTLPDRIT                                             | I     |                                                                                                                                                                                                                                |
|              | IV / 1400 mg SC injectable | Lymphoma                | treatment of Non-Hodgkin Lymphoma with bendamustine and rituximab                                                                                                                                       | LYBENDR                                               | I     |                                                                                                                                                                                                                                |
|              | IV / 1400 mg SC injectable |                         | treatment of indolent B-cell lymphoma with chlorambucil and rituximab                                                                                                                                   | LYCHLRR                                               | I     |                                                                                                                                                                                                                                |
|              | IV / 1400 mg SC injectable |                         | in combination with CHOP (cyclophosphamide, doxorubicin, prednisone, vincristine), in all stages of newly diagnosed diffuse large B-cell lymphoma and mantle cell lymphoma, advanced stage at diagnosis | LYCHOPR                                               | I     |                                                                                                                                                                                                                                |
|              | IV / 1400 mg SC injectable |                         | central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma                                                                                     | LYCHOPRMTX                                            | I     |                                                                                                                                                                                                                                |
|              | IV / 1600 mg SC injectable |                         | treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with bendamustine and rituximab                                                                             | LYCLLBENDR                                            | I     |                                                                                                                                                                                                                                |
|              | IV / 1600 mg SC injectable |                         | treatment of chronic lymphocytic leukemia with chlorambucil and rituximab                                                                                                                               | LYCLLCHLR                                             | I     |                                                                                                                                                                                                                                |
|              | IV / 1600 mg SC injectable |                         | treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab                                                                                        | LYCLLCVPR                                             | I     |                                                                                                                                                                                                                                |
|              | IV / 1600 mg SC injectable |                         | treatment of previously untreated chronic lymphocytic leukemia (CLL) with bendamustine and rituximab                                                                                                    | LYCLLFBR                                              | I     |                                                                                                                                                                                                                                |
|              | IV / 1600 mg SC injectable |                         | treatment of chronic lymphocytic leukemia or prolymphocytic leukemia with fludarabine and rituximab                                                                                                     | LYCLLFLUDR                                            | I     |                                                                                                                                                                                                                                |
|              | IV / 1600 mg SC injectable |                         |                                                                                                                                                                                                         |                                                       | I     | Note: Biosimilar rituximab (RIXIMYO®, RUXIENCE®) is funded for intravenous rituximab started on or after August 1st, 2020. RITUXAN® is funded for intravenous rituximab started prior to and continue beyond August 1st, 2020. |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                    | DOSAGE FORM                | TUMOUR SITE    | APPROVED INDICATIONS                                                                                                                                                                                                                    | PROTOCOL CODES | CLASS | NOTES                                                                                                                                                                                                                          |
|-------------------------|----------------------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| rituximab (cont'd)      | IV / 1400 mg SC injectable | Lymphoma       | treatment of Burkitt's lymphoma and leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab                                                                                                    | LYCODOXMR      | I     | Note: Biosimilar rituximab (RIXIMYO®, RUXIENCE®) is funded for intravenous rituximab started on or after August 1st, 2020. RITUXAN® is funded for intravenous rituximab started prior to and continue beyond August 1st, 2020. |
|                         | IV / 1400 mg SC injectable |                | combination with CVP for advanced stage indolent lymphoma at diagnosis                                                                                                                                                                  | LYCVPR         | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and ritUXimab                                                                                                                                                            | LYDHAPR        | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate                                                                                  | LYEPOCHR       | I     |                                                                                                                                                                                                                                |
|                         | IV / 1600 mg SC injectable |                | treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia with fludarabine, cyclophosphamide and rituximab                                                                                                             | LYFCR          | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | treatment of relapsed indolent lymphoma with fludarabine and rituximab                                                                                                                                                                  | LYFLUDR        | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | treatment of lymphoma with gemcitabine, dexamethasone and platinum with rituximab                                                                                                                                                       | LYGDPR         | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide                                                                                                                                 | LYHDMRTEM      | I     |                                                                                                                                                                                                                                |
|                         | IV / 1600 mg SC injectable |                | treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using idelalisib and rituximab                                                                                                              | LYIDELAR       | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | treatment of Burkitt's lymphoma and leukemia with ifosfamide, mesna, etoposide, cytarabine and rituximab                                                                                                                                | LYIVACR        | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Not Eligible for Transplant using Polatuzumab Vedotin, Bendamustine and Rituximab                                                                                 | LYPOLABR       | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | treatment of relapsed or refractory advanced stage aggressive B-cell non-Hodgkin's lymphoma with ifosfamide, carboplatin, etoposide and rituximab                                                                                       | LYRICE         | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | follicular lymphoma progressive despite alkylating agents and purine analogues (fludarabine or cladribine), post-transplant lymphoproliferative disease, or newly diagnosed (within 6 months) asymptomatic advanced follicular lymphoma | LYRITUX        | I     |                                                                                                                                                                                                                                |
|                         | IV injectable only         |                | Palliative Therapy For Lymphoma Using Radioimmunotherapy: ritUXimab-Priming for 90Y-Ibritumomab tiuxetan (ZEVALIN®)                                                                                                                     | LYRITZ         | I     |                                                                                                                                                                                                                                |
|                         | IV / 1400 mg SC injectable |                | maintenance treatment of indolent lymphoma                                                                                                                                                                                              | LYRMTN         | I     |                                                                                                                                                                                                                                |
| romidepsin              | IV / 1600 mg SC injectable | Pediatric      | treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax and rituximab                                                                                                              | LYVENETOR      | I     |                                                                                                                                                                                                                                |
|                         | IV injectable only         |                | pediatric patients treated on the COG protocols ANHL0221 for CD20 positive post-transplant lymphoproliferative disease following solid organ transplantation and ANHL01P1 for newly diagnosed advanced B-cell leukemia/lymphoma         |                | I     |                                                                                                                                                                                                                                |
| romidepsin              | injectable                 | Lymphoma       | treatment of relapsed or refractory Peripheral T-Cell lymphoma (PTCL) with romidepsin                                                                                                                                                   | ULYROMI        | R     |                                                                                                                                                                                                                                |
| ropeginterferon alfa-2b | injectable                 | Leukemia & BMT | Therapy of Chronic Myeloid Neoplasms and Hypereosinophilic Syndrome                                                                                                                                                                     | ULK0           | R     | Note Apr 1, 2025: Only reimbursable during peginterferon alfa-2a (PEGASYS) shortage                                                                                                                                            |
| ruxolitinib             | tablet                     | Leukemia & BMT | Treatment of Symptomatic Myelofibrosis with Ruxolitinib                                                                                                                                                                                 | LKMFRUX        | I     |                                                                                                                                                                                                                                |
|                         |                            |                | Treatment of Polycythemia Vera with Ruxolitinib                                                                                                                                                                                         | LKPCVRUX       | I     |                                                                                                                                                                                                                                |
| sacituzumab govitecan   | injectable                 | Breast         | Palliative Therapy for Metastatic Triple Negative Breast Cancer                                                                                                                                                                         | BRAVSG         | I     |                                                                                                                                                                                                                                |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG               | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                  | PROTOCOL CODES                                        | CLASS | NOTES                                                                             |
|--------------------|-------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-----------------------------------------------------------------------------------|
| sargramostim (SAP) | injectable  | Pediatric               | pediatric patients with neuroblastoma treated on the COG ANBL0032 protocol                                                                                                                                            |                                                       | I     | Approval from Health Canada Special Access Programme is required for each patient |
|                    |             |                         | pediatric patients with relapsed neuroblastoma treated on the COG ANBL1021 protocol                                                                                                                                   |                                                       | I     |                                                                                   |
|                    |             |                         | treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in combination with sargramostim, aldesleukin and tretinoin |                                                       | I     |                                                                                   |
| selinexor          | tablet      | Myeloma                 | Treatment of Multiple Myeloma using Bortezomib, Selinexor, and Dexamethasone With or Without Cyclophosphamide                                                                                                         | MYBSD                                                 | I     |                                                                                   |
| selpercatinib      | capsule     | Head and Neck           | Therapy of Advanced RET Fusion-Positive Differentiated Thyroid Cancer using Selpercatinib                                                                                                                             | HNOTDSEL                                              | I     |                                                                                   |
|                    |             |                         | Treatment of Advanced RET-Mutant Medullary Thyroid Cancer using Selpercatinib                                                                                                                                         | HNOTMSEL                                              | I     |                                                                                   |
|                    |             | Lung                    | Treatment of RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Selpercatinib                                                                                                                       | LUAVSEL                                               | I     |                                                                                   |
| siltuximab         | injectable  | Lymphoma                | treatment of Multicentric Castleman's Disease (MCD) negative for Human Immunodeficiency Virus (HIV) and Human Herpes Virus-8 (HHV-8) Using siltuximab                                                                 | LYSILTUX                                              | I     |                                                                                   |
| sorafenib          | tablet      | Gastrointestinal        | Therapy for Advanced Hepatocellular Carcinoma using Sorafenib                                                                                                                                                         | GISORAF                                               | I     |                                                                                   |
|                    |             | Genitourinary           | palliative therapy for renal cell carcinoma in patients after cytokine failure                                                                                                                                        | GUSORAF                                               | I     |                                                                                   |
|                    |             | Leukemia & BMT          | therapy of acute myeloid leukemia using azacitidine and sorafenib                                                                                                                                                     | LKAMLAS                                               | I     |                                                                                   |
| streptozocin       | injectable  | Gastrointestinal        | palliative therapy for pancreatic endocrine tumours using streptozocin and doxorubicin                                                                                                                                | GIENDO2                                               | I     | Approval from Health Canada Special Access Programme is required for each patient |
|                    |             | Not Otherwise Specified |                                                                                                                                                                                                                       | Other tumour site code followed by 'NOS' (e.g. GINOS) | I     |                                                                                   |
| sunitinib          | capsule     | Gastrointestinal        | as palliative treatment of advance pancreatic neuroendocrine tumours                                                                                                                                                  | GIPNSUNI                                              | I     |                                                                                   |
|                    |             | Genitourinary           | palliative therapy for renal cell carcinoma in patients who are not suitable candidates for interferon                                                                                                                | GUSUNI                                                | I     |                                                                                   |
|                    |             | Sarcoma                 | second line treatment of advanced c-kit positive gastrointestinal stromal cell tumours (GISTs) after imatinib                                                                                                         | SAAVGS                                                | I     |                                                                                   |
| tamoxifen          | tablet      | Breast                  | Treatment of Adjuvant Breast Cancer using Abemaciclib and Tamoxifen With or Without LHRH Agonist                                                                                                                      | UBRAJABET                                             | R     |                                                                                   |
|                    |             |                         | Adjuvant Treatment of Resected Ductal Carcinoma in Situ using Tamoxifen                                                                                                                                               | BRAJLDTAM                                             | I     |                                                                                   |
|                    |             |                         | Neoadjuvant or Adjuvant Therapy for Breast Cancer Using a LHRH Agonist and Tamoxifen                                                                                                                                  | BRAJLHRHT                                             | I     |                                                                                   |
|                    |             |                         | Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Tamoxifen                                                                                                                                                     | BRAJTAM                                               | I     |                                                                                   |
|                    |             |                         | Palliative Therapy for Breast Cancer Using a LHRH agonist and tamoxifen                                                                                                                                               | BRAVLHRHT                                             | I     |                                                                                   |
|                    |             |                         | Palliative Therapy for Breast Cancer Using Tamoxifen                                                                                                                                                                  | BRAVTAM                                               | I     |                                                                                   |
|                    |             | Gynecology              | Non-Aromatase Inhibitor Hormonal Treatment of Endometrial Cancer                                                                                                                                                      | GOENDH                                                | I     |                                                                                   |
|                    |             |                         | Therapy for Advanced Ovarian Cancer Using Tamoxifen                                                                                                                                                                   | GOOVTAM                                               | I     |                                                                                   |
|                    |             | Head and Neck           | Treatment of Recurrent/Metastatic Salivary Gland Cancers of the Head and Neck With Tamoxifen                                                                                                                          | HNSAVTAM                                              | I     |                                                                                   |
|                    |             | Sarcoma                 | Therapy for Recurrent Desmoid Tumours/Aggressive Fibromatosis Using Tamoxifen                                                                                                                                         | SATAM                                                 | I     |                                                                                   |
| tebentafusp        | injectable  | Skin & Melanoma         | Treatment of Metastatic Uveal Melanoma using Tebentafusp                                                                                                                                                              | USMAVTEB                                              | R     |                                                                                   |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                       | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                                                                                | PROTOCOL CODES                                        | CLASS | NOTES                                                         |
|----------------------------|-------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|---------------------------------------------------------------|
| temozolomide               | capsule     | Neuro-Oncology          | Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation                                                                                                                                                             | CNAJ12TZRT                                            | I     |                                                               |
|                            |             |                         | Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation                                                                                                                                                                          | CNAJTZRT                                              | I     |                                                               |
|                            |             |                         | Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy                                                                                                                                                                 | CNELTZRT                                              | I     |                                                               |
|                            |             |                         | Therapy for Newly Diagnosed Malignant Brain Tumours with MGMT Methylation in Elderly Patients using Temozolomide                                                                                                                                                                    | CNTEM60                                               | I     |                                                               |
|                            |             |                         | Therapy for Malignant Brain Tumours Using Temozolomide                                                                                                                                                                                                                              | CNTEMOZ                                               | I     |                                                               |
|                            |             |                         | Therapy for Malignant Brain Tumours using Metronomic Dosing of Temozolomide                                                                                                                                                                                                         | CNTEMOZMD                                             | I     |                                                               |
|                            |             |                         | Therapy for Recurrent Malignant Brain Tumours using Temozolomide and Etoposide                                                                                                                                                                                                      | CNTMZETO                                              | I     |                                                               |
|                            |             |                         | Palliative Therapy of Metastatic Neuroendocrine Cancer Using Temozolomide and Capecitabine                                                                                                                                                                                          | GIAVTZCAP                                             | I     |                                                               |
|                            |             | Gastrointestinal        |                                                                                                                                                                                                                                                                                     |                                                       |       |                                                               |
|                            |             | Lymphoma                | Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide                                                                                                                                                                             | LYHDMRTEM                                             | I     |                                                               |
|                            |             |                         | Treatment of Relapsed CNS Lymphoma using Temozolomide                                                                                                                                                                                                                               | LYTEM                                                 | I     |                                                               |
|                            |             | Pediatric               | pediatric patients with brain tumours                                                                                                                                                                                                                                               |                                                       | I     |                                                               |
|                            |             |                         | pediatric patients treated on the COG protocol ANBL0421 for recurrent neuroblastoma                                                                                                                                                                                                 |                                                       | I     |                                                               |
|                            |             |                         | pediatric patients with rhabdomyosarcoma treated on the COG ARST08P1 protocol                                                                                                                                                                                                       |                                                       | I     |                                                               |
|                            |             | Sarcoma                 | Therapy for Advanced Solitary Fibrous Tumours and Hemangiopericytoma Using Temozolomide and Bevacizumab                                                                                                                                                                             | SATEMBEV                                              | I     |                                                               |
|                            |             | Skin & Melanoma         | Palliative Therapy for Malignant Melanoma with Brain Metastases Using Temozolomide                                                                                                                                                                                                  | SMAVTMZ                                               | I     |                                                               |
| temsirolimus               | injectable  | Genitourinary           | therapy for advanced renal cancer using temsirolimus                                                                                                                                                                                                                                | GUTEM                                                 | I     |                                                               |
|                            |             | Pediatric               | treatment of recurrent/refractory rhabdomyosarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol                                                                                                                           |                                                       | I     |                                                               |
| teniposide                 | injectable  | Not Otherwise Specified |                                                                                                                                                                                                                                                                                     | Tumour site code followed by 'NOS' (e.g. GUNOS)       | I     |                                                               |
| testosterone enanthate     | injectable  | Breast                  | palliative therapy for metastatic breast cancer                                                                                                                                                                                                                                     | BRAVTEST                                              | I     | Not reimbursed for symptom management or appetite stimulation |
| thioguanine                | tablet      | Not Otherwise Specified |                                                                                                                                                                                                                                                                                     | Tumour site code followed by 'NOS' (e.g. LYNOS)       | I     |                                                               |
| thiotepa                   | injectable  | Miscellaneous Origins   | therapy for solid tumours using intrathecal methotrexate and/or thiotepa and/or cytarabine                                                                                                                                                                                          | MOIT                                                  | I     |                                                               |
|                            |             | Not Otherwise Specified |                                                                                                                                                                                                                                                                                     | Other tumour site code followed by 'NOS' (e.g. GUNOS) | I     |                                                               |
| thyrotropin alfa           | injectable  | Head and Neck           | radioiodine imaging in patients with thyroid cancer and treatment                                                                                                                                                                                                                   | HNOTTSH                                               | I     |                                                               |
| tisagenlecleucel (KYMRIA®) | CAR T-cell  | Pediatric               | Treatment of pediatric and young adult patients up to and including 25 years of age with B-cell acute lymphocytic leukemia (ALL) refractory to or relapsed after allogeneic stem cell transplantation (SCT) or otherwise ineligible for SCT, or experienced second or later relapse | PECARTALL                                             | R     |                                                               |
|                            |             | Lymphoma                | Third line treatment of adults with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)                                                                                                                                                                     | LYCARTDL3                                             | R     |                                                               |
| topotecan                  | injectable  | Gynecology              | treatment of relapsed/progressive epithelial ovarian, fallopian tube or primary peritoneal cancer using topotecan                                                                                                                                                                   | GOOVTOP                                               | I     |                                                               |
|                            | injectable  | Lung                    | second line treatment of recurrent small cell lung cancer                                                                                                                                                                                                                           | LUSCTOP                                               | I     |                                                               |
|                            |             | Pediatric               | pediatric sarcoma                                                                                                                                                                                                                                                                   |                                                       | I     |                                                               |
|                            |             |                         | intermediate-risk (COG ANBL0532) and high risk (COG ANBL0531) pediatric neuroblastoma                                                                                                                                                                                               |                                                       | I     |                                                               |
|                            |             | Sarcoma                 | summary for treatment of recurrent/refractory neuroblastoma, ewing's sarcoma, osteogenic sarcoma or rhabdomyosarcoma with topotecan/cyclophosphamide                                                                                                                                | SAAVTC                                                | I     |                                                               |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG        | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                                                   | PROTOCOL CODES | CLASS | NOTES                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------|-------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| trametinib  | tablet      | Skin & Melanoma  | adjuvant treatment of stage III and IV, BRAF-mutated, fully resected melanoma using dabrafenib and trametinib                                                                                                          | SMAJDT         | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib and trametinib                                                                                                           | SMAVDT         | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using trametinib                                                                                                                          | SMAVTRA        | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| trastuzumab | injectable  | Breast           | neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab                                                                                        | BRAJACTT       | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | neoadjuvant or adjuvant therapy for breast cancer using dose dense therapy: doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab                                                                    | BRAJACTTG      | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel and trastuzumab                                                                                                                         | BRAJDCARBT     | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide followed by docetaxel and trastuzumab                                                                            | BRAJFCDT       | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | Alternative Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE) and Trastuzumab                                                                                                                         | BRAJPNT        | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PAClitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab                                                                                             | BRAJPNCT       | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel and cyclophosphamide                                                                                                                    | BRAJTDCT       | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | Adjuvant Therapy for Breast Cancer using Trastuzumab Following the Completion of Chemotherapy (Sequential)                                                                                                             | BRAJTR         | I     | <p>Note: Biosimilar trastuzumab (HERZUMA®, TRAZIMERA®, ONTRUZANT®) is funded for treatment started on or after February 1st, 2020.</p> <p>HERCEPTIN® is only funded for:</p> <ul style="list-style-type: none"> <li>• treatment started prior to February 1st, 2020, or</li> <li>• treatment started prior to September 1, 2022 when used with pertuzumab for advanced breast cancer (BRAVPTRAD, BRAVPTRAT)</li> </ul> |
|             |             |                  | adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab                                                                                                                                             | BRAJTTW        | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Docetaxel as First-Line Treatment for Advanced Breast Cancer                                                                         | BRAVPTRAD      | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab and Paclitaxel as First-Line Treatment for Advanced Breast Cancer                                                                        | BRAVPTRAT      | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer                                                                      | BRAVPTRVIN     | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | palliative therapy for metastatic breast cancer using trastuzumab and capecitabine                                                                                                                                     | BRAVTCAP       | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | single agent therapy for metastatic breast cancer progressing after 1 prior regimens (e.g., taxane) and responding to trastuzumab in combination with paclitaxel, with paclitaxel and carboplatin, or with vinorelbine | BRAVTR         | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and Capecitabine                                                                                                                          | UBRAVTTCAP     | R     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab                                                                                               | BRLAACDT       | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             | Gastrointestinal | Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab                                                   | GIGAVCCT       | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using cisplatin, infusional fluorouracil and trastuzumab                                        | GIGAVCFT       | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  | palliative treatment of metastatic or locally advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma using capecitabine, oxaliplatin and trastuzumab                                                | GIGAVCOXT      | I     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |             |                  |                                                                                                                                                                                                                        |                |       |                                                                                                                                                                                                                                                                                                                                                                                                                        |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                             | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                                                                                                                                                      | PROTOCOL CODES | CLASS | NOTES                                                                                                                                       |
|----------------------------------|-------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------|
| trastuzumab (cont'd)             | Injectable  | Gastrointestinal | Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin                                                                                                          | GIGAVFFOXT     | I     | Note: Biosimilar trastuzumab (HERZUMA®, TRAZIMERA®, ONTRUZANT®) is funded for treatment started on or after February 1st, 2020. (See above) |
|                                  |             |                  | Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab                                                                                                                      | GIGAVPCOXT     | I     |                                                                                                                                             |
|                                  |             |                  | Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab                                                                                                          | GIGAVPFOXT     | I     |                                                                                                                                             |
|                                  |             |                  | continuation of palliative treatment of metastatic or inoperable, locally advanced gastric or gastroesophageal junction adenocarcinoma using trastuzumab                                                                                                                  | GIGAVTR        | I     |                                                                                                                                             |
| trastuzumab emtansine (KADCYLA)  | injectable  | Breast           | adjuvant therapy for breast cancer using trastuzumab emtansine (KADCYLA)                                                                                                                                                                                                  | UBRAJKAD       | R     |                                                                                                                                             |
|                                  |             |                  | palliative therapy for metastatic breast cancer using trastuzumab emtansine (KADCYLA)                                                                                                                                                                                     | BRAVKAD        | I     |                                                                                                                                             |
| trastuzumab deruxtecan (ENHERTU) | injectable  | Breast           | Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Deruxtecan (ENHERTU)                                                                                                                                                                                    | BRAVENH        | I     |                                                                                                                                             |
| tremelimumab                     | injectable  | Gastrointestinal | First-Line Treatment of Advanced Hepatocellular Carcinoma using Tremelimumab and Durvalumab                                                                                                                                                                               | GITREMDUR      | I     |                                                                                                                                             |
| treosulfan                       | injectable  | Leukemia & BMT   | Treosulfan for patients who previously received busulfan as part of conditioning regimen for stem cell transplant or are deemed high risk for hepatic sinusoidal obstructive syndrome or seizure with busulfan                                                            | BMTNOS         | I     |                                                                                                                                             |
|                                  |             |                  | Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia or myelodysplastic syndromes at increased risk for standard conditioning therapies | BMTNOS         | I     |                                                                                                                                             |
|                                  |             | Pediatric        | pre-conditioning therapy with treosulfan for pediatric patients at risk for busulfan-related toxicity prior to hematopoietic stem cell transplantation for malignant conditions                                                                                           |                | R     |                                                                                                                                             |
| tretinoin (VESANOID®)            | capsule     | Leukemia & BMT   | acute promyelocytic leukemia                                                                                                                                                                                                                                              | LKNOS          | I     |                                                                                                                                             |
|                                  |             |                  | first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide and tretinoin                                                                                                                                                       | LKATOATRA      | I     |                                                                                                                                             |
|                                  |             |                  | first-line induction and consolidation therapy of acute promyelocytic leukemia using arsenic trioxide, tretinoin and daunorubicin                                                                                                                                         | LKATOP         | I     |                                                                                                                                             |
|                                  |             |                  | induction and consolidation therapy of relapsed acute promyelocytic leukemia using arsenic trioxide and tretinoin (All-Trans Retinoic Acid)                                                                                                                               | LKATOR         | I     |                                                                                                                                             |
|                                  |             | Pediatric        | Treatment of Pediatric Patients with De Novo Acute Promyelocytic Leukemia using Arsenic Trioxide In Combination with Tretinoin and with or without Idarubicin and Dexamethasone on the COG AAML1331 Study                                                                 |                | I     |                                                                                                                                             |
|                                  |             |                  | treatment of pediatric patients with high-risk neuroblastoma who achieve a response to prior first-line multi-agent, multimodal therapy using dinutuximab in combination with sargramostim, aldesleukin and tretinoin                                                     |                | I     |                                                                                                                                             |
| trifluridine-tipiracil           | tablet      | Gastrointestinal | Therapy of Advanced Colorectal Cancer using Trifluridine-Tipiracil and Bevacizumab                                                                                                                                                                                        | GIAVTTB        | I     |                                                                                                                                             |
|                                  |             |                  | Third- or Later-Line Therapy of Advanced Gastroesophageal Carcinoma using Trifluridine-Tipiracil                                                                                                                                                                          | GIGAVTT        | I     |                                                                                                                                             |
| tucatinib                        | tablet      | Breast           | Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and Capecitabine                                                                                                                                                                             | UBRAVTTCAP     | R     |                                                                                                                                             |
| vandetanib                       | tablet      | Head and Neck    | treatment for locally advanced or metastatic medullary thyroid cancer using vandetanib                                                                                                                                                                                    | HNOTVAN        | I     |                                                                                                                                             |
| vemurafenib                      | tablet      | Skin & Melanoma  | treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib                                                                                                                                                                            | SMAVVEM        | I     |                                                                                                                                             |
|                                  |             |                  | treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma using vemurafenib and cobimetinib                                                                                                                                                            | SMAVVC         | I     |                                                                                                                                             |
| venetoclax                       | tablet      | Leukemia & BMT   | Therapy of Acute Myeloid Leukemia using Azacitidine and Venetoclax                                                                                                                                                                                                        | ULKAMLAVEN     | R     |                                                                                                                                             |
|                                  |             | Lymphoma         | treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax                                                                                                                                                              | ULYVENETO      | R     |                                                                                                                                             |
|                                  |             |                  | treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma using venetoclax and rituximab                                                                                                                                                | LYVENETOR      | I     |                                                                                                                                             |
|                                  |             |                  | Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Obinutuzumab                                                                                                                                            | LYVENOB        | I     |                                                                                                                                             |



**BC Cancer Benefit Drug List  
May 2025**

| DRUG        | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                        | PROTOCOL CODES                                        | CLASS | NOTES |
|-------------|-------------|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-------|
| vinblastine | injectable  | Genitourinary           | Neoadjuvant Treatment of Urothelial Cancer using Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin                                                            | GUBDDMVAC                                             | I     |       |
|             |             |                         | therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine, doxorubicin and cisplatin                                                          | GUMVAC                                                | I     |       |
|             |             |                         | consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin, ifosfamide and mesna                                                                    | GUVEIP                                                | I     |       |
|             |             | Kaposi's Sarcoma        | therapy for Kaposi's Sarcoma using vinblastine-vincristine                                                                                                                  | KSVB                                                  | I     |       |
|             |             | Lymphoma                | treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine and dacarbazine                                                                                     | LYABVD                                                | I     |       |
|             |             |                         | Treatment of Previously Untreated, Stage III or IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin                                      | LYAVDBV                                               | I     |       |
|             |             |                         | Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with Sequential Brentuximab Vedotin and DOXOrubicin, vinBLAStine and Dacarbazine in Patients 60 Years or Older | LYBVA/DBV                                             | I     |       |
|             |             |                         | treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone                                                                              | LYCVPPABO                                             | I     |       |
|             |             | Sarcoma                 | lymphoma palliative chemotherapy                                                                                                                                            | LYPALL                                                | I     |       |
|             |             |                         | palliative therapy for aggressive fibromatosis using weekly or alternate week methotrexate and vinblastine intravenously                                                    | SAMV                                                  | I     |       |
|             |             | Not Otherwise Specified |                                                                                                                                                                             | Other tumour site code followed by 'NOS' (e.g. LYNOS) | I     |       |
| vincristine | injectable  | Neuro-Oncology          | adjuvant lomustine, cisplatin and vincristine in adult high-risk medulloblastoma or other primitive neuroectodermal tumour                                                  | CNCCV                                                 | I     |       |
|             |             |                         | modified PCV chemotherapy of brain tumours using procarbazine, lomustine and vincristine                                                                                    | CNMODPCV                                              | I     |       |
|             |             | Gynecology              | therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, cyclophosphamide and vincristine    | GOTDEMACO                                             | I     |       |
|             |             |                         |                                                                                                                                                                             |                                                       |       |       |
|             |             | Kaposi's sarcoma        | therapy for Kaposi's Sarcoma using vinblastine-vincristine                                                                                                                  | KSVB                                                  | I     |       |
|             |             | Lung                    | treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin and vincristine                                                                                    | LUOTCAV                                               | I     |       |
|             |             |                         | treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin and vincristine                                                                            | LUSCCAV                                               | I     |       |
|             |             | Lymphoma                | treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine and prednisone                                                                                        | LYCHOP                                                | I     |       |
|             |             |                         | Treatment of ritUXimab-refractory Follicular Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRIStine, predniSONE, and oBINutuzumab                                         | LYCHOPO                                               | I     |       |
|             |             |                         | treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab                                                                             | LYCHOPR                                               | I     |       |
|             |             |                         | central nervous system prophylaxis with high dose methotrexate, CHOP and rituximab in diffuse large B-cell lymphoma                                                         | LYCHOPRMTX                                            | I     |       |
|             |             |                         | treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide, vincristine, prednisone and rituximab                                                            | LYCLLCVPR                                             | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                 | DOSAGE FORM | TUMOUR SITE             | APPROVED INDICATIONS                                                                                                                                                                                                                 | PROTOCOL CODES                                        | CLASS | NOTES |
|----------------------|-------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------|-------|
| vincristine (cont'd) | injectable  | Lymphoma                | treatment of Burkitt's Lymphoma and Leukemia with cyclophosphamide, vincristine, doxorubicin, methotrexate, leucovorin and rituximab                                                                                                 | LYCODOXMR                                             | I     |       |
|                      |             |                         | advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone                                                                                                                                                        | LYCVP                                                 | I     |       |
|                      |             |                         | Treatment of rTUXImab-refractory Follicular Lymphoma with Cyclophosphamide, vinCRISine, predniSONE and oBINutuzumab                                                                                                                  | LYCVPO                                                | I     |       |
|                      |             |                         | treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine and prednisone                                                                                                                                       | LYCVPPABO                                             | I     |       |
|                      |             |                         | treatment of advanced indolent lymphoma using cyclophosphamide, vincristine, prednisone and rituximab                                                                                                                                | LYCVPR                                                | I     |       |
|                      |             |                         | treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone and rituximab with intrathecal methotrexate                                                                               | LYEPOCHR                                              | I     |       |
|                      |             |                         | lymphoma palliative chemotherapy                                                                                                                                                                                                     | LYPALL                                                | I     |       |
|                      |             | Pediatric               | Brentuximab Vedotin in Combination with Doxorubicin, Vincristine, Etoposide and Cyclophosphamide for First Line High Risk Pediatric Hodgkin's Lymphoma                                                                               |                                                       | I     |       |
|                      |             | Sarcoma                 | SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma   | SAALT2W                                               | I     |       |
|                      |             |                         | SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing's Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma | SAALT3W                                               | I     |       |
|                      |             |                         | treatment of sarcomas with vincristine, doxorubicin and cyclophosphamide                                                                                                                                                             | SAVAC                                                 | I     |       |
|                      |             |                         | Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna                                                                                             | SAVACM                                                | I     |       |
|                      |             | Not Otherwise Specified | Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, Dactinomycin and Cyclophosphamide                                                                                                                                           | SAVDC                                                 | I     |       |
|                      |             |                         |                                                                                                                                                                                                                                      | Other tumour site code followed by 'NOS' (e.g. LYNOS) | I     |       |
| vinorelbine          | injectable  | Breast                  | palliative therapy for metastatic breast cancer                                                                                                                                                                                      | BRAVNAV                                               | I     |       |
|                      |             | Gynecology              | Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab, and Vinorelbine as First-Line Treatment for Advanced Breast Cancer                                                                                    | BRAVPTRVIN                                            | I     |       |
|                      |             |                         | Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine                                                                                                                             | GOOVBEVV                                              | I     |       |
|                      |             |                         | palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal cancer                                                                                                                                                    | GOOVVIN                                               | I     |       |
|                      |             | Head and Neck           | combination with cisplatin as treatment of advanced salivary gland cancers with cisplatin and vinorelbine                                                                                                                            | HNSAVNP                                               | I     |       |
|                      |             | Lung                    | adjuvant cisplatin and vinorelbine following resection of stage I, II and IIIA non-small cell lung cancer                                                                                                                            | LUAJNP                                                | I     |       |
|                      |             |                         | combination with cisplatin as treatment for advanced non-small cell lung cancer                                                                                                                                                      | LUAVNP                                                | I     |       |
|                      |             |                         | advanced non-small cell lung cancer in elderly patients                                                                                                                                                                              | LUAVVIN                                               | I     |       |
|                      |             |                         | malignant mesothelioma                                                                                                                                                                                                               | LUMMVIN                                               | I     |       |
|                      |             | Lymphoma                | Treatment of Relapsed or Refractory Hodgkin Lymphoma with Gemcitabine, Vinorelbine and Doxorubicin Pegylated Liposomal                                                                                                               | LYGVLD                                                | I     |       |
|                      |             | Pediatric               | pediatric patients treated on the COG protocol AHOD0521 for refractory/recurrent Hodgkin's disease                                                                                                                                   |                                                       | I     |       |
|                      |             | Pediatric               | treatment of pediatric patients with relapsed Hodgkin lymphoma with a combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV)                                                                                           |                                                       | I     |       |
|                      |             |                         | treatment of recurrent/refractory rhabdomyosarcoma in pediatric patients with cyclophosphamide, vinorelbine and temsirolimus on the COG ARST0921 protocol                                                                            |                                                       | I     |       |

**BC Cancer Benefit Drug List  
May 2025**

| DRUG                             | DOSAGE FORM | TUMOUR SITE      | APPROVED INDICATIONS                                                                                                                        | PROTOCOL CODES                 | CLASS | NOTES |
|----------------------------------|-------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-------|-------|
| vismodegib                       | capsule     | Skin & Melanoma  | treatment of metastatic or locally advanced basal cell carcinoma                                                                            | SMAVVIS                        | I     |       |
| yttrium-90                       | injectable  | Gastrointestinal | Transarterial Radioembolisation (TARE) for Locally Advanced Cholangiocarcinoma or Gallbladder Carcinoma Not Amenable for Surgical Resection | GIBYTT                         | I     |       |
|                                  |             |                  | Transarterial Radioembolisation (TARE) for Hepatocellular Cancer or Neuroendocrine Tumours with Hepatic Disease                             | UGIYTT                         | R     |       |
| zanubrutinib                     | capsule     | Lymphoma         | Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Zanubrutinib                                                  | LYCLLZANU                      | I     |       |
|                                  |             |                  | Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (LPL) using Zanubrutinib                                           | ULYWMZANU (previously ULYZANU) | R     |       |
| zoledronic acid                  | injectable  | Breast           | adjuvant therapy for breast cancer in post-menopausal women using zoledronic acid                                                           | BRAJZOL5                       | I     |       |
|                                  |             |                  | adjuvant therapy for breast cancer in post-menopausal women using 3-monthly zoledronic acid                                                 | BRAJZOL2                       | I     |       |
|                                  |             |                  | treatment of acute bone pain secondary to breast cancer metastases using IV zoledronic acid                                                 | BRAVZOL                        | I     |       |
|                                  |             | Myeloma          | treatment of multiple myeloma with zoledronic acid                                                                                          | MYZOL                          | I     |       |
| <b>Protocol Code Definitions</b> |             |                  |                                                                                                                                             |                                |       |       |
| Bone Marrow Transplantation      |             | BMT              |                                                                                                                                             |                                |       |       |
| Breast                           |             | BR               |                                                                                                                                             |                                |       |       |
| Gastrointestinal                 |             | GI               |                                                                                                                                             |                                |       |       |
| Genitourinary                    |             | GU               |                                                                                                                                             |                                |       |       |
| Gynecologic                      |             | GO               |                                                                                                                                             |                                |       |       |
| Head and Neck                    |             | HN               |                                                                                                                                             |                                |       |       |
| Kaposi's sarcoma                 |             | KS               |                                                                                                                                             |                                |       |       |
| Leukemia                         |             | LK               |                                                                                                                                             |                                |       |       |
| Lung                             |             | LU               |                                                                                                                                             |                                |       |       |
| Lymphoma                         |             | LY               |                                                                                                                                             |                                |       |       |
| Miscellaneous Origin             |             | MO               |                                                                                                                                             |                                |       |       |
| Myeloma                          |             | MY               |                                                                                                                                             |                                |       |       |
| Neuro-Oncology                   |             | CN               |                                                                                                                                             |                                |       |       |
| Ocular                           |             | OC               |                                                                                                                                             |                                |       |       |
| Primary Unknown                  |             | PU               |                                                                                                                                             |                                |       |       |
| Sarcoma                          |             | SA               |                                                                                                                                             |                                |       |       |
| Skin & Melanoma                  |             | SM               |                                                                                                                                             |                                |       |       |
| Tumour Agnostic                  |             | TA               |                                                                                                                                             |                                |       |       |